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quasi-RCTs reporting data from 9721 women were 
identified, considering five generic interventions [pelvic 
floor muscle training (PFMT), electrical stimulation 
(ES), vaginal cones (VCs), bladder training (BT) and 
serotonin–noradrenaline reuptake inhibitor (SNRI) 
medications], in many variations and combinations. 
Data were available for 37 interventions and 68 
treatment comparisons by direct pairwise assessment. 
Mixed-treatment comparison models compared 14 
interventions, using data from 55 trials (6608 women). 
(3) Economic modelling, using a Markov model, to 
find out which combinations of treatments (treatment 
pathways) are most cost-effective for SUI. 
Data extraction: Titles and abstracts identified were 
assessed by one reviewer and full-text copies of all 
potentially relevant reports independently assessed by 
two reviewers. Any disagreements were resolved by 
consensus or arbitration by a third person.
Results: Direct pairwise comparison and MTC analysis 
showed that the treatments were more effective 
than no treatment. Delivering PFMT in a more 
intense fashion, either through extra sessions or with 
Objectives: To assess the clinical effectiveness and 
cost-effectiveness of non-surgical treatments for 
women with stress urinary incontinence (SUI) through 
systematic review and economic modelling. 
Data sources: The Cochrane Incontinence Group 
Specialised Register, electronic databases and the 
websites of relevant professional organisations and 
manufacturers, and the following databases: CINAHL, 
EMBASE, BIOSIS, Science Citation Index and Social 
Science Citation Index, Current Controlled Trials, 
ClinicalTrials.gov and the UKCRN Portfolio Database. 
Study selection: The study comprised three 
distinct elements. (1) A survey of 188 women with 
SUI to identify outcomes of importance to them 
(activities of daily living; sex, hygiene and lifestyle 
issues; emotional health; and the availability of 
services). (2) A systematic review and meta-analysis 
of non-surgical treatments for SUI to find out which 
are most effective by comparing results of trials 
(direct pairwise comparisons) and by modelling 
results (mixed-treatment comparisons – MTCs). A 
total of 88 randomised controlled trials (RCTs) and Abstract
iv
biofeedback (BF), appeared to be the most effective 
treatment [PFMT extra sessions vs no treatment (NT) 
odds ratio (OR) 10.7, 95% credible interval (CrI) 5.03 
to 26.2; PFMT + BF vs NT OR 12.3, 95% CrI 5.35 to 
32.7]. Only when success was measured in terms of 
improvement was there evidence that basic PFMT was 
better than no treatment (PFMT basic vs NT OR 4.47, 
95% CrI 2.03 to 11.9). Analysis of cost-effectiveness 
showed that for cure rates, the strategy using lifestyle 
changes and PFMT with extra sessions followed by 
tension-free vaginal tape (TVT) (lifestyle advice–PFMT 
extra sessions–TVT) had a probability of greater than 
70% of being considered cost-effective for all threshold 
values for willingness to pay for a QALY up to £50,000. 
For improvement rates, lifestyle advice–PFMT extra 
sessions–TVT had a probability of greater than 50% 
of being considered cost-effective when society’s 
willingness to pay for an additional QALY was more 
than £10,000. The results were most sensitive to 
changes in the long-term performance of PFMT and 
also in the relative effectiveness of basic PFMT and 
PFMT with extra sessions.
Limitations: Although a large number of studies 
were identified, few data were available for most 
comparisons and long-term data were sparse. 
Challenges for evidence synthesis were the lack 
of consensus on the most appropriate method for 
assessing incontinence and intervention protocols that 
were complex and varied considerably across studies.
Conclusions: More intensive forms of PFMT appear 
worthwhile, but further research is required to define 
an optimal form of more intensive therapy that is 
feasible and efficient for the NHS to provide, along 
with further definitive evidence from large, well-
designed studies.DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
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BF biofeedback
b.i.d. twice daily
BT bladder training
CI confidence interval
CrI credible interval
DO detrusor overactivity
EMG electromyography
ES electrical stimulation
GP general practitioner
GSI genuine stress incontinence
HRQoL health-related quality of life
HTA Health Technology 
Assessment
ICER incremental cost-effectiveness 
ratio
ICIQ-UI SF International Consultation on 
Incontinence Questionnaire 
– Urinary Incontinence Short 
Form
IDO idiopathic detrusor 
overactivity
IEF incontinence episode 
frequency
IFT interferential therapy
I-QoL Urinary Incontinence Quality 
of Life Scale
LS lifestyle advice
MTC mixed-treatment comparison
MUI mixed urinary incontinence
NA not applicable
NHS National Health Service
NICE National Institute for Health 
and Clinical Excellence
NR not reported
NS not statistically significant
NT no treatment
OR odds ratio
PFMT pelvic floor muscle training
PFMT basic PFMT, delivered with up to 
two sessions or contacts with 
a health-care professional per 
month
PFMT extra 
sessions
PFMT, delivered with more 
than two sessions or contacts 
with a health-care professional 
per month
PGI Patient Generated Index
QALY quality-adjusted life-year
q.d. once daily
RCT randomised controlled trial
SD standard deviation
SIGN  Scottish Intercollegiate 
Guidelines Network
SMD standardised mean difference
SNRI serotonin–noradrenaline 
reuptake inhibitor
SUI stress urinary incontinence
TVT tension-free vaginal tape
TVT-O tension-free transobturator 
vaginal tape
USI urodynamic stress 
incontinence
UUI urgency urinary incontinence 
VC vaginal cone
VPFMC voluntary pelvic floor muscle 
contraction
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Description of proposed 
service
The treatment options for stress urinary 
incontinence (SUI) can be classified as non-surgical 
and surgical. Lifestyle changes, such as weight 
loss, smoking cessation, etc. may reduce the risk of 
leakage but all need continued adherence. Non-
surgical interventions, such as pelvic floor muscle 
training (PFMT), biofeedback (BF), electrical 
stimulation (ES), bladder training (BT), vaginal 
cones (VCs), etc., may also require long-term 
adherence to the taught programmes in order 
to produce continued benefit. However, these 
interventions have few adverse events compared 
with surgical treatment. Alternatively, the leakage 
can be contained using absorbent pads, an 
indwelling urinary catheter or, very rarely, urinary 
diversion.
Epidemiology and 
background
Stress urinary incontinence is the involuntary 
leakage of urine associated with effort or exertion, 
or on sneezing or coughing. Some women may also 
have symptoms of urge incontinence (a sudden 
compelling desire to pass urine, which is difficult 
to defer). Estimates of prevalence suggest that 
over 30% of women aged ≥ 40 years have SUI. 
The annual incidence increases with age (aged 
> 65 years, annual incidence rates ≈ 9%).
Objective
This study aimed to assess the clinical effectiveness 
and cost-effectiveness of non-surgical treatments 
for women with SUI.
Methods
The work comprised three distinct elements: (1) 
a survey of women with SUI to identify outcomes 
of importance to them [using a Patient Generated 
Index (PGI)]; (2) a systematic review and a meta-
analysis of non-surgical treatments for SUI to 
find out which are most effective [this was done 
in two ways, by comparing results of trials (direct 
pairwise comparisons) and by modelling results 
(mixed-treatment comparisons, MTCs)]; and (3) 
economic modelling of non-surgical and surgical 
treatments for SUI to find out which combinations 
of treatments (treatment pathways) are most cost-
effective.
The survey identified areas of importance to 
women who suffer from SUI, using a PGI. A total of 
188 women were invited to take part.
Literature searching included the Cochrane 
Incontinence Group Specialised Register (last 
searched March 2008), electronic databases (1980 
to March 2008) and the websites of relevant 
professional organisations and manufacturers. 
Randomised controlled trials (RCTs) and quasi-
RCTs (alternate allocation) were eligible. Random 
effects models were used to derive summary 
estimates with 95% confidence intervals (CIs) or 
credible intervals (CrIs) of the odds ratio (OR) for 
dichotomous variables and standardised mean 
difference (SMD) for continuous variables (direct 
pairwise comparison only).
To compare the cost-effectiveness of the 
treatment pathways, a Markov model was used. 
The model was developed using data from the 
review of effectiveness and data on resource use 
systematically identified as being relevant to the 
UK National Health Service (NHS). The model 
estimated cost and quality-adjusted life-years 
(QALYs) for a 40-year time horizon. Discounting 
at 3.5% was performed, as was deterministic and 
probabilistic sensitivity analysis.
Results
Survey
Overall, 38 different areas were reported by 
respondents on the PGI. These areas were divided 
into four themes: activities of daily living; sex, 
hygiene and lifestyle issues; emotional health; and 
the availability services.
Executive summaryExecutive summary
x
Number and risk of bias 
in studies included in the 
systematic review
A total of 88 trials reporting data from 9721 
women were identified, considering five generic 
interventions [PFMT, ES, VCs, BT and serotonin–
noradrenaline reuptake inhibitors (SNRI) 
medications], in many variations and combinations. 
PFMT data were split into PFMT basic (fewer than 
two sessions of training per month) and PFMT 
with extra sessions (more than two sessions per 
month). Data were available for 37 interventions 
and 68 treatment comparisons by direct pairwise 
assessment. Mixed-treatment comparison models 
compared 14 interventions, using data from 
55 trials (6608 women). Included studies were 
generally small and had short follow-up periods. 
Fourteen studies (16%) reported both adequate 
random allocation sequence generation and 
concealment.
Summary of clinical 
effectiveness
The direct pairwise comparison analysis and the 
MTC analysis showed that the treatments were, 
on average, more effective than no treatment. 
Delivering PFMT in a more intense fashion, 
either through extra sessions (more than two per 
month) or with BF, appears to be the most effective 
treatment [PFMT extra sessions vs NT odds ratio 
(OR) 10.7, 95% CrI 5.03 to 26.2; PFMT + BF vs 
NT OR 12.3, 95% CrI 5.35 to 32.7]. Only when 
success was measured in terms of improvement was 
there evidence that PFMT basic was better than 
no treatment (PFMT basic vs NT OR 4.47, 95% 
CrI 2.03 to 11.9). Adverse events were uncommon 
except for SNRI medication.
Costs
The perspective adopted for the analysis is that of 
the UK NHS. The total costs for each intervention 
over a 3-monthly period (the cycle length of the 
Markov model) were lifestyle changes £27, PFMT 
basic £189, PFMT with extra sessions £351, drug 
therapy £164, tension-free vaginal tape (TVT) 
£1135, colposuspension £1396 and containment 
products £39.
Using cure rates, a strategy of lifestyle changes and 
PFMT with extra sessions followed by TVT was the 
least costly (£1644) and the most effective (16.20 
QALYs). The strategy that had lifestyle changes 
followed by TVT (LS–TVT) was the most costly 
(£1973).
Using improvement rates, the strategy LS–PFMT 
basic–PFMT extra sessions–TVT was the least costly 
(£1795). The strategy LS–TVT was the most costly 
(£2425).
Quality-adjusted life-years
Using cure rates, the strategy that used lifestyle 
changes and PFMT basic, followed by PFMT with 
extra sessions, followed by SNRI and then TVT 
(LS–PFMT basic–PFMT extra sessions–SNRI–
TVT), was the least effective (15.89 QALYs).
Using improvement rates, the strategy LS–PFMT 
extra sessions–TVT was the most effective (16.37 
QALYs). The strategy LS–TVT was the least 
effective (16.2 QALYs) (and, as noted above, the 
most costly).
Cost-effectiveness
For cure rates, the strategy using lifestyle changes 
and PFMT with extra sessions followed by TVT 
(LS–PFMT extra sessions–TVT) had a probability 
of greater than 70% of being considered cost-
effective for all threshold values for willingness to 
pay for a QALY of up to £50,000.
For improvement rates, LS–PFMT extra sessions–
TVT had a probability of greater than 50% of being 
considered cost-effective when society’s willingness 
to pay for an additional QALY was more than 
£10,000.
Sensitivity analysis
The results were most sensitive to changes in the 
long-term performance of PFMT and also in the 
relative effectiveness of PFMT basic and PFMT 
with extra sessions. The results were not sensitive 
to plausible changes in the structure of the model 
(use of containment products instead of using an 
active treatment, introduction of vaginal cones 
and ES into treatment strategies). The results were 
also insensitive to plausible changes in the age of 
women, time horizon, discount rates, quality-of-life 
estimates, and mortality from surgery.
Limitations of the 
calculations
Few data were available for most comparisons 
and a pragmatic decision was made to include 
women with urgency urinary incontinence (UUI) 
symptoms, but only if the proportion of women DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
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with UUI was less than 50% of the study sample. 
The definitions of outcomes differed between 
studies and the interventions were varied in terms 
of the precise nature of the exercise as well as the 
duration of therapy.
All of these results need to be considered cautiously 
as very few data were available for interventions. 
The 95% central CrIs for these interventions are 
very wide and indicate that we know very little 
about their relative effectiveness. There were few 
long-term data for any of the therapies. These data 
are important determinants of cost-effectiveness, 
yet little is known about how quickly symptoms 
might return.
Other important issues 
regarding implications
There may not be sufficient trained therapists to 
provide the potentially more effective and cost-
effective intensive non-surgical treatments. For the 
use of these therapies to increase, staff would need 
to be recruited, trained and retained.
Within all of the analyses, the preferences of 
women for the process of care have not been 
considered. Women are likely to have preferences 
about who provides the care, where the care is 
provided, and what risks and costs they face 
themselves.
The value of the non-surgical treatments depends 
upon its ability to maintain women’s long-term 
adherence to therapy. How this might be achieved 
in practice will involve a complex interplay of 
factors, including who provides the therapy, how 
it is provided, for how long, the preferences of 
women, and so on. These issues could not be 
fully explored in this study because of the limited 
evidence base.
Implications for practice
Non-surgical treatments for SUI in women are 
effective and could potentially be cost-effective, but 
a judgement is required as to whether the benefits 
are worth the cost.
There is clear evidence that PFMT plus BF and 
PFMT with extra sessions was effective. Several 
other treatments (PFMT plus BT and BF; PFMT 
plus BF and VCs or ES) are promising, but there is 
insufficient evidence to recommend their routine 
use.
There is no evidence that PFMT basic is any better 
than no treatment in terms of cure, although 
it does improve symptoms compared with no 
treatment.
The cost-effectiveness of the non-surgical 
treatments is dependent upon whether their short-
term effectiveness is sustained.
Recommendations for 
further research
Conclusions are based on data from a limited 
number of small trials.
More intensive forms of PFMT appear worthwhile, 
but research is required to define an optimal form 
of more intensive therapy that is feasible and 
efficient for the NHS to provide.
Further definitive evidence from large, well-
designed studies is required in order to provide a 
definitive answer.
Any further research on long-term outcomes, 
benefit assessment or costs should be incorporated 
into an updated economic evaluation, as and when 
it becomes available.
If an effective and efficient follow-up regimen can 
be developed, then the incentives/disincentives 
faced by NHS providers may need to be 
reconsidered to aid its implementation.DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
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Description of underlying 
health problem
Continence mechanisms in health
Efficient mechanisms have evolved to ensure 
reliable urine storage and complete bladder 
emptying at socially convenient times. Mechanisms 
that prevent urine leakage involve the bladder, 
the urethra and the pelvic floor muscles, together 
with their controlling nerve pathways. The 
bladder is a highly compliant organ, allowing the 
storage of increasing quantities of urine without 
rise in pressure, a property underpinned by 
passive stretch and active relaxation of its smooth 
muscle (detrusor). Active central nervous control 
mechanisms in the pons and cerebrum inhibit 
detrusor contraction despite increasing sensation 
of bladder fullness until micturition is appropriate. 
Urethral mechanisms promoting continence are 
less well understood, but are thought to involve 
tonic contraction of smooth muscle in the urethral 
wall, together with a tight seal formed by the 
urethral lining (mucosa) and the highly vascular 
submucosal layer. Contraction of the pelvic floor 
striated muscles acts as an additional guarding 
mechanism, compressing the urethra and 
preventing leakage during actions that raise intra-
abdominal pressure.
These features maintain continence during the 
storage phase of the micturition cycle by ensuring 
that bladder pressure is always lower than urethral 
closure pressure. Incontinence is therefore likely 
to result from deficiency of urethral closure 
mechanisms and/or involuntary detrusor activity, 
aggravated by factors that chronically increase 
intra-abdominal pressure. In general, maximal 
urethral closure pressure is higher in men and 
therefore incontinence is far more prevalent 
amongst women, who are the target population for 
this review.1
Definition of urinary 
incontinence
The symptom of urinary incontinence is defined 
as the involuntary leakage of urine,2,3 and this can 
be subcategorised qualitatively according to the 
patient’s description (Box 1).
This symptom categorisation2,3 is based on a 
detailed history and provides a useful basis 
for discussion of the problem with the patient, 
identification of patient-centred treatment goals 
and initiation of treatment pathways.
When the patient first reports the problem to 
a clinician it is usual for the clinician to define 
possible causative factors and commonly associated 
problems by further questioning, physical 
examination and performance of simple tests. 
The severity of incontinence and the degree of 
bother it causes the individual can be estimated 
by appropriate direct questioning, including pad 
usage, or can be quantified more objectively using 
validated symptom scores4 or bladder diaries.
Further categorisation of incontinence according 
to the underlying functional or anatomical cause 
requires simultaneous measurement of bladder and 
rectal pressure, together with observation of urine 
loss during bladder filling. This invasive clinical 
test, filling cystometry, requires catheterisation of 
the bladder and is therefore generally performed 
only when more accurate categorisation is required, 
for example prior to surgical treatment in women 
with MUI. This test will differentiate urodynamic 
stress incontinence (USI) due to bladder outlet 
weakness from detrusor overactivity (DO) 
incontinence due to involuntary contraction of the 
bladder muscle (Box 2).
Chapter 1  
Background
Stress urinary incontinence (SUI)
Involuntary leakage of urine associated with effort or 
exertion, or on sneezing or coughing
Urgency urinary incontinence (UUI)
Involuntary leakage of urine accompanied, or imme-
diately preceded, by urgency, which is a sudden com-
pelling desire to pass urine that is difficult to defer
Mixed urinary incontinence (MUI)
When complaints of both SUI and UUI coexist
BOX 1  Symptom categories of urinary incontinenceBackground
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The test may be accompanied by radiographic 
visualisation of the bladder outlet to qualitatively 
subcategorise USI according to the degree 
of descent of the bladder neck on coughing 
(hypermobility) or loss of the sealing mechanism 
of the urethra (intrinsic sphincter deficiency). 
The diagnostic and prognostic usefulness of this 
additional imaging, together with related indices 
such as abdominal leak point pressure, is uncertain 
and currently not recommended for routine use by 
the International Continence Society.2
Most people complaining of the symptom of SUI 
will have USI, which is demonstrable on cystometry, 
and this can be aggravated by conditions that 
chronically raise abdominal pressure, such as 
obesity and chronic obstructive pulmonary disease. 
In approximately 10–20% of cases, however, the 
symptom of SUI can result from DO provoked by 
coughing, for example, or from loss of bladder 
compliance due to fibrosis or neurological disease 
(low bladder compliance). It should therefore be 
noted that the symptom of stress incontinence does 
not always relate to weakness of the bladder outlet 
or urethral closure mechanism.
Practical definition of incontinence for outcome 
purposes requires a variable that can be measured 
before and after treatment. This presents a 
particular problem for evidence synthesis, as there 
is a lack of consensus on the most appropriate 
method, with a variety of variables being used 
to define improvement or cure (Box 3). It is also 
recognised that these variables may not capture 
outcomes of prime importance to individual 
women suffering SUI.
Epidemiology and natural 
history
Prevalence
Prevalence estimates vary depending on 
population sampled, definition of incontinence, 
Urodynamic stress incontinence (USI)
Involuntary leakage of urine during increased abdomi-
nal pressure in the absence of a detrusor contraction
Detrusor overactivity (DO) incontinence
Leakage of urine due to an involuntary detrusor 
contraction
BOX 2  Urodynamic diagnostic categorisation of urinary 
incontinence
Patient defined
Self-report of outcome or change in symptom score
Quantified
Change in reported episodes on bladder diaries
Weight of urine loss during exercise pad tests
Clinician defined
Direct observation of urine loss
Cystometric diagnosis
Quality of life defined
Change in generic ratings, such as EQ-5D
Change in condition-specific ratings, such as King’s 
Health Questionnaire
BOX 3  Variables used as primary outcome measures in trials of 
treatment of stress urinary incontinence
severity threshold and survey methodology.5 A 
recent longitudinal study from one county in the 
UK surveyed a random sample of over 15,000 
community-dwelling individuals aged ≥ 40 years 
and found prevalences of 34% in women and 14% 
in men.6 These data were in line with prevalence 
rates among adults living in the UK, summarised 
from previous studies, showing a mean (range) 
of 40% (2–69%) for women and 10% (2–25%) 
for men.7 These ranges were consistent with 
findings from other developed countries, which 
documented rates of 10–72% for women and 
3–20% for men.7
The EPINCONT study surveyed over 34,000 
community-dwelling Norwegian women and 
found that the prevalence of urinary incontinence 
increased during young adult life, reached a broad 
peak between the ages of 45 and 55 years, and 
then showed a further steady increase in the elderly 
(Figure 1).8–12 This study also found that about one-
quarter of women with incontinence rated it as 
severe, a proportion in line with previous reports.13
This study also provided differential prevalence 
rates for symptoms of stress, urge and mixed 
incontinence.10 Overall, SUI was the most common 
type, experienced by 50% of incontinent women, 
whereas 11% reported urgency incontinence alone 
and 36% reported mixed symptoms (Figure 1). The 
pattern does vary, however, according to age group, 
with SUI alone being most frequently reported in 
women who are younger than 50–55 years, after 
which urgency incontinence is reported most often, 
either alone or in combination, possibly reflecting DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
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FIGURE 1  Prevalence of female urinary incontinence by age group and symptomatic type of incontinence. Compiled from data in 
Hannestad and colleagues (2000).8
menopausal status.12 This pattern was also found 
in a large cross-sectional European study using 
validated questionnaires, for which SUI was most 
often reported by women under 60 years old.11 
Overall prevalence rates for urinary incontinence 
amongst older women who are living in supported 
accommodation are usually much higher, reaching 
40–50%.14
This high community prevalence does not tend 
to lead to equivalent rates of consultation with 
a clinician. Studies estimate that only 15% of 
the women identified as suffering from SUI in 
cross-sectional surveys have consulted a health 
professional about the problem.15,16 The reasons 
for this are unclear but may relate to social class, 
mild symptoms, lack of bother, embarrassment, 
disinclination towards treatment options and 
perceived lack of effective treatment.17
Natural history
In comparison with the many cross-sectional 
prevalence surveys, fewer longitudinal studies have 
examined the incidence and remission of urinary 
incontinence symptoms. One study followed a 
large cohort of community-dwelling middle-
aged women (mean age 46 years) for 2 years and 
documented an average annual incidence of new 
incontinence of 9%.18 The incidence increased 
with age, with the majority reporting mild, non-
disabling leakage (Figure 2). Subanalysis of type 
of incontinence showed an annual incidence of 
frequent or severe stress incontinence of about 2% 
(Figure 3). This study also documented a 7% annual 
remission rate among those women reporting 
urinary incontinence at baseline. Similar results 
were found from a cohort of older, postmenopausal 
women (mean age 64 years), followed for 2 years, 
and a further large cohort study of women aged 
> 65 years, with rates of annual incidence for SUI 
of 9% and 9.5%, respectively, and annual remission 
rates of 7% and 8%, respectively.19,20
A number of studies have reported questionnaire 
follow-up of numerically smaller cohorts of younger 
women (mean age 26–30 years) before and after 
their first vaginal delivery and reported the annual 
incidence of new urinary incontinence to be 5%, 
1% and 4% over periods of 4, 10 and 12 years, 
respectively.21–23Background
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FIGURE 2  Two-year incidence of urinary incontinence by severity. Based on a cohort of 33,952 American women. Any incontinence 
defined as leaking at least once per month; occasional incontinence defined as leaking one to three times per month; frequent 
incontinence defined as leaking at least once per week; severe incontinence defined as frequent leaking of quantities at least enough to 
wet the underwear. Adapted from Townsend and colleagues (2007).18
FIGURE 3  Two-year incidence of frequent (at least once weekly) urinary incontinence by incontinence type. Cases of incident 
frequent incontinence; missing data on incontinence type symptoms are excluded from these calculations. Adapted from Townsend and 
colleagues (2007).18
Factors associated with SUI
The main risk factors for female SUI are 
pregnancy, vaginal delivery, increasing parity, 
increasing age, obesity and postmenopausal 
status.24–26 In older women, particularly those 
requiring social care, age-related changes to the 
lower urinary tract (such as reduced bladder 
capacity) and comorbidity in other organ systems 
(such as cardiac or cognitive impairment treated 
with drugs such as diuretics) can precipitate or 
worsen incontinence. Consideration of these 
multiple factors, together with the increasing 
preponderance of mixed urgency and stress 
incontinence symptoms, makes effective 
management of the problem in the elderly more 
difficult.14DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
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Postpartum SUI
Childbearing is the main predisposing factor that 
is specific for SUI, although the exact mechanism 
of pelvic floor injury that contributes to the 
development of outlet weakness during pregnancy 
and vaginal delivery is unclear.26,27 Longitudinal 
studies have reported that two-thirds of women 
with SUI during their first pregnancy continue to 
have symptoms at a follow up of 15 years. Having 
antenatal SUI doubles this risk.28 Immediately 
after childbirth women may expect to have higher 
levels of incontinence, which can often resolve 
spontaneously over the first 6 months. As this 
natural resolution might confound the effect of 
any intervention, data from trials in women in the 
immediate postpartum period were not included 
in the main body of the systematic review or in the 
cost-effectiveness analysis (results are reported in 
Appendix 20).
Other risk factors
In a large population-based cross-sectional study 
of premenopausal women, high body mass index 
(BMI > 30), diabetes mellitus and previous 
urinary incontinence surgery were identified as 
significant risk factors for severe SUI.29 A history of 
gynaecological surgery for prolapse increased the 
risk of developing stress leakage over twofold, and 
hysterectomy and other gynaecological procedures 
also doubled the risk.30,31
Significance in terms of ill 
health
Effect on well-being
Embarrassment associated with urinary 
incontinence may cause withdrawal from social 
situations and reduce quality of life.32 Women 
with a severe or frequent problem find the 
leakage distressing and socially disabling. They 
may avoid going away from home, using public 
transport and sexual activity.33 SUI does not 
generally lead to deterioration in physical health 
but can be associated with depression and other 
psychological morbidity.33 The problem may also 
lead to withdrawal from regular physical activities, 
potentially harming general health.34
Extent of problem in the UK
Assuming an overall prevalence for SUI of 15% 
among women aged over 20 years, it can be 
estimated that there are 3.3 million sufferers in the 
UK.35
Cost to society
The high prevalence of urinary incontinence 
results in a high overall cost of treatment and 
containment. Precise cost is difficult to define 
but a recent study suggested an estimated figure 
for combined health care, personal and societal 
expenditure of £248 per person per year in the 
UK, which would equate to a total annual cost of 
£818M for SUI.36 A further estimate, assuming that 
SUI accounts for 50% of cases, suggested a health 
care cost to the UK National Health Service (NHS) 
of £117M per year.37
Description of interventions
The treatment options for SUI can be classified as 
non-surgical and surgical. Lifestyle changes, such as 
weight loss, smoking cessation, control of chronic 
obstructive pulmonary disease, timed voiding and 
oral fluid management, may reduce risk of leakage 
but all need continued adherence to the required 
adjustments in order to maintain response. Specific 
non-surgical interventions, such as pelvic floor 
muscle training and biofeedback (BF), also require 
long-term adherence to the taught programmes 
in order to produce continued benefit. However, 
these interventions have few or no adverse events. 
Surgical treatment, on the other hand, may have 
a higher rate of benefit but has a greater risk of 
complications.38 Alternatively, the leakage can be 
contained using absorbent pads, an indwelling 
urinary catheter or, very rarely, urinary diversion.
The choice of treatment depends on patient 
preference and professional advice and will take 
into account factors, such as symptom severity, 
degree of interference with lifestyle, presence of 
related problems and degree of comorbidity. The 
importance of patient preference as the primary 
consideration in selecting a particular treatment 
for SUI was underlined by the findings of a recent 
survey which reported that most preferred less 
invasive treatment and management options.39 
From a health service perspective it is important 
to balance short- and long-term efficacy against 
potential adverse events and costs.
Existing guidelines
Epidemiological studies consistently demonstrate 
that proportionally few women who experience 
urinary leakage approach clinicians for advice and 
treatment.15,16 It is likely that most women first seek 
advice from family, friends and the media and, for 
individually varying reasons, decide to manage Background
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the problem themselves. Those who present their 
problem to health-care professionals tend to have 
more severe symptoms, which cause interference 
to their social activities and they are therefore 
generally seeking active treatment. Most countries, 
such as the UK, have attempted to standardise 
the assessment and initial management of women 
with incontinence by publication of consensus 
documents and guidelines.40–44 Despite this, 
uniformity of care remains lacking and will depend 
on individual clinician opinion and local service 
provision.
Current UK NHS care pathway
In the UK, the first port of call is likely to be the 
general practitioner (GP – primary care physician). 
An initial assessment will document the severity 
of the problem and the degree to which it bothers 
the women, and make sure that there are no 
more immediate health-threatening problems. 
Lifestyle advice, such as smoking cessation and 
weight loss, to modify risk factors may be offered. 
It is then possible that conservative therapy, in 
terms of bladder training (BT) or pelvic floor 
education and therapy, will be suggested, with 
referral to a practice nurse, physiotherapist or 
continence nurse specialist. Alternatively, or if 
these approaches subsequently fail, the woman will 
be offered referral to secondary care, to a urologist, 
urogynaecologist or gynaecologist, depending 
on local service arrangements. Such referrals 
will mostly result in further investigation, further 
conservative treatment including the use of drugs 
and eventually the offer of surgery to those with 
predominant SUI.
Lifestyle changes
Symptomatic SUI may be improved or cured by 
changing lifestyle factors. This can be achieved by 
interventions, such as weight loss, fluid restriction, 
reduction of caffeine or alcohol intake, limiting 
heavy activity, stopping smoking and treatment 
of constipation (Table 1). The effect of weight loss 
has been most intensively studied, with evidence 
summarised in a recent systematic review.45 
Successful weight-loss programmes require 
intensive therapy, involving diet, exercise and 
behavioural modification over a prolonged period.
Setting
In the context of a consultation in primary care, the 
possible benefit of lifestyle modifications, such as 
weight loss, would be discussed and reinforced by a 
patient information leaflet, together with the offer 
of further therapeutic help. Intensive weight-loss 
programmes are not widely available at present but 
are most likely to be community based.
Personnel involved
Weight loss or smoking cessation therapy is most 
likely to be effective if it is supervised, preferably on 
a weekly basis, by a therapist who has undergone 
recognised training and obtained appropriate 
qualifications. Such programmes are frequently run 
as group sessions.
Costs
The cost of lifestyle changes will vary according to 
the intensity of the intervention. It might range 
from simple provision of information at a primary 
care consultation with a specialist nurse (£13.95)46 
to the taking of active steps to lose weight. For 
example, a 6-month supervised group weight-
reduction programme with the leading commercial 
provider in the UK, WeightWatchers, would 
currently cost £152,47 with possible additional costs 
to the individual related to dietary changes and 
exercise programme.
Pelvic floor muscle training
Recommendations for the standardisation of 
these treatments have been published by the UK 
Chartered Society of Physiotherapists.40
Basic pelvic floor muscle training 
(PFMT basic)
Popularised by Arnold Kegel,48 basic pelvic floor 
muscle training (PFMT) is generally the first-line 
non-surgical management for SUI. The principle 
behind this intervention is to condition and 
strengthen the striated pelvic floor muscles in 
order to improve the urethral sphincter closure 
mechanism during provocative activity (such as 
coughing) that raises intra-abdominal pressure. 
There is a variety of regimens to provide PFMT 
to women. The simplest involves education about 
pelvic floor structure and function, together with 
demonstration, using digital vaginal examination 
by the therapist or woman herself, of a correct 
and effective pelvic floor muscle contraction. A 
regular exercise programme schedule is then 
agreed between the woman and her therapist, with 
intermittent checks of progress and benefit over 
a 3- to 4-month period. The schedule suggested 
by Kegel was five contractions performed every 
waking hour,49 whereas that recommended 
by recent guidelines is a sequence of eight 
contractions three times daily.43 A summary of 
current recommendations is given in Box 4.DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
7
TABLE 1  Lifestyle changes as treatment for stress urinary incontinence
Lifestyle change Methods Evidence of effectiveness for SUIa
Weight loss Diet
Exercise
Behavioural modification
Level 1a
Adjustment of fluid intake Reduced volume
Avoidance of caffeine
Avoidance of carbonated drinks
Level 2b
Smoking cessation Behavioural modification
Nicotine replacement
Level 4
Exercise modification Avoidance of provocative exercise Level 4
Regularisation of bowel habit Interventions to prevent constipation 
and straining to defecate
Level 4
a  Graded according to Oxford Centre for Evidence Based Medicine (2009).  Available at www.cebm.net/index.
aspx?o=1025.
•  Pelvic floor muscle awareness is taught
•  The pelvic floor is assessed and exercised in functional positions
•  The use of anticipatory pelvic floor muscle contraction immediately prior to an activity that causes urine leakage 
(‘The Knack’) is taught
•  A programme of pelvic floor muscle exercises is tailored to individual patients and includes exercises for both fast- 
and slow-twitch muscle fibres
•  Pelvic floor muscle exercises are performed several times a day until the muscle fatigues
•  Pelvic floor muscle exercises are practised for 15–20 weeks
•  Patients are initially seen weekly, but account may need to be taken of their circumstances and/or the available 
resources
•  Pelvic floor muscle exercises are continued on a maintenance programme
a  Recommendation from Laycock and colleagues (2001).40
BOX 4  Current recommendations for conduct of pelvic floor muscle training programmea
Augmented PFMT
Plus biofeedback (PFMT plus BF)
The addition of BF as a teaching and performance-
enhancing device, in the form of vaginal 
pressure recording using a perineometer or 
electromyographic demonstration of muscle 
activity, can be helpful to visually demonstrate to 
the patient when they are performing a correct 
pelvic contraction and to quantify improvement. 
This feedback should encourage and motivate 
perseverance with a regular exercise programme. 
Digital BF is the practice of assessing pelvic muscle 
strength by vaginal examination, with verbal 
feedback concerning correctness and strength of 
the contraction. Once benefit is established and the 
woman is discharged from the therapist’s care, a 
continued exercise programme is encouraged.
Biofeedback may also be used as a training device 
or as an aid to pelvic floor muscle exercising. 
Women use a pressure perineometer to monitor 
strength and endurance of a series of pelvic floor 
muscle contractions over a period of time, typically 
20–30 minutes, at weekly or monthly intervals.
Plus vaginal cones
As an adjunct to standard pelvic floor training 
programmes, women can be instructed to retain 
graded cone-shaped weights [vaginal cones 
(VCs)] within the vagina to improve pelvic floor 
muscle strength. Starting with the lightest weight, 
women are advised to hold a cone in their vagina 
and prevent it from slipping out, while standing, 
moving around or coughing. It is suggested that 
the use of cones improves compliance with the Background
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exercise schedule, individualises the exercise 
regimen, gives BF and improves knowledge of the 
functional anatomy of the vagina and pelvic floor. 
Cones may also be used as a standalone treatment 
at home for women who do not wish to, or cannot, 
access a health professional.50
Plus electrical stimulation
A further possible adjunct to PFMT is electrical 
stimulation (ES). This causes the pelvic floor 
muscles to contract, either directly or indirectly, 
by excitation of the motor efferent fibres of the 
pudendal nerve. The electrodes can be placed 
on the perineal skin, within the vagina or within 
the anus. The vaginal route is recommended with 
set stimulation parameters (Box 5). It is thought 
that ES may be particularly useful for women who 
are unable to contract their pelvic floor muscles 
voluntarily, or to help build up muscle strength 
prior to a supervised PFMT programme. The 
reported advantages of this intervention include 
high patient acceptability, little or no discomfort 
and home-managed delivery of the treatment.51
Setting
These interventions are organised through 
a primary care continence or physiotherapy 
service, which may be located in a primary health 
care centre or local hospital department. The 
patient will typically attend weekly or fortnightly 
sessions over a 3- to 4-month period, depending 
on compliance and improvement. They will be 
instructed to continue the exercise programme 
at home, during daily activity between visits to 
the therapist, and to continue the programme 
themselves, lifelong, after discharge from the 
therapist’s care.
Personnel involved
These treatments will be typically supervised by 
a chartered physiotherapist who has undergone 
education to degree level and has undertaken 
a recognised professional training programme 
leading to the relevant professional registration. In 
some cases sessions may be delegated to trainees 
or assistants under supervision. Alternatively, the 
treatment will be administered by a continence 
nurse specialist who has undergone training in the 
provision of pelvic floor exercise programmes and 
has achieved appropriate competencies signified by 
additional qualifications.
Costs
Based on Personal and Social Services 
Research Unit (PSSRU) figures, the average 
cost for a consultation with a physiotherapist 
•  Frequency: 35 Hz
•  Pulse width: 250 microseconds (0.25 milliseconds)
•  Current type: biphasic rectangular
•  Intensity: maximum tolerated
•  Duty cycle: 5 seconds on/10 seconds off. Very 
weak muscles: 5 seconds on/15 seconds off
•  Treatment daily/twice daily (home treatment)
•  Treatment time: 5 minutes initially, gradually 
increasing to 20 minutes
a  Recommendation from Laycock and colleagues 
(2001).40
BOX 5  Suggested parameters for intravaginal electrical 
stimulation of the pelvic floor as treatment for stress urinary 
incontinencea
is approximately £13.46 Additional costs for 
PFMT programmes would include overheads 
and consumables for basic intervention (£4), 
and additional equipment for BF (£35) and ES 
(£11). VCs are not provided by the UK NHS, and 
women would have to purchase them commercially 
at a cost of £20.52 The total cost of all these 
interventions is determined by the number of 
sessions the women receive. For basic PFMT, the 
average cost for a 3-month cycle of treatment is 
£189, for BF it is £224 and for ES it is £398. These 
costs are similar if the programme is provided by a 
continence nurse specialist.43
Bladder training
Bladder training to regain control of micturition 
is more predominantly used for UUI or those 
women with mixed symptoms. Typical programmes 
involve a gradually progressive voiding schedule 
to delay micturition, together with distraction 
and relaxation techniques to suppress urgency. 
This would generally involve an initial assessment 
consultation and subsequent visits or telephone 
follow-up over a period of 8–12 weeks. Bladder 
diaries are often used as additional BF and 
outcome tools.53
Setting
The initial assessment would take place in a 
primary health care centre, with follow-up visits in 
the health centre, patient’s home or by telephone 
as appropriate.
Personnel involved
This type of therapy is generally supervised in 
primary care by a designated member of the DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
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district nursing team with expertise in continence 
promotion or by a continence nurse specialist.
Costs
UK NHS reference costs for district nursing 
contacts (CN301AF) average £31 (range £26–
40), while continence nurse specialist contacts 
(CN204AF) are costed at between £48 and £114. 
This would give an approximate total cost, 
assuming fortnightly visits for 12 weeks, of £180–
540.54
Pharmacotherapy
Serotonin–noradrenaline reuptake 
inhibitor
Experimental studies in animals suggest 
that noradrenaline and serotonin 
(5-hydroxytryptamine) act on efferent neurons 
in the sacral spinal cord (Onuf ’s nucleus) to 
encourage contraction of the periurethral striated 
muscle of the urethral sphincter and relaxation 
of the bladder wall muscle (detrusor muscle), 
thereby promoting urine storage and continence. 
Duloxetine hydrochloride, a balanced serotonin–
noradrenaline reuptake inhibitor (SNRI), was 
tested as an antidepressant but found to have an 
effect on reducing stress incontinence in women. 
It is now licensed as a continence-promoting drug 
in women with SUI.55 Although it has been shown 
to improve symptoms of SUI, the usefulness of 
duloxetine is limited by side effects, particularly 
nausea, which result in up to 20% of women 
being unable to tolerate the drug.56 There is 
some evidence to suggest that this drug may be 
more useful as an adjunct to other conservative 
therapies, such as PFMT.57 Despite poor tolerability 
and modest efficacy, the prescribing of this drug 
appears to be increasing in the UK (Figure 4). 
Further details on the current use of SNRI’s 
were obtained from a survey of members of the 
Association of Continence Advisors (ACA). The 
ACA provided a copy of their e-mail distribution 
list and members were surveyed during January 
and February 2009. Out of approximately 650 ACA 
members on the distribution list, 86 responded (a 
13.2% response rate). Of these, 57 provided details 
of their SUI caseload, of which 15/57 (26.3%) 
advisors reported that they had patients using 
duloxetine for the treatment of SUI. The number 
being treated was 92 out of a caseload of 1234 
patients (7.5%); the majority of these, however, 
came from the caseloads of two respondents.
The drug is generally prescribed in divided doses, 
totalling 40–80 mg per day, and the response is 
assessed over a 12-week period. The relatively high 
risk of side effects requires initial close monitoring 
by the specialist or GP.
Setting
The poor tolerability profile of this drug has 
resulted in it mainly being prescribed by specialists 
through hospital clinics.
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FIGURE 4  Serotonin–noradrenaline reuptake inhibitor prescriptions for stress urinary incontinence. UK NHS prescribing data 
obtained from NHS information centre.58Background
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Personnel
The drug is predominantly initiated by hospital 
specialists for women with SUI, who are unsuitable 
for surgery or do not wish to undergo surgery.
Costs
The cost of a 56 × 40-mg tablet pack of duloxetine 
is £30.80.59 This equates to an average annual cost 
per patient, for drugs alone, of £402. If two visits 
to the GP are included the total annual cost rises to 
£474.
Estrogen
Estrogens are thought to affect female continence 
through several modes of action, including 
maintenance of pelvic floor musculature and 
enhancement of urethra mucosal sealing. It was 
therefore considered that therapeutic estrogen 
supplementation in postmenopausal women 
would be beneficial delivered either locally or 
systemically. Overall, there is a high level of 
evidence that oral estrogen replacement therapy 
appears to increase incontinence symptoms 
amongst postmenopausal women,60–62 and its use 
for this indication is therefore not recommended. 
Recent appraisal of evidence for topical vaginal 
estrogen therapy suggests that it may benefit 
women with incontinence but not to any consistent 
degree,63 and it is currently only recommended 
for women with overactive bladder symptoms that 
are associated with mucosal atrophy.43 The opinion 
from the expert group for the current review was in 
agreement with this guidance and so oral or topical 
estrogen were not included as a treatment option 
for SUI.
Adrenergic agonists
Despite a theoretical and experimental expectation 
that alpha-adrenergic drugs should improve 
urethral and bladder neck smooth muscle activity, 
no consistent clinical benefit was found in women 
with stress incontinence.63,64 These drugs are 
neither licensed for this treatment indication nor 
recommended by current guidance,43 and were 
considered to be very rarely used in practice by our 
expert group. On this basis, the use of adrenergic 
agonists as a treatment option for SUI was not 
considered further.
Mechanical devices
Consideration of the underlying urodynamic 
changes that result in SUI has continued to 
encourage the design and testing of intraurethral 
or intravaginal mechanical devices to prevent 
leakage. The mechanism of action of intravaginal 
devices is either by compression of the urethra 
against the inferior margin of the pubis or 
adjunctive bladder neck support with tampons 
such as Contrelle™.65 Intraurethral devices, such 
as NEAT Expandable Tip Continence Device™,66 
and FemSoft™,67 plug the urethral lumen. The 
clinical effectiveness of these devices in comparison 
with no treatment or other conservative methods 
of managing stress incontinence was the subject of 
a recent systematic review.68 This review included 
six trials with a total of 286 participants. The 
mechanical devices used were five intravaginal 
devices and five intraurethral devices. The included 
trials either compared a mechanical device with 
no treatment or with an alternative device. There 
were no published data comparing devices with 
other non-surgical interventions for the treatment 
of SUI. The published data were unsuited to meta-
analysis and the individual trials had small sample 
sizes and poor methodology ratings. The review 
therefore concluded that there was insufficient 
evidence to estimate the effect of mechanical 
devices for the treatment of women with SUI. In 
summary, although these devices are conceptually 
attractive, they do not appear to be widely used at 
present.49 Some further information was obtained 
from the previously described survey of ACA 
members. The respondents had a total caseload 
of 1187 women. A total of 80 women were using 
mechanical devices, although 35 (43.8%) of these 
came from the caseload of a single respondent. The 
vast majority of devices used were vaginal devices, 
used by 78/80 women (97.5%). The most popular 
of these was pessaries, used by 77.5% (62/80) of 
the women. The Contrelle Activeguard was used by 
7/80 (8.8%) women, tampons by 4/80 (5%) women, 
the Incostress device by 2/80 (2.5%) women, and 
vaginal sponges by 3/80 (3.8%) women. The only 
non-vaginal device used was an anal plug used by 
2/80 (2.5%) women.
Setting and personnel
These devices require a preliminary assessment by 
a trained health-care professional, who will also 
instruct the patient on their use. However, this 
could occur in primary or secondary care settings.
Costs
The Contrelle device costs £50 and can be reused, 
whereas the FemSoft urethral insert costs £1.50 and 
has to be changed for a new device after urination.
Electromagnetic stimulation
Experimental studies have shown that 
electromagnetic stimulation of the S3 and S4 DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
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sacral nerves increases maximum urethral closing 
pressure by 34% compared with baseline.69 
However, few randomised controlled trials (RCTs) 
have reported on the cure or improvement of SUI 
using electromagnetic stimulation compared with 
placebo,69,70 and the intervention is not in current 
clinical use. It will not be considered further in this 
review.
Periurethral injectable bulking agents
Stress urinary incontinence can be treated 
by periurethral injections of agents that bulk 
the urethral wall to encourage sealing during 
urine storage and hence improve continence. 
Conceptually, they occupy a ‘grey’ area between 
truly non-surgical treatments and operations. We 
chose to define periurethral injection therapy 
as surgical treatment, as this is carried out by 
surgically qualified clinicians, in an operating 
room environment, with the standard precautions 
and care process that this entails. This treatment 
modality will not therefore be included in 
treatment pathways, but a summary of a recently 
updated Cochrane review of the subject is included 
here for completeness.71 This review looked at the 
effects of periurethral or transurethral injection 
therapy for the treatment of women with urinary 
incontinence. It identified 12 relevant trials, 
including 1318 participants in total, and examined 
eight types of injectable material (Box 6) along with 
one dummy injection (saline).
One study comparing periurethral injection to 
dummy treatment with saline was terminated due 
to safety concerns, although early results had not 
indicated any significant difference in treatment 
effect prior to this.72 There were no relevant studies 
comparing periurethral injection to conservative 
management of urinary incontinence. However, 
in two studies comparing periurethral injection 
with surgery, surgery was reported to result in 
significantly greater improvement as measured 
by clinical observation. Comparisons between 
different types of agents used for periurethral 
injection suggested a variety of new agents to be as 
effective as collagen, and porcine dermal implant 
as effective as silicone, although confidence 
intervals (CIs) were wide and longer-term data 
were required. In general, approximately 50% 
of patients were satisfied in the short term (less 
than 1 year) after injection therapy. The review 
concluded that methodologically robust trials were 
needed, particularly with longer follow-up data 
and when using non-surgical treatments, such as 
PFMT, as comparators. Currently, the lack of useful 
BOX 6  Types of implants used for periurethral bulkinga
Currently available
Macroplastique™ – silicon particles
Durasphere™ – carbon particles
Contigen™ – glutaraldehyde cross-linked bovine 
collagen
Coaptite™ – calcium hydroxylappatite
Uryx™ – ethylene vinyl alcohol copolymer
Permacol™ – porcine dermal collagen
Experimental use
Silicon microballoons
Dextran copolymer
Alginate gels
Autologous chondrocytes
Autologous myoblasts
Discontinued
Autologous fat
Polytef™ – polytetrafluoroethylene
Zuidex™ – dextranomer/hyaluronic acid copolymer
a  Full details available from Keegan and colleagues 
(2007).71
high-quality evidence makes it difficult to draw 
conclusions regarding the place of periurethral 
injection therapy in the care pathway for women 
with SUI and it will not be used in the care 
pathways described in this review.
Surgery for SUI
Since the introduction of the first surgical 
procedure, anterior colporrhaphy with plication 
of the urethra by Kelly and Dumm in 1911,73 the 
number of different surgical procedures used 
to treat stress incontinence has grown to about 
100. They are covered by six published Cochrane 
reviews (Box 7).
The development of a novel theory of causation 
of SUI by Petros and Ulmsten79 has clarified the 
rationale for different surgeries. Older abdominal 
techniques, such as Burch colposuspension and 
pubovaginal sling insertion, aim to reduce mobility 
of the bladder neck and proximal urethra by 
providing fixation to the pubis. Newer techniques 
popularised by Ulmsten aim to increase support Background
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Procedures covered by published Cochrane 
reviews
Open Burch retropubic colposuspension – Lapitan 
and colleagues (2005)38
Laparoscopic colposuspension – Dean and colleagues 
(2006)74
Suburethral slings – Bezerra and colleagues (2005)75
Anterior colporrhaphy – Glazener and Cooper 
(2001)76
Needle urethral suspension – Glazener and Cooper 
(2004)77
Tension-free transvaginal tape (TVT) – Ogah and 
colleagues78
Tension-free transobturator vaginal tape (TVT-O) – 
Ogah and colleagues78
BOX 7  Current surgical procedures to treat stress urinary 
incontinence
to the mid-urethra, typically using a synthetic tape 
introduced through the vagina and fixed either 
suprapubically or in the obturator fossa without 
tension.80,81 These latter two procedures – TVT and 
TVT-O – are currently the most popular surgical 
techniques for treatment of SUI in women, having 
the advantages of a vaginal approach, minimally 
invasive insertion and a favourable adverse event 
profile.82 The procedures involve blind passage 
of a length of monofilament macroporous 
polypropylene tape to provide a ‘hammock’ 
for the mid-urethra. The tape is positioned 
without tension using specially designed curved 
needles through suprapubic (TVT) or medial 
groin (TVT-O) incisions, and an incision in the 
anterior vaginal wall beneath the mid-urethra. 
The procedure can be performed under local 
anaesthetic and sedation or, more usually, a general 
or regional anaesthetic, and can be accomplished 
within a 24-hour hospital stay. The TVT variant 
also requires cystoscopy to detect and correct 
bladder perforation. Burch colposuspension or 
pubovaginal sling insertion, on the other hand, 
are open surgical procedures requiring a formal 
suprapubic incision. They require a general 
anaesthetic and a 2- to 3-day hospital stay. The 
main risk of all such procedures is transient (10%) 
or permanent (1%) voiding difficulty requiring 
intermittent self-catheterisation. Surgical success 
rates after 1–5 years of follow-up vary between 51% 
and 87% for Burch colposuspension/pubovaginal 
sling and between 63% and 85% for TVT/TVT-O, 
according to definition of cure/improvement and 
length of follow-up.80
Setting
All procedures require an appropriately equipped 
hospital or clinic environment for safe surgical 
conduct. This will include a preoperative area, 
a fully equipped operating room and facilities 
for postoperative recovery. The newer minimally 
invasive procedures, such as TVT and TVT-O, can 
be carried out in an ambulatory care unit that is 
designed for stays of up to 24 hours.
Personnel
The procedures require staff for preoperative 
preparation, a surgical team including an 
anaesthetist and appropriately trained surgeon, 
and postoperative recovery staff. Staff and facilities 
to monitor residual urine and teach intermittent 
self-catheterisation when required are also needed.
Cost
UK National Health service reference costs54 
for TVT and TVT-O, classified as ‘lower genital 
tract minor procedures without complications’, 
are, on average (interquartile range), £1135 
(£741–1357) for inpatient treatment (mean stay 
of 2 days) and £629 (£456–828) for day-case 
treatment. Colposuspension classified as an ‘open 
bladder neck procedure in women’ has an average 
(interquartile range) cost of £1396 (£1011–2013) 
for inpatient treatment (mean stay of 2 days).54
Criteria for treatment
Women with incontinence who choose to seek 
clinician advice generally have more severe 
symptoms that are bothersome and therefore 
desire treatment to improve their continence and 
lessen the impact on their day-to-day life. It is 
the clinician’s responsibility to gather evidence of 
the severity, type and degree of bother suffered 
by the individual in order to suggest the most 
appropriate first-line treatment options for 
the patient to consider. Selection of the initial 
treatment is then negotiated according to patient 
choice, clinician opinion and local availability. 
Subsequent consultations will decide on the need 
for further trials of treatment if the initial outcome 
is unsatisfactory. This assessment requires the 
exclusion, by examination and simple testing, of 
complicating factors, such as relevant neurological 
dysfunction, impaired voiding, infection and pelvic DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
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organ prolapse. Those with modifiable lifestyle 
factors, such as high body mass index and smoking, 
should be encouraged and helped to address these 
either before, or concurrent with, more active 
treatment. The selection for active treatment then 
depends on the individual’s desire and motivation, 
the presence of comorbidity and local service 
availability.
For women with a predominant symptom of SUI, 
education about their pelvic floor anatomy and 
function, and supervised training to improve pelvic 
floor muscle function, are the most used first-line 
treatments in the UK. This may sometimes be 
augmented by transvaginal ES or BF techniques, 
including use of VCs. To benefit from these 
therapies, women require sufficient mobility, 
motivation and the ability to attend frequent 
therapy sessions. Following a trial of PFMT, the 
next step is likely to be referral to a specialist for 
consideration of surgery.
Most high-level evidence for the effectiveness of 
each of these treatments is based on randomised 
trials with set inclusion and exclusion criteria. It 
is uncertain how the results of these trials and 
meta-analysis of multiple trials relate to individual 
patients, particularly those who would not meet the 
inclusion criteria (Table 2).
TABLE 2  Summarised inclusion and exclusion criteria for interventions for stress urinary incontinence from studies included in relevant 
Cochrane reviews
Treatment Inclusion criteria Exclusion criteria
PFMT83 SUI
USI
More than two episodes of incontinence 
per week
18–75 years
Urinary tract infection
Incomplete voiding
Neurological disorders
Cognitive impairment
BT53 Age > 35
Urgency or MUI
DO (urodynamic diagnosis)
Previous surgery for incontinence
Neurological disease
Urinary tract infection
Predominant stress incontinence
Diabetes mellitus
Inability to reach toilet unaided
Duloxetine56 Age 30–80 years
SUI
USI
Pregnancy
Breastfeeding
Urinary tract infection
Arrhythmias or liver disease
Advanced pelvic organ prolapse
Continence surgery within 1 year
Prior hip fracture or replacement
Prior formal PFMT
Surgery38,74–77 SUI
USI
Age < 21 years
Age > 65 years
Non-ambulatory
Pregnancy
Current cancer treatment
Systemic disease affecting bladder function
Urethral diverticulum
Recent pelvic surgery
Grade III incontinence
DO
Urinary tract infection
Severe medical diseaseBackground
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Containment options
Methods for containment of urinary incontinence 
do not constitute a means of treatment and are 
therefore not included in the systematic review. 
It is acknowledged, however, that pads are widely 
used by women in all phases of management of 
their incontinence problem and that methods for 
urinary diversion form the ‘last resort’ for women 
with severe incontinence who cannot be treated, or 
have failed repeated attempts at curative treatment, 
typically following multiple surgical procedures. As 
such, the use of containment products is included 
in the economic evaluation as they form part of the 
care that a woman might receive over her lifetime.
Absorbent pads
The most commonly used method of incontinence 
management is absorbent pads. The total 
expenditure on such products is large and, 
although not altering the underlying condition, 
it can be a satisfactory option for women with 
minimal or predictable leakage, or for those who 
are unsuited to treatments or have failed to benefit 
from treatment. The products range from thin 
panty-liners to large nappy (diaper)-type pads. 
Despite their widespread use, little research has 
been conducted concerning patient satisfaction or 
effectiveness, although recent evidence summarised 
in a Cochrane review does suggest that specifically 
designed pant insert pads are superior to those 
designed for menstrual loss.84,85 Containment-using 
pads was also the subject of a previous UK Health 
Technology Assessment (HTA) monograph.86
Urinary diversion
Some women with severe intractable incontinence 
that has not responded to corrective methods 
of management may choose to undergo urinary 
diversion. The simplest method is transurethral 
or suprapubic insertion of an indwelling catheter, 
with continuous drainage into a collection bag. 
Summarised evidence regarding types of catheter 
and policies for their use has previously been 
published.87,88 Generally, indwelling catheters are 
unsuited for women with long life expectancy, 
who are often better served with a formal 
surgical urinary diversion procedure. This can 
be performed using an ileal conduit or continent 
diversion. The techniques, benefits and adverse 
events have been described in a Cochrane review.89DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
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Chapter 2  
Aims and objectives
T
he aim of this study was to estimate the 
effectiveness and cost-effectiveness of non-
surgical treatment for women with SUI.
The objectives are to:
•  develop a series of management pathways that 
describe potential sequence of non-surgical and 
surgical treatments for SUI
•  determine the clinical effectiveness of the 
different individual treatments for SUI
•  determine the safety in terms of the magnitude 
of any risks or side effects of treatments for SUI
•  estimate the cost-effectiveness of the alternative 
management pathways
•  identify areas for future research.
The remainder of the report is structured as 
follows:
•  Chapter 3 describes the definition of the 
decision problems and the patient treatment 
pathway.
•  Chapter 4 presents the results of a survey 
performed on women with SUI to identify the 
outcomes of importance to them.
•  Chapter 5 describes the methods used for 
reviewing clinical effectiveness and provides 
information on the inclusion and exclusion 
criteria, search methods for identification of 
studies, data collection and analysis.
•  Chapter 6 describes the studies included in the 
systematic review of clinical effectiveness.
•  Chapter 7 assesses the clinical effectiveness 
of the major treatments using direct pair-wise 
(head-to-head) comparisons.
•  Chapter 8 assesses the clinical effectiveness 
of the treatment using a mixed-treatment 
comparison (MTC) model.
•  Chapter 9 assesses the cost-effectiveness using 
an economic model; this chapter describes the 
basics of the modelling approach and the key 
assumptions underpinning the estimates of 
cost-effectiveness results.
•  Chapter 10 discusses the results of the study.
•  Chapter 11 is the conclusion, which highlights 
the implications of the findings for the NHS, 
women and research.DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
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T
he impact of SUI on individual women with 
the condition, their families and carers, and 
on the NHS, as a whole, is huge.43 There are 
many potential methods for treating SUI which 
might be used alone or as part of a management 
strategy. However, while there is some evidence of 
the relative effectiveness of individual treatments, 
there is a lack of evidence on how the various 
interventions might be combined into management 
strategies. We therefore sought to identify plausible 
treatment strategies comprising sequences of 
non-surgical and surgical interventions. The 
clinical pathways were based on advice from 
the health-care professionals and patient group 
representatives who were involved in the study on 
what interventions patients could receive and the 
sequencing of the interventions. Even though the 
focus of this study is on non-surgical treatments, 
surgery is considered, as it may form part of a 
treatment strategy. For example, it may be a viable 
alternative for some women seeking treatment for 
SUI. For other women, surgery may be resorted to 
if a non-surgical intervention fails to satisfactorily 
resolve symptoms.
The Agency for Healthcare Research and Quality 
(AHRQ)90 and the third International Consultation 
on Incontinence91 have published a comprehensive 
literature review and consensus opinion of 
treatment guidelines for therapeutic interventions 
for SUI (the AHRQ has declared its guidelines 
obsolete). It is generally accepted that there is no 
‘perfect’ therapy for all patients with SUI. Many 
factors should be considered when determining 
the optimal therapy for SUI in women. These 
include the aetiology and type of SUI, bladder 
capacity, renal function, sexual function, severity 
of the leakage and degree of bother to the patient, 
the presence of associated conditions – such as 
vaginal prolapse – or concurrent abdominal or 
pelvic pathology requiring surgical correction, 
prior abdominal and/or pelvic surgery, and, finally, 
willingness to accept the costs, risks, morbidity 
and success (or failure) rates associated with each 
intervention.
For most women with SUI it is sensible to 
discuss first the most reversible, simplest, least 
invasive and least expensive service-provider 
interventions, such as lifestyle changes and 
PFMT. The clinical consensus appears to be that 
the initial treatments for SUI involve a variety 
of non-surgical interventions, including lifestyle 
modification, PFMT with or without BF, and other 
accessory teaching aids, such as electronic devices 
and VCs. Further strategies can be formulated, 
which would consist of sequences of non-surgical 
and surgical interventions. These strategies will 
take into account the mechanism by which the 
treatment works and will also place limits on 
the number of retreatments allowed, based on 
current concepts of the use and effectiveness 
of the different procedures. More invasive or 
expensive interventions, such as surgery, are 
pursued if the clinician and patient decide that the 
current therapy is either ineffective or otherwise 
undesirable.
The importance of patient preference as the 
primary consideration in selecting a particular 
treatment for SUI was underlined by the findings 
of a recent survey which reported that most women 
preferred less invasive options.92,93 From a health 
service perspective it is important to balance 
short- and long-term effectiveness against the 
potential adverse events and costs. Compared with 
surgical treatments, non-surgical treatments, such 
as lifestyle changes and physical therapies (such as 
PFMT), are associated with limited side effects and 
do not preclude future changes in management. 
Hence, non-surgical procedures have been 
considered to be the choice of primary treatments 
for SUI.43 In developing the care pathways we 
have categorised treatments as being either non-
surgical or surgical procedures and then considered 
how these treatments might be combined into 
management strategies for women presenting with 
SUI. While it is true that the specific treatment 
strategy adopted will vary from woman to woman, 
broad exemplars of specific strategies can be 
defined. In the following sections, descriptions of 
possible management strategies of women with SUI 
are presented, which vary in terms of the type and 
sequences of treatments that might be offered.
Chapter 3  
Definition of the decision problemDefinition of the decision problem
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Descriptions of the patient 
treatment pathways
Figure 5 describes the treatment pathways that are 
compared within the economic model reported 
in Chapter 9. Potentially there are a very large 
number of alternative pathways that might be 
considered, and the pathways selected were 
derived following discussion with the health-
care professionals and patient representatives 
involved in this study. They represent plausible 
care pathways that women might follow and might 
also be used to infer the value of other potential 
pathways not otherwise considered.
Patient treatment pathway 1
Patient treatment pathway 1, in Figure 5, details 
one plausible strategy of care for a woman 
presenting with SUI. The first line of treatment 
that women presenting with SUI are offered is 
lifestyle modification. Lifestyle modification may 
involve a combination of one or more elements. 
These are dietary factors, reduction of caffeine 
intake, fluid intake, smoking, weight, physical 
exercise, alcohol consumption and limiting heavy 
activity (it may be possible that there are several 
ways lifestyle modifications can be performed so 
that they can be considered as different treatments, 
therefore allowing someone to get more than one 
lifestyle modification treatment). There are three 
states that could arise after treatment: ‘continent’, 
‘incontinent’ or ‘dead’ (from natural causes). The 
continent state includes women who report that 
they are completely cured and those that feel that 
their condition has improved to the extent that 
they require no further treatment at the present 
time. Women could remain continent and hence 
require no further treatment, but some of them 
may experience a return or worsening of symptoms 
of SUI at some point in the future and then require 
further treatment. The women who report that 
they are not cured are said to be in the incontinent 
state. These women could either require or not 
require further treatment. The women who require 
further treatment get the next treatment option 
in the pathway they are following. In the first 
care pathway, all of the women who need further 
treatment are offered the second line of treatment: 
physical therapy. There are different forms of 
physical therapies that women can receive. These 
include PFMT alone or in combination with an 
adjunct, such as BF, ES or VCs. Based on the 
number of sessions women receive, PFMT can be 
classed as ‘basic’, when a patient has a maximum 
of two sessions per month, or ‘PFMT with extra 
sessions’, when the patient receives more than two 
sessions per month. This pathway offers only basic 
PFMT without any adjunct. Women who are not 
cured and do not receive any further treatment 
may use containment products, such as pads, to 
manage symptoms.
If women are not cured after PFMT they progress 
to the third line of treatment, which is surgery. 
Those who are not cured and need further 
treatment are offered a second surgical procedure. 
If the second surgical procedure does not work 
then women use containment products until they 
die. It is appreciated that women may also use 
containment products even when they are receiving 
other possible interventions. Figure 6 provides a 
detailed description of pathway 1. Similar figures 
could have been developed for all of the other 
pathways.
Patient treatment pathway 2
The treatment pathway option 2 is similar to 
that depicted in option 1. The only difference 
is that PFMT with extra sessions is offered as an 
additional non-surgical treatment between basic 
PFMT and surgery.
Patient treatment pathway 3
Pathway 3 extends pathway 2 by adding a drug 
therapy (an SNRI) between PFMT with extra 
sessions and surgery.
Patient treatment pathway 4
The treatment pathway 4 is substantially the same 
as pathway 1. The difference is that women receive 
PFMT with extra sessions straight away, instead of 
PFMT basic.
Patient treatment pathway 5
Pathway 5 extends pathway 4 by adding SNRI 
therapy between PFMT extra sessions and surgery.
Patient treatment pathway 6
In this pathway women would, as in all other 
pathways, initially receive the relevant advice 
or treatment aimed at modifying lifestyle. If 
they experienced a recurrence, had insufficient 
improvement or no improvement, they would 
proceed straight to surgery. Such a strategy might 
be appropriate for some subgroups of women. 
Alternatively, it may be popular with some women 
because it gives the prospect of relatively rapid 
relief from symptoms.DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
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Patient treatment pathway 7
This treatment pathway is similar to pathway 1 
but with VCs as a treatment option between basic 
PFMT and surgery.
Patient treatment pathway 8
This treatment pathway is similar to pathway 1 but 
with ES as a treatment option between basic PFMT 
and surgery.
These patient care pathways will be used in the 
study to inform the economic model reported 
in Chapter 9. These pathways will also assist in 
identifying outcomes of interest for the systematic 
review of effectiveness and identify the data 
required to populate the model. The key outcome 
of these pathways is that any need for further 
treatment is heavily influenced by whether the 
prior treatment has resulted in sufficient resolution 
of symptoms.DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
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Introduction
It has been recognised for many years that 
the embarrassment associated with urinary 
incontinence may cause withdrawal from social 
situations and reduce quality of life.32 Many women 
with SUI show symptoms of depression and 
introverted behaviour, together with dysfunctional 
interpersonal relationships.33 Furthermore, SUI 
may lead to withdrawal from regular physical 
activities and hence impair women’s general 
health.34 One of the problems with the assessment 
of incontinence is that outcome measures 
frequently used in primary research may not 
perfectly map on to outcomes of importance to 
women. For example, the commonly reported 
outcome measure in clinical trials is ‘cure’, which 
is the satisfactory resolution (or near resolution) of 
symptoms. Using this definition usually means the 
patient self-report of the absence of incontinence. 
However, the ideal measure of how women are 
after treatment should reflect the ability to lead a 
normal social life, which may be compatible with 
improvements in the level of continence.
Given that much of the available literature focuses 
on clinical outcomes, which, as a result, may have 
limited relevance to the lives of women with SUI, 
the aim of this survey was to provide evidence on 
outcomes of importance to women.
The purpose of this work was to prospectively 
survey women with SUI to provide information on 
outcomes of importance to them; a secondary aim 
was to identify additional outcomes that ought to 
be collected in future primary studies and hence to 
define relevant outcomes for systematic reviews of 
the literature.
Methods
In order to identify the areas of importance to 
women who suffer from SUI, a questionnaire was 
designed. A Patient Generated Index (PGI)94 was 
used to allow respondents to state and evaluate 
the areas of their life affected by SUI. In addition 
to the PGI, the questionnaire included the King’s 
Health Questionnaire,95 the EQ-5D, and questions 
relating to socioeconomic and demographic 
information. The rationale for choosing the PGI 
was that as it is an individualised instrument – it 
would provide information on the specific concerns 
of women with SUI. In addition, these outcomes 
could then be compared with generic measures, 
such as the King’s Health Questionnaire and the 
EQ-5D.
The questionnaire
The PGI is an individualised patient-reported 
health instrument that allows the respondent 
to select, weight and rate the importance of a 
particular health outcome.96 The PGI was designed 
with the aim of producing a valid measure of 
outcome that reflected areas of importance to 
patients’ lives.94 The PGI involves the respondent 
deciding what factors are important to her. 
Examples of the types of factors that may be 
important are included to provide guidance. The 
aim of the PGI is therefore to capture the diverse 
range of concerns or priorities of respondents. 
Using the PGI, respondents can vary the weight 
they attach to these concerns or priorities, which 
provides researchers with an insight into each 
respondent’s viewpoint. An overall score for the 
PGI for each respondent can then be calculated by 
multiplying the rating for each health area by the 
proportion of points allocated to that particular 
area.
The PGI is completed in three stages. In the first 
stage, respondents are asked to identify up to five 
areas of their life that are affected by their SUI. 
Respondents are given a list of outcomes to act 
as prompts to help them think about which areas 
of their life might be affected by their condition. 
Respondents can then choose from these options or 
provide their own examples. In addition to the five 
boxes, there is a sixth box that enables respondents 
to rate all other areas of their life affected by their 
SUI. Examples of the factors to include as prompts 
on the PGI were drawn from three sources. The 
first of these was the King’s Health Questionnaire,95 
Chapter 4  
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which was used to generate a list of outcomes 
under the broad headings of: ‘role limitations’, 
‘physical limitations’, ‘social limitations’ and 
‘personal relationships and emotions’. These 
outcomes were supplemented from Cochrane 
reviews of non-surgical treatments.56,75,83,97 Finally, 
a general literature search was also conducted, 
although this did not provide further additions 
to the 17 different outcomes identified from the 
King’s Health Questionnaire and the Cochrane 
reviews. These outcomes were then narrowed 
down to broad categories of those considered most 
relevant by members of the project team. These 
were ‘work’, ‘household tasks’, ‘social activities’, 
‘feeling depressed/anxious’, ‘personal hygiene’ and 
‘affecting sleep’. In addition to the methods used 
to generate the prompt list, further qualitative 
work could have been conducted. This could have 
included a focus group of women with SUI to 
further refine the areas to include in the prompt 
list. This is an area that could be considered in 
future use of the PGI.
In stage two of the PGI, respondents were asked to 
score each area listed in stage one of the PGI on a 
scale ranging from 0 to 6. The score given in stage 
two was intended to reflect how the individual was 
affected by their SUI in the past month. A score of 
0 would signify that the effect on their life was as 
bad as it could possibly be and a score of 6 would 
correspond to an effect that was as good as it could 
possibly be.
Finally, in stage three, respondents were asked 
to ‘spend’ 10 points to indicate the relative 
importance of each of the areas mentioned in stage 
one. Respondents were requested to spend more 
points on areas that were the most important to 
them.
As noted above, in addition to the PGI, the 
questionnaire also contained the King’s Health 
Questionnaire and the EQ-5D. The King’s Health 
Questionnaire is a condition specific questionnaire 
that aims to assess the impact of urinary 
incontinence on an individual’s quality of life. It 
contains questions set in nine domains relating 
to: general health perception, incontinence 
impact, role limitations, physical limitations, social 
limitations, personal relationships, emotions, sleep 
and energy, and severity. With the exception of the 
final part of the questionnaire (severity measures) 
scores can be calculated for each domain (0–100). 
The higher the score the worse off an individual 
feels they are and the lower they perceive their 
quality of life to be.
The EQ-5D is a standardised instrument used to 
measure quality of life. The EQ-5D is applicable to 
a wide range of health conditions and treatments 
and it provides a simple descriptive profile and 
a single index value for health status.98 The EQ-
5D has five dimensions (mobility, self-care, usual 
activities, pain/discomfort and anxiety/depression) 
that can be converted into a utility score.
Sample
The Bladder and Bowel Foundation (formerly 
‘InContact’ and the ‘Continence Foundation’) 
is a national charity that provides information 
and support to people with bladder and bowel 
problems, representing the interests of people 
with continence problems with the aim of ensuring 
they have access to the latest information and 
services available.99 In 2006 a survey conducted by 
InContact was completed by 755 people affected 
by bladder and bowel problems.100 Of these, 188 
women with SUI gave consent for future contact 
about relevant research and formed the sample 
for the current study. In July 2007 these women 
were sent questionnaires for the current study 
by InContact. Given that this is a self-selected 
sample of women suffering from SUI and not a 
random sample of the population, it is not known 
how representative this sample is of the wider 
population.
Ethical issues
The 2006 survey in which the participants were 
originally identified was a service evaluation 
in which The Bladder and Bowel Foundation 
surveyed people who had previously been in touch 
with the charity. As such, no ethical approval was 
necessary. The 2006 survey materials contained 
an explicit assurance that confidentiality would be 
maintained and that identifiable data would not be 
passed on to third parties. Respondents were asked 
if they were willing to be contacted in the future for 
research purposes. For this study questionnaires 
were sent in July 2007 to 188 women with SUI who 
gave their consent for further contact relating to 
research. The questionnaires were returned directly 
to the charity and, after screening only anonymous 
data, were subsequently forwarded to the authors 
in accordance with the Medical Research Council’s 
guidance on the use of personal information in 
medical research and the Data Protection Act 
1998.101,102DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
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Theme/specific issue N %
Activities of daily living: work, home and social
Going out/socialisinga 58 13.7
Sleepa 47 11
Shoppinga 33 7.8
Physical activity 30 7.1
Worka 24 5.7
Travel 18 4.2
Going on holiday/staying away from home 12 2.8
Household tasks 10 2.4
Family activities 4 0.9
Travelling on public transport 1 0.2
Being housebound 1 0.2
Inability to study/write 1 0.2
Activities outside the home 1 0.2
Total 56.6
Sex, hygiene, lifestyle issues
Personal hygienea 53 12.5
Sexual relationships 10 2.4
Personal relationships 7 1.7
Sneezing/coughing/laughing 7 1.7
Affecting choice of clothes 6 1.4
Infections/skin irritations 4 0.9
Loss of independence 3 0.7
Limiting liquid intake 2 0.5
Theme/specific issue N %
Continually going to toilet when not 
necessary
1 0.2
Feeling cold 1 0.2
Worry about leaving wet stains 1 0.2
Total 22.4
Emotional health
Depressiona 32 7.5
Anxietya 24 5.7
Bladder controlling life 2 0.5
Embarrassment 2 0.5
Affecting confidence 1 0.2
Body image 1 0.2
Feeling unfeminine 1 0.2
It annoys me 1 0.2
Long-term effect it is having on me 1 0.2
Failure 1 0.2
Total 15.6
Services
Lack of public toilets 11 2.6
Need to use products/pads 8 1.9
Time spent at doctor’s surgery/hospital 3 0.7
Public queues 1 0.2
Total 5.4
Results
All data were analysed in spss version 17.0. 
Descriptive statistics and correlations of the sample 
were analysed and EQ-5D and PGI scores were 
calculated. In total, 105 out of 188 respondents 
(55.9%) completed and returned the questionnaire. 
Table 3 shows the areas of an individual’s life that 
they reported to be affected by their SUI, divided 
into four different themes. These themes were: (1) 
activities of daily living (work, home and social); 
(2) sex, hygiene and lifestyle issues; (3) emotional 
health; and (4) services. In total, 38 different areas 
were reported by respondents. Activities of daily 
living were the most frequently reported areas to 
be affected by SUI, followed by sex, hygiene and 
lifestyle issues and emotional health.
Out of 105 respondents, 73 respondents were 
categorised as having answered the PGI correctly. 
A further nine respondents made mistakes in the 
PGI and 23 respondents did not fully complete 
it (Table 4). Of the 73 respondents who correctly 
completed the questionnaire, 61 answered the 
PGI with no mistakes (all sections were completed 
satisfactorily). The remaining 12 respondents 
made a small error in completion of the PGI. This 
small error always occurred in section three of the 
PGI, where respondents had to spend 10 points. 
These respondents did in fact spend 10 points 
but they missed out spending points in area 6 
(all other areas of their life affected by SUI) and 
totalled to 10 in box 6. This error is likely to have 
occurred due to the layout of the PGI. An example 
of the PGI used can be seen in Appendix 1.
Table 5 shows the demographic information of the 
sample, as a whole and for those individuals who 
correctly and incorrectly completed the PGI. The 
mean age for the sample as a whole was 57 years 
TABLE 3  Area of life identified by respondents as being affected by stress urinary incontinence
a  Areas provided in prompt list in the PGI.Outcomes of importance to women with SUI
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TABLE 4  Patient Generated Index responses
Responses Frequency Percentage Notes
PGI answered correctly 73 69.5 PGI correct: 61
PGI put total in box 6: 12
Mistake in PGI 9 8.6
PGI not fully completed 23 21.9
Total 105 100.0
‘PGI answered correctly’, those respondents who had fully completed PGI (outcomes, scores and points); includes those 
who mistakenly totalled their points in box 6, but points summed to 10; ‘Mistake in PGI’, those respondents who fully 
competed the PGI but who did not sum to 10; ‘PGI not fully completed’, not all sections of the PGI were completed.
TABLE 5  Demographic and socioeconomic information
Variable Total sample (n = 105) Correct PGI (n = 73) Incorrect PGI (n = 32)
Mean age of respondents 
(range, years)
56.90 (28–89) 55.16 (28–89) 60.84 (37–87)
Age ranges (%)
25–34 3 (2) 3 (4) –
35–44 15 (14) 11 (15) 4 (13)
45–54 39 (37) 28 (38) 11 (35)
55–64 21 (20) 15 (21) 6 (19)
65–74 8 (8) 6 (8) 2 (6)
75+ 19 (18) 10 (14) 9 (28)
Income (valid %)
£6000 10 (11) 7 (11) 3 (11)
£6001–10,000 16 (17) 12 (19) 4 (15)
£10,001–15,000 20 (22) 11 (17) 9 (33)
£15,001–20,000 13 (14) 9 (14) 4 (15)
£20,001–25,000 5 (5) 3 (5) 2 (7)
£25,001–30,000 10 (11) 7 (11) 3 (11)
£30,001–35,000 8 (9) 6 (9) 2 (7)
£35,001+ 10 (11) 10 (15) –
Education (%)
None 2 (2) 1 (1) 1 (3)
Secondary school 39 (37) 22 (30) 17 (53)
College 29 (28) 21 (29) 8 (25)
University 35 (33) 29 (40) 6 (19)
(range 28–89). As can be seen in Table 5, those 
respondents who correctly completed the PGI were, 
on average, younger than those who completed 
it incorrectly. In addition, those who correctly 
completed the PGI appear to be better educated 
and in higher-income groups.
In addition to listing the outcomes of importance 
to women who suffer from SUI, a score of overall 
quality of life can also be calculated from the PGI. 
The score ranges from 0 to 6, with 0 reflecting 
a very low quality of life (‘it’s as bad as it could 
possibly be’) and 6 reflecting a very high quality 
of life (‘it’s as high as it could possibly be’). An DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
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example of the PGI and the method used to 
calculate the score is given in Table 6. For the 
respondents who successfully completed the 
PGI the mean score was 2.4 (SD 1.4, range 0–6). 
Given that a score of 6 on the PGI reflects the 
highest quality of life, a mean score of 2.4 in this 
population reflects that their quality of life falls 
significantly short of their hopes and expectations. 
In total, 101 out of 105 returned questionnaires 
had a fully completed EQ-5D. Scores on the EQ-5D 
ranged from –0.17 to 1. The mean EQ-5D score 
was 0.598 (SD 0.339). Correlation between the 
mean PGI score and the mean EQ-5D score was, as 
expected, positive and statistically significant.
Scores (out of 100) for each domain in the King’s 
Health Questionnaire can be seen in Table 7. The 
higher the score, the worse off an individual feels. 
In addition to the domains of the King’s Health 
Questionnaire, it also contains a section detailing 
the respondent’s bladder problems and how much 
they affect the individual’s life.
Correlations of the PGI and seven domains of the 
King’s Health Questionnaire were also performed. 
Given the scoring system of the King’s Health 
Questionnaire we would expect to find a negative 
correlation between the PGI and King’s Health 
Questionnaire. All correlations were negative but 
only two were statistically significant: personal 
relationships (p = 0.004) and severity measures 
(p = 0.003).
In addition, correlations between the EQ-5D 
score and the domains of the King’s Health 
Questionnaire were also calculated. We found all 
seven of the King’s Health Questionnaire domains 
to be significantly (negatively) correlated with the 
EQ-5D. This result is to be expected, as many 
of the EQ-5D and King’s Health Questionnaire 
domains are similar.
Summary
The PGI has been used to quantify the effect of 
SUI on the quality of women’s lives for the first 
time. In stage one of the PGI, 38 different areas of 
a woman’s life affected by SUI were reported. The 
most frequently mentioned areas were: going out 
or socialising, with 14% of all respondents listing 
this as one of the areas of their life affected by their 
condition; personal hygiene (13%); and the effect 
their condition has on their sleep (11%). Shopping 
(8%), depression (8%), physical activity (6%), work 
(6%), anxiety (6%), travel (4%), household tasks 
(2%), personal (1%) and sexual relationships (2%) 
were all also listed as areas of their life affected by 
SUI.
The respondents are a self-selected sample of 
women who had previously been in touch with a 
patient support charity and who may be considered 
to be active help-seekers. However, there is no 
reason to suspect that their experience of SUI 
and the relative perceived impact of SUI on 
various aspects of their lives are different from 
the wider population of women affected. Nearly 
70% of respondents successfully completed the 
questionnaire. A further 9% attempted the PGI 
but made mistakes in its completion, and 22% 
failed to fully complete the PGI (the majority of 
these respondents completed stage one of the 
PGI but failed to complete stages two or three). 
Those respondents who successfully completed 
the questionnaire were found to be younger, in 
TABLE 6  Example of Patient Generated Index scoring
Part 1: list areas of life affected by 
urinary incontinence
Part 2:  
score (0–6)
Part 3: spend your  
10 points Final PGI score
1. Interrupted sleep 1 3 0.3
2. Affects my social life 6 1 0.6
3. Affects my work 3 2 0.6
4. Personal relationships 2 2 0.4
5. It makes me feel depressed 4 1 0.4
6. All other areas of your life affected by 
your urinary incontinence
5 1 0.5
Total 2.8
Notes: [1 × 3/10] + [6 × 1/10] + [3 × 2/10] + [2 × 2/10] + [4 × 1/10] + [5 × 1/10] = 2.8.Outcomes of importance to women with SUI
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TABLE 7  King’s Health Questionnaire – descriptive statistics
N Minimum Maximum Mean SD
KHQ scores for role limitation 101 0.00 100.00 53.30 30.64
KHQ physical limitation scores 100 0.00 100.00 61.83 30.09
KHQ social limitation 95 0.00 100.00 45.61 30.98
KHQ score for personal relationships 73 0.00 100.00 37.90 35.92
KHQ score for emotions 98 0.00 100.00 60.32 31.67
Sleep energy 100 0.00 100.00 60.67 31.02
Severity measures 98 6.67 100.00 68.50 22.55
KHQ, King’s Health Questionnaire.
higher-income groups and to have a higher level 
of education. For the PGI to be used as a valid 
and reliable measure of outcomes of importance 
to women with SUI and to be able to accurately 
quantify the effect of SUI on their lives, the 
response rate and successful completion of the PGI 
would need to be improved. Of the respondents, 
31% had difficulty in completing the questionnaire 
and there was also a low response rate to the survey 
in general (56%).
In order to improve this response rate and the 
chance of successful completion, alterations could 
be made to the layout of the PGI to make it more 
user-friendly. The PGI, or instruments like it, have 
been criticised in the past. Some authors question 
whether they reflect the patient’s view point or, 
conversely, whether they are simply reflecting 
the views of the researchers who designed the 
questionnaire.103 In this survey, while we did find a 
varied response in the number of outcomes listed 
by respondents, the majority of these did in fact 
come from the prompt list provided in the PGI. Of 
the 10 most mentioned areas, eight of these were 
from the prompt list. Other studies have found 
similar associations between the prompt list and 
final outcomes listed by respondents. However, it is 
unclear whether this association is due to the most 
relevant examples being selected from the prompt 
list, or due to respondents being unwilling or 
unable to think of their own examples because the 
prompt list is already comprehensive.104
We correlated the mean PGI score with the mean 
EQ-5D scores. This correlation was, as expected, 
found to be positive and statistically significant. 
In addition to this, correlations between the 
King’s Health Questionnaire and the PGI were 
performed. Although all correlations of the PGI 
and King’s Health Questionnaire were as expected 
(negative), only two were found to be statistically 
significant. Given that the PGI outcomes and the 
domains of the King’s Health Questionnaire do 
not correlate well, and that many of the aspects 
respondents mentioned in the PGI list of outcomes 
do not map very well on to the dimensions of the 
EQ-5D, this might suggest that generic measures, 
like the EQ-5D, may not be a very good reflection 
of the preferences of people with incontinence. The 
PGI in this instance may therefore be capturing 
concerns of women who suffer from SUI which are 
not adequately captured by generic instruments, 
such as the EQ-5D. This is of particular interest in 
the context of health technology appraisals such 
as this, where EQ-5D has become the accepted 
standard for calculation of quality-adjusted life-
year (QALY) indices for use in determination of 
cost-effectiveness.105 As will be described in later 
chapters, health-state utilities derived from the 
EQ-5D have been used to estimate QALYs in 
the economic evaluation. Hence, in the light of 
findings reported in this chapter, evidence on 
cost-effectiveness of interventions needs careful 
consideration.
Conclusion
Much of the available literature on SUI focuses 
on doctor-selected clinical outcomes. Given the 
undoubted social and personal impact of SUI, 
these outcomes may have limited relevance to the 
women who suffer this condition. Thirty-eight 
different areas of an individual’s life affected by 
SUI were identified by the PGI. The PGI succeeded 
in capturing a diverse range of outcomes of 
importance to women suffering from SUI, although 
some respondents found the PGI difficult to 
complete.DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
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The PGI was not found to correlate well with the 
domains of the King’s Health Questionnaire, nor 
to map well on to the dimensions of the EQ-5D or 
the King’s Health Questionnaire. This suggests that 
generic measures may not be a very good reflection 
of the preferences of people with incontinence.
Ideally, the information obtained from this survey 
would be used to help define outcome measures 
for the systematic review of clinical effectiveness. 
However, these outcomes were often not considered 
in primary studies and hence their inclusion in a 
systematic review was not possible. Nevertheless, 
it would be important to include them in future 
research in this area.DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
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T
he next four chapters present the systematic 
review of clinical effectiveness. This includes 
the review methods (this chapter), characteristics 
of the included studies (Chapter 6), direct head-to-
head comparisons (Chapter 7), followed by MTC 
models (Chapter 8).
Inclusion and exclusion 
criteria
Types of studies
The types of studies considered were RCTs and 
quasi-RCTs (alternate allocation). Trial data 
reported in conference abstracts, as well as full-text 
papers, were included. For abstracts, solely those 
identified from the Cochrane Incontinence Group 
Specialised Register of trials were used.
Types of participants
The participants were women with SUI or 
incontinence that was predominantly SUI (however 
diagnosed). Classification of diagnoses was 
accepted as defined by the trialists.
Owing to the small number of studies per 
intervention available, a pragmatic decision was 
made to include studies where the majority (≥ 50%) 
of the sample consisted of women with SUI or 
predominant SUI. Studies were therefore included 
if:
•  all women had SUI alone (type-1 population)
•  at least 50% of women had SUI alone; the 
remainder could have UUI or MUI (type-2 
population)
•  under 50% of women had stress incontinence 
alone but the majority (50% or more) had MUI 
with stress symptoms as a predominant pattern; 
the remainder could have SUI, UUI or MUI 
(type-3 population).
Studies were excluded if the proportion of women 
with predominantly SUI was not reported, if the 
type of incontinence (stress, urge, mixed) was 
unknown or undiagnosed, or if predominant 
symptoms (stress or urgency) of women with MUI 
were not specified.
Women with urinary incontinence whose symptoms 
might be due to significant factors outside 
the urinary tract were excluded, for example 
neurological disorders, cognitive impairment, and 
lack of independent mobility. Studies investigating 
nocturnal enuresis in women were also excluded.
Incontinent women during pregnancy or in the 
early postpartum period were considered for 
inclusion. Data from these childbearing women 
were analysed separately on the assumption that 
the effect of PFMT might differ in this group due 
to the physiological changes of pregnancy and 
in the postpartum period. Studies investigating 
prevention of incontinence among childbearing 
women were excluded.
Studies that recruited mixed populations of 
men and women with different types of urinary 
incontinence were eligible for inclusion, providing 
that demographic and outcome data were reported 
separately for women with predominantly SUI.
Types of interventions
We defined non-surgical treatment as that which 
could be undertaken in a heath-care professional’s 
office or clinic and patients’ homes. Any of the 
following interventions, alone or in combination, 
were included. Treatment definitions used were as 
according to Cochrane Reviews where possible.
Lifestyle interventions
•  Weight loss, decreased physical exertion, fluid 
manipulation, decreased caffeine, nicotine or 
alcohol consumption, treatment of constipation 
and dietary interventions.106
Physical or behavioural therapy
•  Pelvic floor muscle training, with or without 
biofeedback – defined as ‘a programme 
of repeated voluntary pelvic floor muscle 
contractions taught and supervised by a 
health care professional’.83 This includes ‘The 
Knack’, the use of a timed contraction of 
the pelvic floor muscles before and during a 
cough (Miller 1998).107 However, it excludes 
PFMT introduced by a leaflet only, without 
any contact with a health-care professional 
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(which was classified as being equivalent to no 
treatment).
•  Electrical stimulation (non-implanted) – local 
stimulation of pelvic floor muscles. Electrical 
nerve stimulation (e.g. sacral nerve) was 
excluded.
•  Weighted vaginal cones.
•  Bladder training, either described by trialists as 
bladder training, bladder retraining, bladder 
drill or bladder re-education or an intervention 
‘which included mandatory schedule or self 
schedule with the aim of increasing the interval 
between voids’.53 Prompted or timed voiding 
or urge suppression techniques alone with 
no mention of mandatory schedule or self-
schedule were not considered as BT.
Pharmacotherapy
•  SNRIs.
•  Local administration (in form of cream or 
pessaries) of intravaginal low-dose estrogens, 
given as an adjunct to other therapy (e.g. 
PFMT) in postmenopausal women. Hormonal 
treatment (estrogens) given on its own was 
excluded.
Trials comparing methods of delivering services 
(e.g. nurse-led care) were considered for inclusion 
if they involved one of the included interventions 
listed above. The use of non-surgical therapies 
for prevention of incontinence was excluded. 
Complementary therapies, such as acupuncture, 
hypnosis and herbal medicines, were also excluded.
Where studies reported a comparison involving 
a programme of interventions (e.g. PFMT plus 
BT), then these studies were included, provided 
that every participant in the intervention arm 
received all of the specified treatments. If, on the 
other hand, treatments were tailored according to 
participants’ diagnosis (e.g. PFMT for participants 
with stress incontinence alone and PFMT plus BT 
for participants with mixed or urge incontinence) 
and some participants did not receive all 
components available, studies were excluded, as it 
was not possible to distinguish effects of individual 
treatments for SUI.
A valid comparator was one of the included 
interventions or no treatment. Studies that 
compared non-surgical with surgical interventions 
were included in order to enable the performance 
of MTCs of non-surgical treatment. However, 
studies were excluded if the comparator was an 
excluded intervention (e.g. PFMT vs adrenergic 
agonists).
Types of outcome measures
The standardisation committee of the International 
Continence Society recommended that research 
investigating the effect of therapeutic interventions 
for urinary incontinence in adult women 
should incorporate outcome measurements in 
the following five domains: (1) the patient’s 
observations (symptoms); (2) quantification of 
symptoms (e.g. urine loss); (3) the clinician’s 
observations (anatomical or functional); (4) 
quality of life; and (5) socioeconomic measures.108 
Following this recommendation, the following 
measures of outcomes were sought in this review:
Primary outcomes
•  Number of women cured.
•  Number of women cured or improved (this 
outcome is henceforth referred to in the text as 
improvement).
•  Adverse events.
•  Condition-specific (and generic measures of 
health-related) quality of life.
Secondary outcomes
•  Quantification of symptoms:
  – number of incontinent episodes over 
24 hours
  – number of pad changes over 24 hours
  – mean volume or weight of urine loss on 
pad test
  – number of micturitions over 24 hours.
•  Participant satisfaction or desire for further 
treatment.
•  Long-term data:
  – number of women having incontinence 
surgery
  – return of symptoms/recurrence.
•  Socioeconomic measures.
•  Other intermediate, explanatory or treatment-
specific outcomes:
  – measure of pelvic floor muscle function
  – treatment adherence
  – volume and type of fluid intake or change 
in body mass index.
The cure and improvement rate may be ascertained 
via women’s observation (self-report), quantification 
of symptoms (typically based on incontinence 
diaries or pad tests) or clinician’s observation. 
There was a considerable variability in the way 
these outcomes were defined by the trialists, which 
limited the possibilities for quantitative synthesis. 
We therefore chose to combine data on the cure 
and improvement rate from different sources. The 
women’s observation was given priority but for 
studies in which it was not reported, the rate based DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
33
on diaries was used as a proxy. Where diary data 
were also not reported, the rate based on pad tests 
or any other definitions chosen by the trialists was 
used.
The choice of quality of life measures again varied 
across studies. In addition, scores were reported 
either as final values or changes from baseline. 
Final values were preferred, but where these were 
not reported, a change score was used. Quantitative 
synthesis was performed separately for final values 
and change scores.
Search methods for 
identification of studies
Literature searching was performed in two stages. 
First, relevant trials were identified from the 
Cochrane Incontinence Group Specialised Register 
of controlled trials of interventions for urinary 
incontinence (last searched 20 March 2008). 
When last searched for this project, the Register 
contained trials identified from: MEDLINE 
(covering January 1966 to week 4 of January 2008), 
the Cochrane Central Register of Controlled Trials 
(CENTRAL) (Issue 1, 2008), CINAHL (covering 
January 1982 to December 2000), and from 
hand searching relevant journals and conference 
proceedings.
Second, an extensive electronic search was carried 
out to identify reports of relevant published 
and ongoing studies, as well as grey literature 
and recent meeting abstracts from sources that 
are not currently covered for the Cochrane 
Incontinence Group Specialised Register of trials. 
A highly sensitive search strategy based upon the 
one developed for the Cochrane Incontinence 
Review Group was adopted.109 This strategy used 
controlled vocabulary and text word terms that 
reflected the clinical condition, interventional 
procedures and study designs that were considered 
within the scope of this project. The following 
additional databases were searched:
•  CINAHL (January 1982 to week 1 of December 
2007)
•  EMBASE (January 1980 to week 49 2007)
•  BIOSIS (January 1985 to 13 March 2008)
•  Science Citation Index and Social Science 
Citation Index (1970 to 2 February 2008)
•  Current Controlled Trials (searched on 29 May 
2008)
•  ClinicalTrials.gov (searched on 9 June 2008)
•  UKCRN Portfolio Database (replaces UK 
National Research Register).
An Internet search included the websites of relevant 
professional organisations and manufacturers that 
had not been covered by the Specialised Register 
or the other bibliographic database searches. No 
language or date restrictions were applied to the 
searches.
Searches were run for the intervention areas listed 
above on each of the databases listed. The main 
searches were run during September to November 
2007, with updates in December 2007/January–
February 2008. A set of urinary incontinence terms 
was combined with a set of terms to cover the 
main interventions listed above. These terms were 
combined with a study design filter as appropriate 
for each database. InterTasc website design filters 
were assessed and adapted if suitable.110 Full 
details of the search strategies used are provided in 
Appendix 2.
Data collection and analysis
Selection of studies
The titles and abstracts identified by the searches 
were assessed by one reviewer, having already been 
assessed by the Cochrane Incontinence Group 
Trials Search Co-ordinator. Full-text copies of all 
potentially relevant reports were obtained and 
independently assessed by two reviewers, using 
a form developed to determine whether the 
reports met the inclusion criteria (Appendix 3). 
Any disagreements were resolved by consensus or 
arbitration by a third person.
Data extraction
A data extraction form was developed to record 
details of study design, methods, participants, 
interventions and outcomes (Appendix 4). One 
reviewer extracted data and another reviewer 
checked the extracted data. Any disagreements that 
could not be resolved by discussion were referred to 
an arbiter.
For studies in which the majority of participants 
had stress incontinence alone (types 1 and 2 
above), data were extracted for both primary and 
secondary outcomes. For studies where stress-
predominant MUI was the majority (type 3) and 
studies of childbearing women, data were extracted 
for primary outcomes only. General background Methods for reviewing clinical effectiveness
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and methodological information was collected from 
all studies.
Assessment of risk of bias in 
included studies
Two reviewers independently assessed all of the 
studies that met selection criteria for potential 
risk of bias. The assessment used the adapted 
version of a checklist developed by the Cochrane 
Incontinence Group (Appendix 5).109
Data synthesis
Data analysis was performed in two stages: (1) 
pairwise (head-to-head) comparison (Chapter 7), 
and (2) a mixed-treatments comparison (Chapter 
8).
Pairwise comparisons
For trials with multiple publications, only the most 
up-to-date or complete data for each outcome 
were included. Overall, there was inconsistency in 
outcome measures chosen by the trialists. For this 
reason, quantitative synthesis was performed on 
primary outcomes only. A random effects model 
was used to derive summary estimates with 95% CI 
of odds ratio (OR) for dichotomous variables (cure 
and improvement rates) and standardised mean 
difference (SMD) for continuous variables (quality-
of-life measures). The random effects model was 
chosen because of variability in the characteristics 
of included studies in terms of participants’ 
diagnoses (inclusion of women with stress, urge or 
mixed incontinence), variation in the treatment 
programmes, and the frequency and duration of 
treatment. Odds ratios were used because of their 
symmetry compared with relative risks and were 
therefore unaffected by outcome definitions (e.g. 
number of women cured or not cured). Odds ratios 
were also chosen to fulfil a requirement of the MTC 
model.
Publication bias was not formally assessed in the 
analysis, as the number of studies available for 
each comparison was very limited. Heterogeneity 
between studies was assessed by visual inspection 
of plots of the data, the chi-squared test for 
heterogeneity and the I2 statistic.111 Possible 
reasons for heterogeneity were explored, such 
as differences in the populations studied, the 
treatment given or the way in which the outcomes 
were assessed. Studies were grouped and sorted 
by types of participants: studies solely comprising 
women with SUI alone (type 1), studies where the 
majority of participants (50% or more) had stress 
incontinence alone (type 2) and studies where the 
majority (50% or more) of participants had MUI 
with stress as the predominant pattern (type 3). 
Where a quantitative synthesis was considered to 
be inappropriate or not feasible, then a narrative 
synthesis of the results was provided. Analysis was 
performed in stata.112
The duration of treatment varied between 
studies. No attempt was made to standardise 
the treatment duration. Data at the end of the 
prescribed treatment phase, or at the first outcome 
assessment, if later, were used in quantitative 
synthesis. This may mean that any treatment 
effects shown were measured when they may be 
considered to be showing the maximum effects. 
Data from further follow-ups after the end of the 
initial treatment phase are reported in the text but 
are not included in the meta-analysis.
Data from primary studies were often reported 
ambiguously, particularly the number of people 
contributing data for an outcome (i.e. there were 
problems caused by missing data). For example, 
some studies had reported percentages without 
reference to an actual number of participants, or 
where studies claimed to have used an ‘intention-
to-treat’ method but this was not clearly described. 
Where possible, we used the number of participants 
with available outcome data as the denominator 
for the relevant time point (i.e. we did not make 
the assumption that all participants who dropped 
out ‘failed’ and were not cured). We did consider 
the reasons for missing data caused by withdrawal/
dropout reported by the trialists and these are 
highlighted (Chapter 7) where these appear to be 
treatment related. This is particularly problematic 
where there is differential withdrawal between trial 
arms.
Further analysis was planned on the following 
patient subgroups:
•  nature of presentation – postpartum (within 
12 months of childbirth) versus at any other 
time
•  nature of the incontinence – stress urinary 
incontinence alone versus mixed/any urinary 
incontinence
•  presence or absence of a co-existing anterior 
vaginal wall prolapse.
In the event this was not performed due to a lack of 
available data.DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
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Mixed-treatment comparison
This review aimed to assess the effectiveness of 
several treatments for SUI. With direct, head-
to-head, comparisons alone it is often not clear 
which treatment is the most effective.113 Multiple 
treatment comparison models attempt to address 
this problem by analysing all of the treatments and 
all of the trials together in one single model. In 
such a model it is possible to estimate the OR of 
all pairs of treatments, using direct and indirect 
evidence.
Multiple treatment comparison models were used 
for key treatments and outcomes (i.e. cure and 
improvement rates). The models were evaluated 
using Bayesian methods within winbugs software.114 
A full description is given in Chapter 8.DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
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Results of the search
Number of studies identified
The results of the initial searches are summarised 
in Table 8. These results were then assessed for 
potential relevance to the project and to remove 
duplicates already present in the Specialised 
Register that could not be removed by reference 
manager duplicate checking. As described above, 
the numbers retrieved for CINAHL, EMBASE, 
BIOSIS and Science Citation Index include only 
the additional reports identified after excluding 
those identified in the Cochrane Incontinence 
Register. A total of 7103 titles and abstracts were 
identified, of which 378 were selected for full 
assessment.
Number and type of studies 
included
Of the papers selected for full text assessment 
the level of agreement between reviewers about 
whether a paper met the inclusion criteria was 
very high, and 176 papers from the search met the 
inclusion criteria for the review. These described 88 
studies, which covered 37 distinct treatments (Table 
9) and 68 treatment comparisons (Table 10). The 
list of included studies and associated references 
are listed in Appendix 6.
Excluded studies, with reasons 
for specific exclusions
A total of 199 papers were obtained but did not 
meet the inclusion criteria (Figure 7). Of these, 
113 were excluded on the basis of study design, 
populations, interventions or outcomes. A further 
86 papers (describing 56 studies) that did include 
relevant populations or interventions as part of 
the study were retained for further assessment 
and subsequently excluded through the consensus 
within the research team that it was impossible 
to attribute an effect to a particular intervention 
for women with SUI. Reasons for exclusions for 
the 86 papers excluded on further assessment are 
described in more detail in Appendix 7.
Ongoing studies
A list of ongoing trials is provided in Appendix 8.
Risk of bias in included 
studies
A summary of the assessment of risk of bias for the 
88 included RCTs is presented in Table 11, and a 
detailed assessment for each of the included studies 
is reported in Appendix 9.
Fourteen studies (15.9%) reported both adequate 
random allocation sequence generation and 
concealment.57,115,117,129,137,139–141,143,144,164,181,182,199 A 
further two studies reported adequate allocation 
concealment, although the method of allocation 
sequence generation was not clear.133,153 Five 
studies reported inadequate methods of sequence 
generation and allocation concealment, namely 
consecutive/alternate assignment,157,162,190 
assignment based on hospital casenote number116 
or assignment based on time of arrival at the 
clinic and severity of incontinence.127 Allocation 
concealment was also considered to be suboptimal 
(sealed envelopes with no indication of third party 
involvement) in a further five studies.120,147,150,172,183 
The remainder (n = 47, 53.4%) did not describe 
the methods used in sufficient detail to assess 
proneness to selection bias related to random 
allocation sequence generation and concealment.
The majority of studies did not clearly stipulate 
whether participants, health-care providers or 
outcome assessors were ‘blinded’ to participants’ 
treatment status. For example, some studies 
would state ‘double blind’ but would not detail 
whether this referred to participants, health-care 
providers or outcome assessors. In addition, for 
some treatments (e.g. PFMT) it was not considered 
feasible to blind the health-care providers or 
participants to group allocation.
Nevertheless, 19 studies (21.6%) reported 
participant blinding.57,117,128,130–134,136–145,189 Twelve 
of these involved drug therapy and used a placebo 
to blind participants.57,117,136–145 In the other seven 
studies, participants were blinded through sham 
ES,130–134,189 or imitation or placebo PFMT.57,128 Six 
studies (6.8%) reported that health-care providers 
were blinded.57,133,140,144,183,189 However, in one of 
these, which was a four-arm trial comparing drug 
therapy with active or imitation PFMT versus 
PFMT with active or placebo drug,57 blinding 
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TABLE 8  Search results – numbers of hits retrieved
Database Number of hits
Number of full 
text papers 
selected for 
assessment
Number of 
reports included 
in final review
Published reports
Cochrane SR 645 (date of last search: 20 March 2008) 322 175
CINAHL 1115 (date of last search: 5 February 2008) 4 0
EMBASE  1031 (date of last search: 10 December 2007) 23 0
BIOSIS 204 (date of last search: 13 March 2008) 9 3a
SCI, SSCI 3228 (date of last search: 6 February 2008) 5 1b
Eli Lilly website 15 (date of last search: 29 May 2008) 15 0
Subtotal 6238 378 179
Ongoing trial list
UKCRN Portfolio 
Databasec
34 (date of last search: 9 June 2008) NA NA
CCT 549 (date of last search: 29 May 2008) NA NA
ClinicalTrials 282 (date of last search: 9 June 2008) NA NA
Subtotal 865
Total 7013 378 179
CCT, Current Controlled Trials; Cochrane SR, Cochrane Incontinence Group Specialised Register of trials; NA, not 
applicable; SCI, Science Citation Index; SSCI, Social Science Citation Index.
a  EAU conference abstracts – 12 reports of this trial had already been identified in the SR (Bø and colleagues, 1990)115 
and full text reports of these trials had already been identified in the SR.116,117
b  This was a new trial but also picked up by SR MEDLINE search shortly after – related to timing of searches.118
c  Replaces National Research Register.
was only possible for the drug treatment aspect 
of the study and not for PFMT. Blinded outcome 
assessment should be possible but only 17 studies 
(19.3%) reported that this was done.115,121,122,127,
128,130,131,133,134,147,153,163,164,166,182,189,199 Based on the 
available information on blinding, the majority of 
studies may be considered to be at modest risk of 
performance and detection bias.
While no study reported that groups had been 
treated differently in any other way apart from 
the named intervention, in two studies140,181 it was 
doubtful whether groups had been treated the 
same in all other ways. In one of these studies 
this was due to a large proportion of participants 
in one arm opting out of the allocated treatment 
(weighted VCs) and receiving the comparator 
treatment (PFMT).181 In the other, participants 
randomised to drug therapy were permitted to 
reduce their dosage, suspend their treatment or 
augment it with other treatments.140
Thirty-three studies (37.5%) stated numbers 
and reasons for withdrawals in sufficient 
detail,57,115–118,123,127,128,131,133,134,137–140,143,146,147,153,156,159,
164,166,167,175,178,181,183,187,189,197–199 while another 
33 studies (37.5%) stated the number of 
withdrawals but did not describe reasons for 
withdrawals.107,119,121,122,129,130,132,135,141,142,144,145,150,152,154,
155,162,163,165,168,172,176,179,180,184,185,188,190–193,196 The 
remaining 22 studies (25.0%) did not provide 
sufficient information about withdrawals, dropouts 
and those lost to follow-up.
The majority of studies (52.3%) failed to report 
results for everyone who entered into the 
trial,57,115–119,122,124,129–133,135,137–141,143–145,150,152,154,156,159,162,
164,166–168,176,178,180,183,185,187–190,196–199 while in 24 
studies (27.3%), it was unclear whether results 
accounted for all participants originally 
randomised.107,120,121,134,136,142,148,153,157,158,160,161,165,169–174,
179,186,193–195 Few studies explicitly stated that 
participants were analysed in the groups that 
they had been originally allocated to but no study 
showed clear evidence that this was not done.DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
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TABLE 9  Included interventions with available data
Type of interventions
NT
PFMT
PFMT + BF
ES
VC
BT
SNRI 80 mg
SNRI 40 mg
SNRI 30 mg
SNRI 20 mg
SNRI 40 mg b.i.d., starting with 40 mg b.i.d. 
SNRI 40 mg b.i.d., starting with 40 mg q.d. 
SNRI 40 mg b.i.d., starting with 20 mg b.i.d. 
PFMT + ES
PFMT + VC
PFMT + BF + BT
PFMT + SNRI
PFMT with additional sessions
PFMT with audiocassette
Strength and motor relearning PFMT
Motor relearning PFMT
PFMT in supine position
PFMT in supine and upright position
Modified pilates
PFMT (maximal contraction) + BF
PFMT (submaximal contraction) + BF
PFMT + urethral electrical conductance
PFMT + BF (vaginal)
PFMT + BF (vaginal and abdominal)
PFMT + BF + ES (faradism)
PFMT + BF + ES (IFT)
PFMT+BF + ES (maximal intensity at clinic)
PFMT + BF + ES (low intensity at home)
VC passive
VC active
PFMT + VC + BF
Surgery
b.i.d., twice daily; IFT, inferential therapy; NT, no 
treatment; q.d., once daily.
Characteristics of included 
studies
The sample size ranged from 11 to 683, with a total 
of 9721 participants.139,166 This includes 9163 non-
childbearing women and 558 childbearing women 
(Table 12). A large proportion of the participants 
(n = 4197) came from 11 pharmaceutical 
trials comparing SNRI with placebo. Trials of 
physical or behavioural interventions for non-
childbearing women were generally small; only 
four trials57,123,129,183 had 200 or more participants 
and this included one trial57 comparing PFMT 
with SNRI. Participants’ baseline characteristics 
are provided in Appendix 10. A brief summary 
of the baseline characteristics of the participants 
in the included studies, such as mean age, is 
also provided in Chapter 7, although it was not 
possible to summarise severity of incontinence 
of the participants in the included studies in any 
meaningful way because this was reported using 
diverse measures.
The main characteristics of active treatments are 
summarised in Appendices 11–15. The majority 
of included studies involved PFMT as part of their 
interventions. The PFMT programme that was 
used varied in a number of ways: for example, 
whether a correct pelvic floor muscle contraction 
was confirmed prior to training, the frequency and 
type (e.g. strength and endurance) of contractions 
performed per day, the duration of training, the 
number of clinic sessions provided and whether 
training was provided individually or in groups. 
Advice on lifestyle change or strategies for 
symptoms of urge and/or frequency may also be 
given. However, without any structured regimen, 
such advice was considered as part of a broad 
PFMT programme and not a separate treatment.
Biofeedback may also be provided for the purpose 
of teaching a voluntary pelvic muscle floor 
contraction. A single episode of BF in the initial 
teaching but not thereafter was similarly considered 
as part of a broad PFMT programme. This 
excludes BF that was used repeatedly to monitor or 
assist PFMT, which was classified separately as an 
adjunct treatment (PFMT with BF). An intravaginal 
device is also included in the BF comparison.
While it is likely that the success or otherwise of 
PFMT may be contingent on the level of intensity 
of the training programme, characterising 
or categorising PFMT is difficult. We chose 
supervisory intensity (the frequency of clinic 
visits or any face-to-face contacts with health-care 
professionals) as a crude measure of differentiating 
PFMT programmes. The current guidelines43 of 
the National Institute for Health and Clinical 
Excellence (NICE) estimated from the Guidance 
Development Group members that four to eight 
sessions were typically offered for PFMT over 
3 months (six visits over 3 months or two visits 
per month). Following this guideline, in this Description of studies
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TABLE 10  Number of studies and participants for each intervention assessed
Comparison
Number of 
trials Participants References
Lifestyle change 1 84 119
Comparison with no treatment
PFMT vs NT 14 958 57, 107, 115, 118, 120–129
PFMT + BF vs NT 2 110 120, 122
ES vs NT 8 446 115, 124, 126, 130–134
VC vs NT 2 220 115, 129
BT vs NT 1 131 135
SNRI 80 mg vs NT 11 3891 57, 117, 136–144
SNRI 40 mg vs NT 2 342 144, 145
SNRI 30 mg vs NT 1 60 145
SNRI 20 mg vs NT 2 344 144, 145
SNRI 40 mg b.i.d., starting with 40 mg b.i.d. vs NT 1 256 138
SNRI 40 mg b.i.d., starting with 40 mg q.d. vs NT 1 247 138
SNRI 40 mg b.i.d., starting with 20 mg b.i.d. vs NT 1 253 138
PFMT + ES vs NT 3 257 121, 123, 126
PFMT + SNRI vs NT 1 99 57
Comparison of different PFMT variants
PFMT vs PFMT + BF 15 609 120, 122, 146–158
PFMT vs PFMT with additional sessions 4 178 116, 159–161
PFMT vs PFMT with audiocassette 2 157 162, 163
Strength and motor relearning PFMT vs motor relearning 
PFMT
1 128 164
PFMT in supine position vs PFMT in supine and upright 
position
1 44 165
PFMT vs modified pilates 1 11 166
PFMT (maximal contraction) + BF vs PFMT (submaximal 
contraction) + BF
1 37 167
PFMT + perineometer vs PFMT + urethral electrical 
conductance
1 34 168
PFMT + BF (vaginal) vs PFMT + BF (vaginal and abdominal) 1 38 169
PFMT + BF vs PFMT + ES 2 90 170, 171
Comparison of different variants of ES
PFMT + BF + ES (faradism) vs PFMT + BF + ES (IFT) 1 30 157
PFMT+BF + ES (maximal intensity at clinic) vs 
PFMT+BF + ES (low intensity at home)
1 49 172
Comparison of different variants of VC
VC passive vs VC active 1 61 173
Comparison of different SNRI doses
SNRI 80 mg vs SNRI 40 mg 1 277 144
SNRI 80 mg vs SNRI 20 mg 1 278 144
SNRI 40 mg vs SNRI 30 mg 1 59 145
SNRI 40 mg vs SNRI 20 mg 2 342 144, 145
SNRI 30 mg vs SNRI 20 mg 1 60 145
SNRI 40 mg b.i.d., starting with 40 mg b.i.d. vs  
SNRI 40 mg b.i.d., starting with 40 mg q.d.
1 263 138DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
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Comparison
Number of 
trials Participants References
SNRI 40 mg b.i.d., starting with 40 mg b.i.d. vs  
SNRI 40 mg b.i.d., starting with 20 mg b.i.d.
1 269 138
SNRI 40 mg b.i.d., starting with 40 mg q.d. vs  
SNRI 40 mg b.i.d., starting with 20 mg b.i.d.
1 260 138
Comparison of different treatments (single modality)
PFMT vs ES 7 222 115, 124, 126, 174–177
PFMT vs VC 6 426 115, 129, 152, 178–180
PFMT + BF vs VC 2 141 152, 181
PFMT vs BT 1 84 182
PFMT + BF vs BT 1 137 183
PFMT vs SNRI 1 102 57
PFMT vs surgery 2 105 184, 185
ES vs VC 4 191 115, 186–188
Comparison of different treatments (dual modality)
PFMT vs PFMT + ES 7 473 121, 123, 126, 185, 189–191
PFMT + BF vs PFMT + BF + ES 2 115 157, 172
PFMT + BF vs PFMT + BF + ES (faradism)a 1 30 157
PFMT + BF vs PFMT + BF + ES (IFT)a 1 30 157
PFMT + BF vs PFMT + BF + ES (maximal intensity at clinic)a 1 45 172
PFMT + BF vs PFMT + BF + ES (low intensity at home)a 1 46 172
PFMT vs PFMT + VC 1 46 192
PFMT vs PFMT + SNRI 1 102 57
PFMT + BF vs PFMT + BF + BT 1 136 183
PFMT + ES vs ES 1 22 126
PFMT + VC vs VC 1 42 188
PFMT + BF + BT vs BT 1 135 183
PFMT + SNRI vs SNRI 1 104 57
Comparisons considered not relevant for direct head-to-head comparisonsb
PFMT vs PFMT + BF + ES (faradism) 1 30 157
PFMT vs PFMT + BF + ES (IFT) 1 30 157
PFMT + ES vs VC 1 60 193
PFMT + ES vs surgery 1 54 185
PFMT + VC vs ES 1 41 188
PFMT + BF + VC vs ES 1 46 132
PFMT + SNRI vs surgery 1 197 194
PFMT + ES + BF vs VC 1 120 195
PFMT + ES + BF vs PFMT + VC 1 102 196
Childbearing women only
PFMT, VC or both vs NT 1 230 197
PFMT vs NT 1 264 198
PFMT vs PFMT + abdominal training vs NT 1 68 199
a  Included in comparison of PFMT + BF vs PFMT + BF + ES noted above 
b  Results reported in Appendix 17, Comparison 23; some comparisons were included in the MTC analysis.
TABLE 10  Number of studies and participants for each intervention assessed (continued)Description of studies
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113 reports not meeting inclusion criteria:
34   – not RCT
58   – not relevant population (men; women who 
     were continent or who had predominant 
     urge urinary incontinence; elderly with lack 
     of independent mobility)
7   – not relevant interventions
1   – no relevant outcome
13   – provision of background data
86 reports not meeting inclusion criteria:
27   – women with (predominant) stress urinary 
     incontinence consisted < 50% of the sample
18   – type of urinary incontinence (stress, urge, 
     mixed) unknown or undiagnosed
6   – proportion of women with (predominant) 
     stress urinary incontinence not reported
18   – a package of interventions where treatments 
     were tailored according to diagnosis (unable 
     to distinguish effects of specific intervention)
8   – not relevant interventions
3   – historical control
1   – included male participant
5   – awaiting classification
7013 initial search
6635 studies excluded
265 retained for further assessment
179 reports included (88 studies)
378 full-text papers selected for assessment
FIGURE 7  Flow chart for study selection.
TABLE 11  Summary of assessment of risk of bias for the included randomised controlled trials (N = 88)
Criteria Yes (n, %) Unclear (n, %) No (n, %)
1.  Was the allocation sequence adequately generated? 30 (34.1) 53 (60.2) 5 (5.7)
2.  Was allocation adequately concealed? 16 (18.2) 63 (71.6) 9 (10.2)
3.  Were participants ‘blind’ to treatment status? 19 (21.6) 56 (63.6) 13 (14.8)
4.  Were health-care providers ‘blind’ to treatment status? 6 (6.8) 63 (71.6) 19 (21.6)
5.  Were outcome assessors ‘blind’ to treatment status? 17 (19.3) 65 (73.9) 6 (6.8)
6.  Were the groups treated identically other than for the named 
intervention?
86 (97.7) 0 (0.0) 2 (2.3)
7.  Was there a description of withdrawals, dropouts and those lost 
to follow-up?
33 (37.5) 33 (37.5) 22 (25.0)
8.  Was the analysis on intention to treat? That is:
(a) Were trial results reported for everyone who entered the 
trial?
18 (20.5) 24 (27.3) 46 (52.3)
(b) Were participants analysed in the groups they were originally 
allocated to?
75 (85.2) 13 (14.8) 0 (0.0)DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
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TABLE 12  Number of studies and participants included in the review by study size
Number of studies
Number of 
participants Type 1 Type 2 Type 3
Lifestyle 0 1 0 84
Physical/behavioural, ≥ 200 participants per trial 1 2 1 843
Physical/behavioural, 100–199 participants per trial  6 4 1 1459
Physical/behavioural, < 100 participants per trial 56 1 1 2583
Pharmaceutical (SNRI vs placebo)a 3 1 7 4194
Studies with childbearing women only 1 2 0 558
Total 67 11 10 9721
a  No studies meeting the inclusion criteria were identified involving intravaginal low-dose estrogens.
Type 1, studies solely comprising women with SUI alone; type 2, studies where ≥ 50% of women had SUI alone; type 3, 
studies where 50% of women had stress-predominant MUI (see Chapter 5, Types of participants).
review a PFMT programme with up to two clinic 
visits per month is considered as PFMT with 
basic supervisory intensity (or ‘PFMT basic’), and 
the programme with more than two clinic visits 
per month is considered as PFMT with intensive 
supervision (or ‘PFMT extra sessions’) (Appendices 
11 and 12). This is regardless of the amount or 
type of pelvic floor muscle contractions performed 
per day or the duration and precise nature of 
supervision; such data were poorly reported and 
hence could not be incorporated into our analysis.
The comparison group may be another active 
treatment or no treatment. No treatment in 
this review is equivalent to no active treatment. 
Leaflet-only PFMT, which was not taught by a 
health-care professional, is also considered as 
‘no treatment’, based on the assumption that 
the distribution of guidelines has a small effect 
on behaviour200 and also that patients are not 
naive and can obtain knowledge of PFMT from 
anywhere (e.g. internet). Within the 30 studies 
of non-childbearing women classified as having 
a ‘no-treatment’ arm, participants received no 
treatment,107,118,120–122,124,125,135 advice on continence 
device or pads,115,127 sham ES,126,130–134 placebo 
PFMT,128 imitation PFMT with placebo drug,57 
placebo drug alone,117,136–142,144,145 a booklet 
including the entire training programme for 
self-administration123 or an educational leaflet, 
encouragement to keep an exercise diary and an 
equal number of clinic visits to the comparator 
arm.129 Of the three studies of childbearing women, 
one199 provided a relaxation massage, whereas the 
other two197,198 provided standard or routine care 
for the ‘no-treatment’ arm.
The treatment protocol for ES varied widely 
between studies. A common problem associated 
with ES is that there is no consistency in the 
criteria used to describe ES.201 Treatment could 
be described on the basis of the type of current 
being used (e.g. faradic stimulation, interferential 
therapy), the structure being targeted (e.g. 
neuromuscular ES), or the current intensity, etc. 
No attempt was made in this review to categorise 
different treatment protocols.
The VCs treatment was relatively homogeneous 
and so was SNRI drug therapy, which was based 
on duloxetine. Nevertheless, one study by 
Kinchen and colleagues140 was a ‘naturalistic’ 
study, for which participants could, at any point 
after randomisation, choose to remain on SNRI 
as randomised, reduce drug doses, add other 
treatments to SNRI, or suspend SNRI and receive 
other treatments. The additional treatments 
used by the study participants included estrogen 
products, anticholinergic medications and PFMT. 
There was differential withdrawal due to adverse 
events between SNRI and placebo groups in all 
10 studies with available data (see Chapter 7, 
Serotonin–noradrenaline reuptake inhibitors drug 
therapy).117,137–145 Nine studies117,136–139,142–145 stated 
that they had either received sponsorship, funding 
or support from the manufacturer of duloxetine 
(Eli Lilly and Company).DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
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T
his chapter describes the results from direct 
pairwise (head-to-head) comparisons. Results 
are grouped into three sections: comparison with 
no treatment and variation within comparators, 
comparison between different treatments (single 
modality), and comparison between different 
treatments (dual modality).
A summary of the baseline characteristics of the 
participants and interventions in the included 
studies is provided at the beginning of each 
section. This is described in more detail in 
Appendix 10.
The focus is on the primary outcome data (cure, 
improvement, adverse events and quality of life) 
and, in particular, those that are relevant to the 
MTC analysis in the following chapter (Chapter 
7). There was a great variability in the way cure 
and improvement was defined by the trialists. This 
is detailed in Appendix 16. As noted in Chapter 
5 (see Types of outcome measures), we chose to 
substitute woman’s observation (measurement 
type 1) with quantified symptoms or clinician’s 
observation (measurement type 2), if the former 
was missing. The type of outcome measurement for 
each study is shown on the right hand side of the 
quantitative synthesis figure (measurement type – 
see Box 8). For quantitative synthesis, data at the 
end of the prescribed treatment phase, or at the 
first outcome assessment, if later, were used. Data 
from further follow-ups and other relevant primary 
outcome data are reported in the text and also in 
Appendix 17.
Studies with different population types are analysed 
together. The type of population included in each 
trial is also shown on the right hand side of the 
figure (population type – Box 8). The quantitative 
analysis for cure and improvement rates was also 
performed with studies that included women 
diagnosed as having SUI only (population type 
1); the results are presented in Appendix 18. 
Quantitative data syntheses for condition-specific 
quality of life were limited due to lack of available 
data; these are given in Appendix 19. Studies of 
childbearing women were analysed separately and 
provided in Appendix 20. Secondary outcome 
data of all relevant comparisons are reported in 
Appendix 21.
Chapter 7  
Assessment of clinical effectiveness
Type of outcome measurement
1.  Women’s observation
2.  Quantification of symptoms or clinician’s 
observation
Type of population
1.  All women had SUI alone
2.  ≥ 50% of women had SUI alone; the remainder 
could have UUI or MUI
3.  ≥ 50% of women had MUI with stress symptoms 
as a predominant pattern; the remainder could 
have SUI, UUI or MUI
BOX 8  Classification of sample populations and outcome 
measurements
Comparison with no 
treatment and variation 
within comparators
Lifestyle change
No studies were found comparing lifestyle change 
with no treatment. The only relevant study119 was 
a crossover trial evaluating the effect of increasing 
or decreasing fluid intake on urinary symptoms in 
women (Table 13). Women were randomised in the 
order in which they increased or decreased fluids. 
All women were instructed to restrict caffeine. No 
information was available on any of the specified 
outcomes.
PFMT with and without BF
PFMT, with or without BF, vs no 
treatment
The characteristics of included studies comparing 
PFMT (with and without BF) and no treatment 
are summarised in Table 14. Fourteen studies were 
eligible for this comparison, in which a total of 
958 participants were randomised. Studies varied 
widely in terms of the duration of treatment 
prescribed by the trialists, as well as supervisory 
intensity (measured in terms of the number of 
clinic visits or any face-to-face contacts with a 
health-care professional). No studies reported data 
on further follow-up after the end of the prescribed Assessment of clinical effectiveness
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TABLE 13  Baseline characteristics of randomised controlled trials comparing lifestyle changes to no treatment
Study ID
Population 
type
Duration 
(month) Comparator
N 
randomised
Age 
(years)
Supervisory 
intensitya
Swithinbank 
2005119
2 2 Increase fluid 84  
(crossover trial)
54.8 Intensive
Decrease fluid 84  
(crossover trial)
Intensive
a  Intensive, more than two clinic visits per month.
treatment phase. The comparison groups 
received no treatment,107,118,120–122,124,125 advice 
on continence device or pads,115,127 sham ES,126 
placebo PFMT,128 imitation PFMT with placebo 
drug,57 a booklet including the entire behavioural 
training programme for self-administration123 or an 
educational leaflet, the equal number of clinic visits 
as the PFMT arm and encouragement to keep an 
exercise diary.129
Pelvic floor muscle training plus sham ES was 
classified as being equivalent to PFMT. Where both 
PFMT and PFMT plus sham ES were present in 
a trial,121 the dichotomous data were combined 
(added up).
Cure and improvement rate
Figures 8 and 9 show the number of women who 
were either cured or improved, respectively, in 
the PFMT group (with or without BF) versus the 
no-treatment group at the end of the prescribed 
treatment phase. Pooled data for cure rates showed 
higher cure rates for PFMT with or without BF, but 
with significant heterogeneity (Figure 8: PFMT vs 
no treatment – 23% vs 7%, OR 5.41, 95% CI 1.64 
to 17.82; PFMT with BF vs no treatment – 42% 
vs 2%, OR 21.54, 95% CI 3.65 to 126.98). The 
source of the heterogeneity appeared to be the 
inclusion of studies with women with SUI with or 
without UUI symptoms (population types 2 or 3). 
In these studies the direction and magnitude of 
effect varied across studies. Of note is that the two 
studies reporting the lowest effect size123,129 not only 
included women with different types of urinary 
incontinence, but also had the largest sample size, 
less intensive supervision (fewer clinic visits) and 
relatively substantial provision of care for the no-
treatment group (e.g. self-administered behavioural 
training, clinic visits), which may have contributed 
to the relatively small effect size.
Removing these studies reduced the statistical 
heterogeneity but also widened the CI (as fewer 
data were available for meta-analysis) (Appendix 
18, Comparison 01: PFMT vs no treatment – 39% 
vs 3%, OR 15.15, 95% CI 5.50 to 41.75; PFMT with 
BF vs no treatment – 80% vs 0%, OR 77.00, 95% CI 
3.75 to 1581.71).
Results for improvement rates similarly favoured 
PFMT with or without BF compared with no 
treatment, though statistical heterogeneity was 
again evident across studies (Figure 9: no BF, OR 
11.75, 95% CI 3.49 to 39.55; with BF, OR 24.20, 
95% CI 2.02 to 290.58). One additional cause of 
heterogeneity for this outcome was the greater 
variability in the way ‘improvement’ was defined 
between studies, as the heterogeneity remained 
even after removing studies with mixed diagnoses 
(Appendix 18, Comparison 02: OR 27.07, 95 
CI 4.72 to 155.35). Crucially, the smallest effects 
were found in those studies with placebo or 
imitation PFMT57,128 in the no-treatment arm 
and with women with mixed types of urinary 
incontinence.123,129
Adverse events
Adverse events were uncommon in the PFMT 
group (Table 15). Nevertheless, two studies127,129 
reported that up to 12% of women experienced 
adverse events during PFMT.
Quality of life
Condition-specific quality of life was reported using 
various measures, including the Social Activity 
Index, the Urinary Incontinence Quality of Life 
(I-QoL) scale, the Leicester Impact Scale, the 
Incontinence Impact Questionnaire (IIQ) and the 
Bristol Female Lower Urinary Tract Symptoms 
(B-FLUTS) (Appendix 19, Comparison 01). In all 
but two trials,123,129 results were better for the PFMT 
group (with or without BF). One study115 reported 
this outcome using two instruments (Social Activity 
Index and B-FLUTS), with results consistently 
favouring PFMT. As the outcome measures varied 
between studies and not all studies reported data 
amenable to meta-analysis, quantitative synthesis 
was not performed.DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
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TABLE 14  Background characteristics of studies comparing pelvic floor muscle training (plus biofeedback) with no treatment or 
comparing variation within comparators
Study ID
Population 
type
Duration 
(month) Comparator
N 
randomised Age
Supervisory 
intensitya Notes
Aksac 
2003120
1 2 PFMT 20 52.5 Intensive
PFMT + BF 20 51.6 Intensive
NT 10 54.7 None
Bidmead 
2002121
1 3.5 PFMT 40b 46.2 Basic
PFMT + sham ES 42b 51.5 Basic
NT 20b 47.5 None
Bø 1999115 1 6 PFMT 29 49.6 Intensive
NT 32 51.7 None Advice on 
Continence 
Guard™
Burns 
1993122
2 2 PFMT 43c 63.0 Intensive
PFMT + BF 40c 63.0 Intensive
NT 40c 63.0 None
Ghoniem 
200557
1 3 PFMT 50 54.0 Basic Placebo drug
NT 47 51.0 Basic Placebo drug 
and imitation 
PFMT
Goode 
2003123
3 2 PFMT 66 57.7 Basic ‘Behavioural 
training’
NT 67 55.9 None Self-
administered 
behavioural 
training
Henalla 
1989124
1 3 PFMT 26 NR Intensive
NT 25 NR None
Henalla 
1990125
1 1.5 PFMT 8 54 NR
NT 7 NR
Hofbauer 
1990126
1 1.5 PFMT 11 51.0 Intensive
NT 10 59.8 Intensive Sham ES
Kim 2007118 1 3 PFMT 35 76.6 Intensive
NT 35 76.6 None
Lagro-
Janssen 
1991127
1 3 PFMT 33 46.1 Basic
NT 33 44.6 None Advice on 
continence pads
Miller 
1998107
1 0.25 PFMT 13 68.4 Intensive The Knack
NT 14 None
Ramsay 
1990128
1 3 PFMT 22 NR NR
NT 22 NR NR Placebo PFMT
Williams 
2006129
2 3 PFMT 79 55.9 Basic
NT 79 56.7 Basic Leaflet, clinic 
visits and 
exercise diary
NR, not reported.
a  None, no clinic visit for training, treatment or supervision; basic, up to two clinic visits per month; intensive, more 
than two clinic visits per month.
b  N randomised unclear due to poor reporting.
c  N in analysis; N randomised in each group unclear.Assessment of clinical effectiveness
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TABLE 15  Adverse events: pelvic floor muscle training versus no treatment
PFMT NT
Notes
Population 
type n/N % n/N %
Lagro-Janssen 1991127 4/33 12 0/33 0 Pain, uncomfortable feeling during exercise 1
Williams 2006129 2/79 3 0/79 0 Urinary tract infection 2
Two studies115,123 reported general health-related 
quality of life (HRQoL) using SF-36 and the 
Norwegian version of the Quality of Life Scale 
(QoLS-N). One of these studies115 reported higher 
quality of life for the PFMT group, whereas 
the other123 reported no statistically significant 
difference between the groups (Appendix 17, 
Comparison 01).
PFMT vs PFMT plus BF
Fifteen studies120,122,146–158 evaluated the effect of 
adding BF to PFMT (Table 16). In two studies 
by Glavind and colleagues150 and Wilson and 
colleagues,157 the women randomised to use BF had 
more clinic visits than the PFMT group. There was 
also a potential difference in supervisory intensity 
in a further study by Pages and colleagues,154 in 
which the PFMT group had group therapy for 
60 minutes, five times a week, whereas the BF 
group had individual therapy for 15 minutes, five 
times a week.
In addition to devices specifically designed 
to provide visual and/or audio BF, the use of 
intravaginal resistance device,149 an endotrainer151 
and an exerciser155 were also classified as BF for the 
purpose of this review.
Cure and improvement rate
Pooled data showed that at the end of the 
prescribed treatment phase the addition of BF to 
PFMT resulted in significantly higher cure and 
improvements than with PFMT alone (Figures 
10 and 11: cure rates 34% vs 49%, OR 0.48, 
95% CI 0.30 to 0.77; improvement rates 76% vs 
86%, OR 0.41, 95% CI 0.18 to 0.97). Among the 
studies showing the largest effect size were studies 
by Glavind and colleagues150 and Wilson and 
colleagues,157 which had additional supervisory 
visits in the BF group relative to the PFMT 
group. The study by Pages and colleagues,154 
which was also a trial with a potential difference 
in supervisory intensity, also suggested a large 
treatment effect in the cure data.
Two studies150,157 conducted a further follow-up 
after the end of the supervised treatment in which 
all women were advised to continue PFMT at home 
without BF or any close supervision by a health-
care professional. The first study157 with 6-month 
follow-up (4.5 months after the end of 6-week 
treatment) reported that women who did not use 
BF in the treatment phase were significantly less 
likely to improve than those who trained with BF 
(Appendix 17, Comparison 02, 4/15 vs 9/14, OR 
0.20, 95% CI 0.04 to 0.98). In the second study150 
with 2.5 years of follow-up, the results for cure and 
improvement also favoured the BF group, although 
the differences were not statistically significant 
(Appendix 17, Comparison 02, cure 0/14 vs 5/19, 
OR 0.09, 95% CI 0.01 to 1.80; improvement 4/14 
vs 8/19, OR 0.55, 95% CI 0.13 to 2.40).
Adverse events
Adverse events were uncommon but in two 
studies146,153 that did report incidents, more 
participants (15–27%) experienced adverse events 
if they were using BF. Some women found the 
device unpleasant or painful (Table 17).
Quality of life
Five studies120,147,152,153,158 reported condition-specific 
quality of life using four different measures (Table 
17). In four of these studies results were similar 
for both groups, but in one study,158 women 
reported statistically significantly better quality 
of life in the PFMT group than with those using 
BF. Quantitative synthesis did not demonstrate 
a statistically significant difference between the 
groups (Appendix 19, Comparison 01, SMD for 
total score, –0.29, 95% CI –0.62 to 0.03; SMD for 
change in score, 0.49, 95% CI –0.14 to 1.12).
PFMT vs PFMT with additional sessions
The characteristics of included studies comparing 
PFMT with and without additional supervisory 
clinical sessions are summarised in Table 18.
Cure and improvement rate
Cure and improvement rates were consistently 
higher for women who received additional 
supervisory sessions (Figures 12 and 13: cure 
rate, 15% vs 43%, OR 0.11, 95% CI 0.03 to 0.43; DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
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TABLE 16  Baseline characteristics of studies comparing pelvic floor muscle training (PFMT) with PFMT plus biofeedback
Study ID
Population 
type
Duration 
(month) Comparator
N 
randomised Age
Supervisory 
intensitya Notes
Aksac 
2003120
1 2 PFMT 20 52.5 Intensive
PFMT + BF 20 51.6 Intensive
Aukee 
2002146 
1 3 PFMT 15 50.8 Basic
PFMT + BF 15 51.8 Basic Home BF
Berghmans 
1996147
1 1 PFMT 20 50.4 Intensive
PFMT + BF 20 46.4 Intensive
Burns 
1993122
2 2 PFMT 43 63.0 Intensive
PFMT + BF 40 63.0 Intensive Clinic BF
Castleden 
1984148
1 1 PFMT 19 (crossover) 55.0 NR
PFMT + BF 19 (crossover) NR Home BF
Ferguson 
1990149
1 1.5 PFMT 10 35.8 Basic
PFMT + BF 10 37.1 Basic IVRD
Glavind 
1996150
1 3b PFMT 20 45.0 Basic
PFMT + BF 20 Basic Additional visits 
for clinic BF
Klingler 
1995151
1 3 PFMT 21 53.0 Intensive
PFMT + BF 20 51.8 Intensive Endotrainer
Laycock 
2001152
1 3 PFMT 20 NR Basic
PFMT + BF 40 NR Basic Home BF
Mørkved 
2002153
2 6 PFMT 50 45.4 Intensive
PFMT + BF 53 47.8 Intensive Home + clinic BF
Pages 
2001154
1 3 PFMT 27 51.1 Intensive Group therapy
PFMT + BF 24 Intensive Individual 
therapy; clinic BF
Shepherd 
1983155
1 4.5c PFMT 11 48.4 Basic
PFMT + BF 11 48.2 Basic Exerciser
Taylor 
1986156
1 2.25 PFMT 13 (number 
in each group 
unclear)
NR Intensive
PFMT + BF NR Intensive Clinic BF
PFMT + BF NR Intensive Clinic + home BF
PFMT + BF NR Intensive Home BF 
without vaginal 
sensor to 
be used as a 
resistive device
Wilson 
1987157
1 1.5 PFMT 15 46.8 Basic
PFMT + BF 15 Intensive Clinic BF
Wong 
1997a158
1 2 PFMT 7 48.2 Intensive
PFMT + BF 10 Intensive
IVRD, intravaginal resistance device.
a  None, no clinic visit for training, treatment or supervision; basic, up to two clinic visits per month; intensive, more 
than two clinic visits per month.
b  Treatment for 4 weeks, and measurement at 3 months.
c  Treatment for 6 weeks, and measurement at 3 months after end of treatment.Assessment of clinical effectiveness
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TABLE 17a  Adverse events: pelvic floor muscle training (PFMT) versus PFMT plus biofeedback
PFMT PFMT + BF
Notes
Population 
type n/N % n/N %
Aukee 2002146 3/15 20 4/15 27 Pain while training (of which 3/7 
premenopausal)
1
Mørkved 2002153 3/46 7 7/48 15 PFMT + BF: 7/48 found use of 
apparatus ‘unpleasant’; PFMT: 3/46 
found PFMT itself ‘unpleasant’; 
‘However, they all followed the 
training protocol in spite of this’
2
TABLE 17b  Quality of life: pelvic floor muscle training (PFMT) versus PFMT plus biofeedback
PFMT PFMT + BF
Reported 
p-value Notes
Population 
type N Value N Value
Social Activity Index
Aksac 2003120 20 7.5 (1.2) 20 8.1 (0.8) Score (median, SD) 1
Mørkved 2002153 34 9.5 (0.74) 36 9.6 (0.61) Score (mean, SD) at 6 
months
1
Modified PRAFAB
aBerghmans 1996147 20 13.1 (8.6) 20 11.1 (5.9) NS Score (mean, SD) 1
King’s Health Questionnaire
Laycock 2001152 16 8.13 (9.06) 22 6.14 (6.20) NS Change in score (mean 
increase, SD)
1
Incontinence Impact Questionnaire
Wong 1997a158 7 24.5 (10.8) 10 8.5 (19.9) < 0.05 Change in score (mean 
reduction, SD)
1
NS, not statistically significant.
a  Lower scores reflect better quality of life.
improvement rate, 54% vs 97%, OR 0.05, 95% CI 
0.01 to 0.28).
One small study159 with 15 years of follow-up 
also reported that the number of women who 
remained continent (cured) after they were left 
to continue PFMT on their own was higher in 
the group who had additional sessions during 
the initial supervised treatment phase, although 
this difference was not statistically significant 
(Appendix 17, Comparison 03, 16% vs 30%, OR 
0.44, 95% CI 0.11 to 1.87).
Adverse events
No studies reported any adverse events.
Quality of life
Condition-specific quality of life measures varied, 
but all studies consistently reported that PFMT 
with additional sessions was associated with better 
quality of life (Table 19). Two studies116,159 provided 
data amenable to quantitative synthesis; results 
showed a statistically significant difference between 
the groups favouring PFMT with additional 
sessions (Appendix 19, Comparison 02, SMD 
–1.07, 95% CI –1.98 to –0.15).
Comparisons of other PFMT variants
A further 10 studies162–171 compared other 
variations in the method of delivering PFMT 
(Table 20). Not all studies collected data for the DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
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TABLE 18  Baseline characteristics of studies comparing pelvic floor muscle training (PFMT) and PFMT with additional supervisory 
clinical sessions
Study ID
Population 
type
Duration 
(month) Comparator N randomised Age
Supervisory 
intensitya
Bø 1990159 1 6 PFMT 31 45.9 Basic
PFMT with 
additional sessions
26 44.9 Intensive
Konstantinidou 
2007116
1 3 PFMT 15 47.8 Basic
PFMT with 
additional sessions
15 Intensive
Wong 1997b160 1 1 PFMT 26 48.8 Basic
PFMT with 
additional sessions
21 Intensive
Zanetti 2007161 1 3 PFMT 21 54.0 Basic
PFMT with 
additional sessions
23 56.0 Intensive
a  None, no clinic visit for training, treatment or supervision; basic, up to two clinic visits per month; intensive, more 
than two clinic visits per month.
same outcome and it was therefore not possible 
to combine results in a meaningful way. The 
detailed information for comparators is reported 
in Appendix 17, Comparisons 04–09. Within the 
data available from the six studies that reported at 
least one of the specified primary outcomes,164–169 
there was insufficient evidence to suggest that any 
of these variants of PFMT were more effective than 
the comparator treatment shown in Table 20.
Other physical and behavioural 
interventions
The characteristics of included studies comparing 
physical or behavioural interventions other than 
PFMT (with and without BF) are summarised in 
Table 21.
Electrical stimulation vs no treatment
Eight studies115,124,126,130–134 compared ES with no 
active treatment. Five studies provided treatment 
by means of a device for home use, and compared 
it with either sham treatment130,131,133,134 or no 
treatment.115 The other studies provided treatment 
at clinic, compared with sham treatment126,132 or no 
treatment.124
Cure and improvement rate
Pooled data showed no statistically significant 
difference between the groups in the cure rate 
(6% vs 6%, OR 1.10, 95% CI 0.41 to 2.94), but ES 
showed a significantly higher rate for improvement 
(37% vs 13%, OR 3.93, 95% CI 1.43 to 10.80) 
compared with no active treatment, although there 
was some evidence of heterogeneity (Figures 14 
and 15). The source of heterogeneity is unclear 
but it appears to be caused by the study by Bø 
and colleagues.115 Removal of this study reduced 
statistical heterogeneity and the difference between 
the groups was still statistically significant (OR 
2.46, 95% CI 1.14 to 5.30, figure not shown).
Adverse events
Only two studies115,134 reported any incidence of 
adverse events (Table 22). All recorded cases were 
attributed to the treatment device, whether it was 
used for active or sham ES. In the study by Bø and 
colleagues,115 seven of the 32 participants in the ES 
group stopped treatment due to adverse events.
Quality of life
Two studies115,131 reported condition-specific 
quality of life, with one of these studies131 using 
two instruments (questionnaires). Results were 
inconsistent across and within studies (Table 22 and 
Appendix 19, Comparison 03).
There were no statistically significant differences in 
general HRQoL scores (SF-36) between the groups 
in two studies (Appendix 17, Comparison 10).131,134
Comparison of different variants of ES
Two studies157,172 assessed different variants of ESs. 
One of these studies157 compared faradism and 
interferential therapy (IFT), both as an adjunct 
treatment to PFMT with clinic-based BF, for a 
period of 6 weeks. After this initial supervised 
treatment phase, all participants (N = 30) 
continued with PFMT and were followed up for 
6 months.Assessment of clinical effectiveness
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TABLE 19  Pelvic floor muscle training (PFMT) versus PFMT with additional sessions
PFMT
PFMT + additional 
sessions
Reported 
p-value Notes
Population 
type N Value N Value
Social Activity Index 
Bø 1990159 29 8.2 (2.06) 23 9.3 (0.73) < 0.01 Sum score (mean, 
SD) at 6 months
1
Quality-of-life index
aKonstantinidou 
2007116
10 3.6 (1.5) 12 1.7 (0.8) 0.000 Score (mean, SD) 1
Incontinence Quality of Life
Zanetti 2007161 21 79 23 89 0.0456 Score (median) 1
a  Lower scores reflect better quality of life.
TABLE 20  Baseline characteristics of studies comparing different variants of pelvic floor muscle training
Study ID
Population 
type
Duration 
(months) Comparator
N 
randomised Age
Supervisory 
intensitya
Borello-
France 2006165
1 2.25–3 PFMT in supine position 22 51.7 Intensive
PFMT in supine and upright 
position
22 53.6 Intensive
Edwards 
2000170
1 3 PFMT + BF 10?
46
NR
PFMT + ES 10? NR
Gallo 1997162 1 1–1.5 PFMT 43
60
Basic
PFMT with audiocassette 43 Basic
Hay-Smith 
2003164
3 5 Strength and motor 
relearning PFMT
64 48.7 Basic
Motor relearning PFMT 64 48.9 Basic
Johnson 
2001167
1 1.5 PFMT (maximal 
contraction) + BF
37
49.5 NR
PFMT (submaximal 
contraction) + BF
51.0 NR
Mayne 1988168 1 4 PFMT + perineometer
34
45.0 Basic
PFMT + urethral electrical 
conductance
56.0 Basic
Nygaard 
1996163
2 3 PFMT
71
53.0 Basic
PFMT with audiocassette Basic
Pohl 2004171 1 3 PFMT + BF
70
NR NR
PFMT + ES NR NR
Savage 2005166 1 3 PFMT 5 54.6 Basic
Modified pilates 6 48.2 Basic
Wong 2001169 1 3 PFMT + BF (vaginal) 19 47.6 Basic
PFMT + BF (vaginal and 
abdominal)
19 44.4 Basic
a  None, no clinic visit for training, treatment or supervision; basic, up to two clinic visits per month; intensive, more 
than two clinic visits per month.Assessment of clinical effectiveness
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TABLE 21  Baseline characteristics of physical and behavioural interventions other than pelvic floor muscle training and lifestyle change
Study ID
Population 
type
Duration 
(month) Comparator N randomised Age
Supervisory 
intensitya Notes
Bø 1999115 1 6 ES 32 47.2 Basic Maximum 
intermittent 
vaginal 
stimulation
VC 29 49.2 Basic
NT 32 51.7 None
Brubaker 
1997130
2 2 ES 148 56.0 Basic Transvaginal 
stimulation
NT 57.7 None Sham ES
Burton 
1993173
1 NR VC passive 31 NR NR VC in static 
position
VC active 30 NR NR VC while doing 
activities
Fantl 
1991135
2 1.5 BT 65 66.0 Intensive
NT 66 68.0 None
Henalla 
1989124
1 3 ES 25 NR Intensive IFT
NT 25 NR None
Hofbauer 
1990126
1 1.5 ES 11 59.7 Intensive Faradic
NT 10 59.8 Intensive Sham ES
Jeyaseelan 
2000131
1 2 ES 14 NR NR Patterned 
neuromuscular 
stimulation
NT 13 NR NR Sham ES
Knight 
1998172
1 6 PFMT+BF + ES 
(max)
24 NR Intensive ES = maximal 
stimulation at 
clinic
PFMT+BF + ES 
(low)
25 NR Intensive ES = overnight 
at low intensity 
at home
Laycock 
Trial 2 
1993132
1 2–3 ES 15 43.7 Intensive IFT
NT 15 46.2 Intensive Sham ES
Luber 
1997133
1 3 ES 26 54.1 Basic
NT 28 53.6 Basic Sham ES
Sand 
1995134
1 3 ES 35 50.9 Basic
NT 17 57.7 Basic Sham ES
Williams 
2006129
2 3 VC 80 58.2 Basic
NT 79 56.7 Basic Leaflet, clinic 
visits and 
exercise diary
Wilson 
1987157
1 1.5 PFMT + BF + ES 
(faradism)
15 46.8 Intensive
PFMT + BF + ES 
(IFT)
15 Intensive
a  None, no clinic visit for training, treatment or supervision; basic, up to two clinic visits per month; intensive, more 
than two clinic visits per month.DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
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TABLE 22a  Adverse events: electrical stimulation versus no treatment
ES NT
Type of AEs
Population 
type n/N % n/N %
N experiencing AEs
Bø 1999115 10/32 31 0/32 0 Smarting (tenderness, bleeding, discomfort), 
motivation problem, difficulty in using the 
stimulator
1
Sand 1995134 14/35 40 7/17 41 All cases added up, although unclear if the same 
patient experienced more than one adverse event; 
vaginal irritation: ES 5/35, NT 2/17; occasional 
pain: ES 3/35, NT 1/17; vaginal infection: ES 4/35, 
NT 2/17; urinary tract infection: ES 1/35, NT 2/17
1
TABLE 22b  Quality of life: electrical stimulation versus no treatment
ES NT
Reported 
p-value Notes
Population 
type N Value N Value
Social Activity Index
Bø 1999115 25 0.6 (1.02) 30 –0.2 (1.68) Change in score 
(mean, SD)
1
Incontinence Impact Questionnaire
aJeyaseelan 
2000131
12 –4.1 (16.4) 12 –9.1 (17.1) NS Change in score 
(mean, SD)
1
Urogenital Distress Inventory
aJeyaseelan 
2000131
12 –11.8 (15.9) 12 –3.3 (8.3) 0.01 Change in score 
(mean, SD)
1
a  Lower scores reflect better quality of life.
The other study172 compared maximal ES 
(provided at clinic) with low intensity ES (provided 
overnight at home), both performed in conjunction 
with PFMT and a home BF device. Participants 
(N = 49) received these treatments with supervision 
for 6 months and were then instructed to perform 
PFMT with BF for a further 6 months.
Results showed that improvement was more likely 
for faradism and clinic-based maximal stimulation 
than for interferential therapy and home-based 
low-intensity stimulation, respectively, both after 
the supervised treatment phase and at 6 months 
after the end of the supervised phase (Appendix 
17, Comparisons 11–12). However, CIs were 
wide and did not rule out clinically important 
differences that could favour either treatment. No 
information was available on cure, adverse events 
or quality of life.
VCs vs no treatment
Cure and improvement rate
Two studies115,129 comparing VCs with no treatment 
reported conflicting data on improvement (Figure 
16). This may stem from a range of factors such 
as difference in study populations (SUI with or 
without UUI symptoms) and sample size, duration 
of treatment and supervisory intensity. The 
intervention for the ‘no-treatment’ group also 
differed, with one study by Bø and colleagues115 
offering instructions on a disposable vaginal device 
(Continence Guard™) only, whereas the other study 
by Williams and colleagues129 provided the same 
number of clinic visits as the treatment group, with 
leaflets giving advice on the pelvic floor muscles. 
Cure rates were not reported.
Adverse events
In one study115 62% (18/29) of the women who 
used weighted VCs reported abdominal pain DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
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and vaginitis, as well as difficulty in using cones 
and motivational problems. In the other study,129 
3% (2/80) in the cones group reported urinary 
infection. No adverse events were reported for 
women receiving no treatment (Table 23).
Quality of life
There was no evidence of a difference between the 
groups in either study (Table 23).
Comparison of different variants of VC
One study173 of 61 women with SUI compared 
VCs used in a static position (‘passive cones’) with 
VCs used while doing activities that previously 
made them incontinent (‘active cones’). The results 
showed a slightly higher cure rate for the active 
cones (Appendix 17, Comparison 13, 58% vs 70%, 
OR 0.59, 95% CI 0.21 to 1.71).
BT vs no treatment
Only one study135 compared BT with no treatment 
among women with different types of urinary 
incontinence (SUI with or without UUI symptoms). 
The results favoured BT in terms of both cure and 
improvement, although CIs were wide (Table 24). 
Condition-specific quality of life similarly favoured 
BT. The study reported no significant difference 
TABLE 23a  Adverse events: vaginal cones versus no treatment
VC NT
Notes
Population 
type n/N % n/N %
Bø 1999115 18/29 62 0/32 0 Abdominal pain, vaginitis, bleeding, 
motivation problems, trouble in using the 
cones
1
Williams 2006129 2/80 3 0/79 0 Urinary tract infection 2
TABLE 23b  Quality of life: vaginal cones versus no treatment
VC NT
Reported 
p-value Notes
Population 
type N Value N Value
Social Activity Index
Bø 1999115 27 0.1 (1.06) 30 –0.2 (1.68) Change in score 
(mean, SD)
1
The Leicester Impact Scale
aWilliams 2006129 79 2 (0.0 to 5.0) 75 1.5 (0.0 to 5.0) 0.658 Score (0–42, 
median, interquartile 
range)
2
a  Lower scores reflect better quality of life.
by incontinence diagnosis (stress, mixed or urge 
incontinence) (Table 24).
SNRI drug therapy
The characteristics of included studies comparing 
SNRI drug therapy (duloxetine) with no treatment 
are summarised in Table 25.
SNRI vs no treatment
All but one57 of the 12 trials compared SNRI 
(duloxetine) with placebo. The other study 
by Ghoniem and colleagues57 was a four-arm 
trial comparing duloxetine with placebo, both 
combined with either active or imitation PFMT. 
For cure and improvement as well as quality of life, 
data from two arms were compared (SNRI with 
imitation PFMT vs placebo with imitation PFMT), 
while for adverse events, data from all four arms 
were combined (SNRI with active or imitation 
PFMT vs placebo with active or imitation PFMT). 
All but three studies57,136,137 included women with 
SUI with UUI symptoms (population types 2 and 
3).
The majority of studies used a daily dose of 
80 mg, although participants in the SNRI group DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
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TABLE 24a  Cure and improvement rates: bladder training versus no treatment
BT NT
OR (95% CI) Measure
Population 
type n/N % n/N %
Cure rate
Fantl 1991135 7/60 12 2/63 3 4.03 (0.80 to 20.23), p = 0.091 2 2
Improvement
Fantl 1991135 45/60 75 15/63 24 9.60 (4.22 to 21.87), p < 0.001 2 2
TABLE 24b  Quality of life: bladder training versus no treatment
BT NT
Reported 
p-value Notes Population type N Value N Value
Incontinence Impact Questionnaire
aFantl 1991135 39 0.25 (0.29) 39 0.5 (0.59) 0.0001 Composite score  
(range 0–3, mean, SD)
2
a  Lower scores reflect better quality of life.
in the Cardozo and colleagues study137 ingested 
80 mg daily for 4 weeks, escalating to 120 mg 
daily for another 4 weeks. Another four-arm 
trial by Castro-Diaz and colleagues138 varied a 
starting dose in the first 2 weeks (20 mg twice a 
day, 40 mg once a day or 40 mg twice a day), with 
all participants in the SNRI group taking 40 mg 
twice daily in the subsequent weeks. In this study, 
cure and improvement rates and quality of life 
were measured at the end of 8 weeks, whereas 
adverse events were reported at the end of 
4 weeks when all participants had at least 2 weeks 
of ingesting 40 mg twice a day. In the study by 
Kinchen and colleagues,140 the participants were 
allowed to reduce or suspend study drug or 
use other modalities of treatment (e.g. PFMT) 
simultaneously with SNRI. One study by Manning 
and colleagues142 did not specify dosage and this 
was assumed to be 80 mg per day.
Cure and improvement rate
Cure and improvement rates were consistently 
higher across studies for SNRI than with placebo, 
regardless of the dosage (80, 40 or 20 mg per day) 
(Figures 17 and 18). Pooled data for a daily dosage 
of 80 mg showed that cure was reported in 11% 
(67/609) of the participants using SNRI compared 
with 8% (53/683) for placebo, and improvement 
was reported in 65% (1254/1939) for SNRI 
compared with 46% (803/1733) for placebo. The 
difference between the groups in improvement 
reached statistical significance (Figure 18: OR 2.02, 
95% CI 1.67 to 2.44) but for cure this was not the 
case. The results also appeared to show a noticeable 
placebo effect. The study by Cardozo and 
colleagues137 showed a higher OR for improvement 
than other studies. The reason for this is unclear, 
but may partly stem from the fact that the study 
recruited women with SUI only and also provided a 
higher drug dosage.
While most studies provided treatment for a period 
of 2–3 months, one study140 continued treatment 
for a total of 9 months and provided data on 
improvement; the results favoured the treatment 
group, although the difference was not statistically 
significant (Appendix 17, Comparison 14, 49% vs 
41%, OR 1.37, 95% CI 0.93 to 2.01).
A small number of studies using a daily dosage of 
40, 30 or 20 mg reported similar results. Pooled 
data for improvement from two studies144,145 using 
a daily dosage of 40 and 20 mg showed statistical 
heterogeneity, which may be partly explained by 
different sample populations, with one study145 
recruiting women with stress incontinence alone 
and the other144 including women with different 
types of incontinence.
Adverse events
Table 26 shows the number of participants who 
experienced any treatment-related adverse events Assessment of clinical effectiveness
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TABLE 25  Baseline characteristics of studies comparing serotonin–noradrenaline reuptake inhibitor drug therapy (duloxetine) with no 
treatment
Study ID
Population 
type
Duration 
(month) Comparator N randomised Age
Supervisory 
intensity
Bump 2004136 1 1 SNRI80 34 NR NA
NT 31 NR NA
Cardozo 2004137 1 2 SNRI80 55 54.5 NA
NT 54 52.4 NA
Castro-Diaz 
2007138
3 2 SNRI40 b.i.d., 
starting with 40 
b.i.d.
136 53.3 NA
SNRI40 b.i.d., 
starting with 40 q.d.
127 52.3 NA
SNRI40 b.i.d., 
starting with 20 
b.i.d.
133 53.5 NA
NT 120 52.7 NA
Dmochowski 
2003139
3 3 SNRI80 344 52.3 NA
NT 339 53.3 NA
Ghoniem 200557 1 3 SNRI 52 53.0 NA
NT 47 51.0 NA
Kinchen 2005140 3 3 SNRI80 224 52.7 NA
NT 227 53.5 NA
Mah 2006141 3 2 SNRI80 61 50.7 NA
NT 60 48.5 NA
Manning 2005142 3 2 SNRI80 306 NR NA
NT 311 NR NA
Millard 2004143 3 3 SNRI80 227 53.7 NA
NT 231 52.6 NA
Norton 2002144 2 3 SNRI80 140 49.3 NA
SNRI40 137 49.4 NA
SNRI20 138 49.4 NA
NT 138 50.2 NA
van Kerrebroeck 
2004117
3 3 SNRI80 247 52.0 NA
NT 247 54.0 NA
Zinner 1998145 1 1.5 SNRI40 33a NR NA
SNRI30 26a NR NA
SNRI20 34a NR NA
NT 34a NR NA
NT, no treatment; SNRI80, serotonin–noradrenaline reuptake inhibitors 80 mg per day.
a  n in analysis; total N randomised = 140.DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
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TABLE 26  Adverse events: serotonin–noradrenaline reuptake inhibitors versus no treatment
SNRI NT
Notes
Population 
type n/N % n/N %
N experiencing adverse events
SNRI 80 mg vs NT
Cardozo 2004137 43/46 93 37/52 71 Adverse events that occurred in more than 
10% of participants: nausea, constipation, 
headache, dry mouth, fatigue, dizziness, 
insomnia, somnolence and vomiting; serious 
adverse events: cardiovascular (not significantly 
different in both arms); increasing the dose 
from 80 mg to 120 mg daily did not increase 
efficacy or side effects
1
Ghoniem 200557 85/104 82 58/97 60 Adverse events that were significantly more 
common with SNRI than with placebo 
(with PFMT or imitation PFMT): nausea, 
dizziness, dry mouth, constipation, insomnia, 
somnolence, aesthesia
1
Norton 2002144 102/140 73 84/138 61 Adverse events that occurred in ≥ 5% of 
subjects in any treatment arm: nausea, 
headache, diarrhoea, constipation, dry 
mouth, dizziness, insomnia, sinusitis, fatigue, 
nasopharyngitis
2
Castro-Diaz 2007138 
(40 mg b.i.d. starting 
dose)
87/136 64 53/120 44 Adverse events that occurred in ≥ 2 
patients in first 4 weeks: nausea, dry 
mouth, constipation, somnolence, dizziness, 
insomnia, fatigue, headache, diarrhoea
3
Castro-Diaz 2007138 
(40 mg q.d. starting dose)
76/127 60 53/120 44 As above 3
Castro-Diaz 2007138 
(20 mg b.i.d. starting 
dose) 
69/133 52 53/120 44 As above 3
Dmochowski 2003139 255/344 74 170/339 50 Adverse events significantly more common 
with SNRI and occurring in ≥ 5% of subjects 
on SNRI: nausea, fatigue, insomnia, dry 
mouth, constipation, somnolence, dizziness, 
headache, diarrhoea
3
Kinchen 2005140 198/224 88 159/227 70 Adverse events for which there are 
statistically significant differences between 
groups: nausea, fatigue, insomnia, dizziness, 
headache, somnolence, dry mouth, 
constipation, diarrhoea, vomiting, increased 
sweating, decreased appetite, anxiety, tremor, 
decreased libido, lethargy, nightmare, fungal 
infection
3
Mah 2006141 50/61 82 19/60 32 Adverse events that occurred in ≥ 5% of the 
women randomised to the SNRI group or 
which occurred significantly more often with 
SNRI than with placebo: nausea, dizziness, 
anorexia, fatigue, lethargy, abdominal 
discomfort, somnolence, constipation, 
headache, dry mouth
3
Millard 2004143 173/227 76 137/231 59 Adverse events: significantly more common 
with, and occurring in, ≥ 5% of subjects 
with SNRI: nausea, headache, insomnia, 
constipation, dry mouth, dizziness, fatigue, 
somnolence, anorexia, vomiting, increased 
sweating, anxiety
3
continuedAssessment of clinical effectiveness
68
SNRI NT
Notes
Population 
type n/N % n/N %
van Kerrebroeck 2004117 200/247 81 158/247 64 Adverse events occurring in at least 5% of 
patients on SNRI or occurring significantly 
more often with SNRI than placebo: nausea, 
dry mouth, constipation, fatigue, insomnia, 
dizziness, headache, increased sweating, 
vomiting, somnolence, tremor
3
SNRI 40 mg vs NT
Norton 2002144 93/137 68 84/138 61 Adverse events that occurred in ≥ 5% of 
subjects in any treatment arm: nausea, 
headache, diarrhoea, constipation, dry 
mouth, dizziness, insomnia, sinusitis, fatigue, 
nasopharyngitis
2
SNRI 20 mg vs NT
Norton 2002144 86/138 62 84/138 61 Adverse events that occurred in ≥ 5% of 
subjects in any treatment arm: nausea, 
headache, diarrhoea, constipation, dry 
mouth, dizziness, insomnia, sinusitis, fatigue, 
nasopharyngitis
2
Discontinuation due to adverse events
SNRI 80 mg vs NT
Cardozo 2004137 18/55 33 3/54 6 1
Castro-Diaz 2007138 
(40 mg b.i.d. starting 
dose)
22/136 16 7/120 6 3
Castro-Diaz 2007138 
(40 mg q.d. starting dose)
15/127 12 7/120 6 3
Castro-Diaz 2007138 
(20 mg b.i.d. starting 
dose)
10/133 8 7/120 6 3
Dmochowski 2003139 83/344 24 14/339 4 3
Ghoniem 200557 28/104 27 8/97 8 1
Kinchen 2005140 20/224 9 5/227 2 3
Mah 2006141  21/61 34 5/60 8 3
Manning 2005142 53/306 17 9/311 3 3
Millard 2004143 39/227 17 4/231 2 3
Norton 2002144 21/140 15 7/138 5 2
van Kerrebroeck2004117 53/247 21 12/247 5 3
SNRI 40 mg vs NT
Norton 2002144 17/137 12 7/138 5 2
SNRI 20 mg vs NT
Norton 2002144 13/138 9 7/138 5 2
TABLE 26  Adverse events: serotonin–noradrenaline reuptake inhibitors versus no treatment (continued)DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
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TABLE 27  Quality of life: serotonin–noradrenaline reuptake inhibitors versus no treatment
SNRI NT
Reported 
p-value Notes
Population 
type N Value N Value
I-QoL
SNRI80 vs NT
Cardozo 2004137 52 10.6 (19.1) 52 2.4 (9.4) 0.003 Change in score 
(mean, SD)
1
Ghoniem 200557 50 8.3 45 4.8 Mean percentage 
score increase
1
Norton 2002144 130 9.3 132 5.8 0.03 Change in score 
(mean)
2
aCastro-Diaz 
2007138
344 12.9 112 5.7 < 0.001 Change in score 
(mean).
3
Dmochowski 
2003139
334 11.1 (14.8) 332 6.8 (13.8) < 0.001 Change in score 
(mean, SD)
3
Kinchen 2005140 208 13 218 10.4 0.07 Change in score 
(mean)
3
Mah 2006141 56 63.41 57 60.23 Total score (mean) 3
Millard 2004143 220 69.2 (23.8) 229 64.7 (24.9) Total score (mean, 
SD)
3
van Kerrebroeck 
2004117
240 72.2 245 68.5 0.127 Total score (mean) 3
SNRI40 vs NT
Zinner 1998145 33 8.2 (10.8) 34 2.6 (8.8) < 0.05 Change in score 
(mean, SD)
1
Norton 2002144 129 7.8 132 5.8 0.16 Change in score 
(mean)
2
SNRI30 vs NT
Zinner 1998145 26 10 (6.4) 34 2.6 (8.8) < 0.05 Change in score 
(mean, SD)
1
SNRI20 vs NT
Zinner 1998145 34 12 (16) 34 2.6 (8.8) < 0.05 Change in score 
(mean, SD)
1
Norton 2002144 132 5.3 132 5.8 0.6 Change in score 
(mean)
2
King’s Health Questionnaire
SNRI80 vs NT
bManning 2005142 306 –9.2 311 –2.6 < 0.0001 Change in score 
(mean)
3
ICIQ-UI SF
SNRI80 vs NT
bCastro-Diaz 
2007138
344 –2.8 112 –1.7 0.004 Change in score 
(mean)
3
ICIQ-UI SF, International Consultation on Incontinence Questionnaire – Urinary Incontinence Short Form; I-QoL, 
Urinary Incontinence Quality of Life Scale.
a  No significant difference among the three groups with different starting dose.
b  Lower scores reflect better quality of life.Assessment of clinical effectiveness
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TABLE 28  Baseline characteristics of studies comparing pelvic floor muscle training plus adjunct treatment versus no treatment
Study ID
Population 
type
Duration 
(month) Comparator
N 
randomised Age
Supervisory 
intensitya Notes
Bidmead 
2002121
1 3.5 PFMT + ES 82? 50.4 Basic
NT 20? 47.5 None
Ghoniem 
200557
1 3 PFMT + SNRI 52 54.0 Basic
NT 47 51.0 Basic Placebo drug and 
imitation PFMT
Goode 
2003123
3 2 PFMT + ES 67 54.9 Basic
NT 67 55.9 None Self-administered 
behavioural training
Hofbauer 
1990126
1 1.5 PFMT + ES 11 62.9 Intensive
NT 10 59.8 Intensive Sham ES
a  None, no clinic visit for training, treatment or supervision; basic, up to two clinic visits per month; intensive, more 
than two clinic visits per month.
and also lists all adverse events that were defined 
by trialists as being significant (in terms of quantity 
rather than severity): the latter is not a list of all 
adverse events. adverse events were experienced 
by 52–93% of participants in the SNRI group.137,138 
Notably, 32–64% of participants in the placebo 
group also reported adverse events.117,141 Nausea 
was the most commonly reported adverse event 
with SNRI. Castro-Diaz and colleagues138 reported 
that at 4 weeks (when all SNRI-treated participants 
had had at least 2 weeks’ use of 40 mg twice a day) a 
low starting dose of 20 mg, twice daily, significantly 
reduced the incidence of nausea and dizziness 
compared with other drug regimens.
It should be noted that the discontinuation rate 
among participants due to adverse events was high, 
at 8–34% in the SNRI group, compared with 2–8% 
in the placebo group (Table 26).
Serious adverse events were reported by three 
studies. One of these studies57 reported one case of 
rectal bleeding in the SNRI group but this was not 
attributed to the study drug. The second study144 
reported that five subjects had adverse events 
that required hospitalisation (one event before 
randomisation, one event in the group taking SNRI 
20 mg per day, two events in the group taking SNRI 
40 mg per day, and one event in the group taking 
SNRI 80 mg per day): only one of these events (a 
rash) was judged by the study authors to be related 
to the study drug. The third study140 recorded 
serious adverse events (details not reported) in 
eight of the 224 participants (16 events) in the 
SNRI group and seven of the 227 participants 
(eight events) in the placebo group. Of these, two 
of the events in the placebo group but none in the 
SNRI group was considered by the study author to 
be related to the study drug (active or placebo).
Quality of life
A total of 11 studies provided information on 
condition-specific quality of life using various 
outcome measures and drug doses (Table 27). 
With respect to studies using a daily dosage of 
80 mg, all 10 studies favoured SNRI-treated 
participants. This difference was reported to be 
statistically significant in all but two studies117,140 
that performed a statistical test. One study138 using 
two outcome measures reported consistent results 
favouring duloxetine. Only three studies reported 
data amenable to meta-analysis, with one reporting 
a total score at the final evaluation,143 and the other 
two reporting a change in score from baseline to 
the final evaluation.137,139 Pooled data from the 
two studies137,139 reporting a change in score found 
a statistically significant difference between the 
groups (Appendix 19, Comparison 04, OR 0.35. 
95% CI 0.16 to 0.55).
One study140 provided information for a longer 
treatment duration of 9 months; no significant 
difference between the groups was reported 
(Appendix 17, Comparison 14).
Two studies144,145 used a daily dose of 40, 30 and 
20 mg, with one study145 favouring duloxetine and 
the other144 reporting no statistically significant 
difference between SNRI and placebo (Table 27).DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
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Comparison of different SNRI doses
Two small studies144,145 compared different doses 
of SNRI. Data on cure and improvement rates are 
reported in Appendix 17, Comparison 15. In one 
study,144 slightly more participants taking a higher 
dose of SNRI were improved than those taking 
a lower dose (80 mg: 44%, 57/130; 40 mg: 37%, 
48/129; 20 mg: 31%, 41/132), but no such pattern 
was found for cure rates (80 mg: 19%, 23/123; 
40 mg: 24%, 30/123; 20 mg: 16%, 21/128). The 
other smaller study145 also did not find any dose 
dependence for improvement rates (40 mg: 45%, 
15/33; 30 mg: 31%, 8/26; 20 mg: 44%, 15/34).
With respect to adverse events, the direction of 
effect was consistent across all comparisons, with 
more participants experiencing adverse events with 
a higher dose than with a lower dose (Appendix 17, 
Comparison 15).
There is no strong evidence to say whether a 
lower dose is associated with a better quality of life 
(Appendix 17, Comparison 16).
PFMT with adjunct treatment
The characteristics of included studies comparing 
PFMT with adjunct treatment versus no treatment 
are summarised in Table 28.
PFMT plus ES vs no treatment
Cure and improvement
Three studies121,123,126 compared PFMT with adjunct 
ES versus no treatment (Figures 19 and 20). Pooled 
data from two of these studies with data123,126 
showed a higher improvement rate (but not cure 
rate) in the intervention group, although the CI 
was wide (Figure 20: OR 8.69, 95% CI 1.87 to 
40.32).
Adverse events
Only one study123 reported adverse events: 6% 
(4/67) of the participants using ES experienced 
vaginal irritation (Table 29).
Quality of life
The same study123 found no significant difference 
between the groups in condition-specific quality of 
life (Table 29) and general quality of life (Appendix 
17, Comparison 17).
PFMT plus SNRIs vs no treatment
One four-arm trial57 reported data for a 
combination of PFMT plus a drug therapy (SNRI) 
compared with no treatment (Table 30). The ‘no-
treatment’ arm received placebo drugs and also 
performed imitation PFMT. The PFMT-plus-SNRI 
group was associated with higher improvement 
rates and higher (better) quality of life than the 
no-treatment group. adverse events associated with 
SNRI (with PFMT or imitation PFMT) are reported 
separately in Table 27. No adverse events associated 
with PFMT were reported.
Comparison between 
different treatments: single 
modality
Table 31 summarises the characteristics of included 
studies comparing different single interventions. 
PFMT augmented with BF is included here as a 
‘single’ intervention.
PFMT vs ES
Seven studies provided at least one of the 
specified primary outcomes.115,124,126,174–177 Of these, 
five studies, namely Bernardes and colleagues 
(2000),174 Bø and colleagues (1999),115 Henalla 
and colleagues (1989),124 Hofbauer and colleagues 
(1990)126 and Laycock and colleagues (1988),176 
provided intensive supervision (more than two 
sessions per month) for both groups. In addition, 
the study by Bø and colleagues (1999)115 also 
provided intensive supervision for the PFMT group 
but basic supervision (two or fewer sessions per 
month) for the comparator group.
Cure and improvement
Pooled data for cure and improvement indicated 
that PFMT was more effective than ES in terms 
of both cure (Figure 21: OR 2.65, 95% CI 0.82 to 
8.60) and improvement (Figure 22: OR 2.18, 95% 
CI 0.76 to 6.28). The direction and magnitude 
of effects varied across studies, particularly for 
the improvement rate which displayed statistical 
heterogeneity at the 10% level (p = 0.070). The 
source of heterogeneity was unclear. However, it is 
noteworthy that all but one study (Laycock 1988)176 
that provided intensive supervision for the PFMT 
group showed ORs (point estimate) of greater than 
one (favouring PFMT on average) for both cure 
and improvement data.
Adverse events and quality of life
Information on adverse events and condition-
specific quality of life was provided by one small 
study only115 (Table 32). In this study, adverse events 
were experienced in 31% (10/32) of the participants 
using ES but none in the PFMT group. Seven 
participants in the ES group withdrew. Condition-
specific quality-of-life scores were similar for both 
groups (Table 32).Assessment of clinical effectiveness
72
S
t
u
d
y
O
R
 
(
9
5
%
 
C
I
)
E
v
e
n
t
s
,
 
t
r
e
a
t
m
e
n
t
E
v
e
n
t
s
,
 
c
o
n
t
r
o
l
%
W
e
i
g
h
t
M
e
a
s
u
r
e
P
o
p
u
l
a
t
i
o
n
 
t
y
p
e
H
o
f
b
a
u
e
r
 
1
9
9
0
1
2
6
8
.
6
5
 
(
0
.
3
9
 
t
o
 
1
9
1
.
5
8
)
 
3
/
1
1
0
/
1
0
2
6
.
2
2
1
1
G
o
o
d
e
 
2
0
0
3
1
2
3
1
.
0
0
 
(
0
.
3
9
 
t
o
 
2
.
5
9
)
 
1
0
/
6
7
1
0
/
6
7
7
3
.
7
8
2
3
O
v
e
r
a
l
l
 
(
I
2
=
 
4
2
.
6
%
,
 
p
=
 
0
.
1
8
7
)
1
.
7
6
 
(
0
.
2
7
 
t
o
 
1
1
.
5
4
)
1
3
/
7
8
1
0
/
7
7
1
0
0
.
0
0
N
O
T
E
:
 
W
e
i
g
h
t
s
 
a
r
e
 
f
r
o
m
 
r
a
n
d
o
m
 
e
f
f
e
c
t
s
 
a
n
a
l
y
s
i
s
1
0
.
0
0
5
2
2
1
9
2
F
a
v
o
u
r
s
 
N
T
F
a
v
o
u
r
s
 
P
F
M
T
+
E
S
S
t
u
d
y
O
R
 
(
9
5
%
 
C
I
)
E
v
e
n
t
s
,
 
t
r
e
a
t
m
e
n
t
E
v
e
n
t
s
,
 
c
o
n
t
r
o
l
%
W
e
i
g
h
t
M
e
a
s
u
r
e
P
o
p
u
l
a
t
i
o
n
 
t
y
p
e
H
o
f
b
a
u
e
r
 
1
9
9
0
1
2
6
3
5
.
0
0
 
(
1
.
6
3
 
t
o
 
7
5
2
.
7
1
)
 
7
/
1
1
0
/
1
0
2
3
.
7
9
1
1
G
o
o
d
e
 
2
0
0
3
1
2
3
5
.
6
3
 
(
1
.
1
2
 
t
o
 
2
8
.
2
7
)
 
4
5
/
4
7
3
2
/
4
0
7
6
.
2
1
1
3
O
v
e
r
a
l
l
 
(
I
2
=
 
7
.
5
%
,
 
p
=
 
0
.
2
9
9
)
8
.
6
9
 
(
1
.
8
7
 
t
o
 
4
0
.
3
2
)
5
2
/
5
8
3
2
/
5
0
1
0
0
.
0
0
N
O
T
E
:
 
W
e
i
g
h
t
s
 
a
r
e
 
f
r
o
m
 
r
a
n
d
o
m
 
e
f
f
e
c
t
s
 
a
n
a
l
y
s
i
s
F
a
v
o
u
r
s
 
N
T
F
a
v
o
u
r
s
 
P
F
M
T
+
E
S
1
0
.
0
0
1
3
3
7
5
3
F
I
G
U
R
E
 
1
9
 
C
u
r
e
 
r
a
t
e
s
:
 
p
e
l
v
i
c
 
fl
o
o
r
 
m
u
s
c
l
e
 
t
r
a
i
n
i
n
g
 
a
n
d
 
e
l
e
c
t
r
i
c
a
l
 
s
t
i
m
u
l
a
t
i
o
n
 
v
e
r
s
u
s
 
n
o
 
t
r
e
a
t
m
e
n
t
.
F
I
G
U
R
E
 
2
0
 
I
m
p
r
o
v
e
m
e
n
t
 
r
a
t
e
s
:
 
p
e
l
v
i
c
 
fl
o
o
r
 
m
u
s
c
l
e
 
t
r
a
i
n
i
n
g
 
a
n
d
 
e
l
e
c
t
r
i
c
a
l
 
s
t
i
m
u
l
a
t
i
o
n
 
v
e
r
s
u
s
 
n
o
 
t
r
e
a
t
m
e
n
t
.DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
73
TABLE 29a  Adverse events: pelvic floor muscle training plus electrical stimulation versus no treatment
PFMT + ES NT
Notes
Population 
type n/N % n/N %
Goode 2003123 4/67 6 0/67 0 Vaginal irritation 3
TABLE 29b  Quality of life: pelvic floor muscle training plus electrical stimulation versus no treatment
PFMT + ES NT
Notes
Population 
type N Value N Value
Incontinence Impact Questionnaire
Goode 2003123 67 No difference 67 No difference Total score 3
TABLE 30a  Improvement rate: pelvic floor muscle training plus serotonin–noradrenaline reuptake inhibitors versus no treatment
PFMT + SNRI NT
OR (95% CI) Measure
Population 
type n/N % n/N %
Improvement rate
Ghoniem 200557 36/51 71 19/45 42 3.28 (1.41 to 7.64), 
p = 0.006
1 1
TABLE 30b  Quality of life: pelvic floor muscle training  plus serotonin–noradrenaline reuptake inhibitors versus no treatment
PFMT + SNRI NT
Notes
Population 
type N Value N Value
I-QoL
Ghoniem 200557 51 13.1 50 8.3 Change in score (mean 
percentage score increase)
1
TABLE 31  Background characteristics of studies comparing different treatments (single modality)
Study ID
Population 
type
Duration 
(month)
Compa-
rator
N 
randomised
Age 
(years)
Supervisory 
intensitya Notes
Arvonen 
2001178
1 4 PFMT 20 47.0 Basic
VC 20 49.0 Basic
Bernardes 
2000174
1 0.3 PFMT 7 44.1 Intensive
ES 7 53.3 Intensive
Bø 1999115 1 6 PFMT 29 49.6 Intensive
ES 32 47.2 Basic Maximum 
intermittent vaginal 
stimulation
VC 29 49.2 Basic
continuedAssessment of clinical effectiveness
74
Study ID
Population 
type
Duration 
(month)
Compa-
rator
N 
randomised
Age 
(years)
Supervisory 
intensitya Notes
Cammu 
1998181
1 3 PFMT + BF 30 55.9 Intensive
VC 30 56.3 Basic
Delneri 
2000186
1 0.5 ES 10 49.5 Intensive Functional ES
1 VC 10 41.5 NR
Ghoniem 
200557
1 3 PFMT 50 54.0 Basic Placebo drug
SNRI 52 53.0 Basic Imitation PFMT
Hahn 
1991175
1 6 PFMT 10 47.2 Basic IFT
ES 10 Basic
Haken 
1991179
1 2.5 PFMT 33 48.0 Basic
VC 31 Basic
Henalla 
1989124
1 3 PFMT 26 NR Intensive
ES 25 NR Intensive IFT
Hofbauer 
1990126
1 1.5 PFMT 11 51.0 Intensive 12 visits
ES 11 59.7 Intensive 18 visits; faradism
Klarskov 
1986184
1 4 PFMT 24 48.0 Basic
Surgery 26 NR
Laycock 
1988176
1 1–2? PFMT 16 44.0 Intensive Weekly visit
ES 20 Intensive 2–3 visits per 
week; IFT
Laycock 
2001152
1 3 PFMT 20 NR Basic
PFMT + BF 40 NR Basic
VC 41 NR Basic
Oláh 
1990187 
3 1 ES 36 47.9 Intensive 12 visits
VC 33 43.2 Intensive 4 visits; IFT
Peattie 
1988180
1 1 PFMT 22 NR Intensive
VC 22 NR Basic
Sherburn 
2007182
1 5 PFMT 43 72.0 Intensive
BT 41 Intensive
Smith 
1996177
1 4 PFMT 9 48.0 Basic?
ES 9 53.0 Basic? Intravaginal 
neuromuscular 
stimulation
Tapp 
1989185 
1 3 PFMT 27 NR Intensive
Surgery 28 NR NR
Williams 
2006129
2 3 PFMT 79 55.9 Basic
VC 80 58.2 Basic
Wise 
1993188
1 3 ES 20 NR Basic Maximal vaginal ES
VC 21 NR Basic
Wyman 
1998183
2 3 PFMT + BF 69 62.0 Basic
BT 68 60.0 Basic
a  None, no clinic visit for training, treatment or supervision; basic, up to two clinic visits per month; intensive, more 
than two clinic visits per month.
TABLE 31  Background characteristics of studies comparing different treatments (single modality) (continued)DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
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TABLE 32a  Adverse events: pelvic floor muscle training versus electrical stimulation
PFMT ES
Notes
Population 
type n/N % n/N %
N experiencing AEs
Bø 1999115 0/29 0 10/32 31 Smarting (tenderness, bleeding, 
discomfort), motivation problem, 
difficulty in using the stimulator
1
TABLE 32b  Quality of life: pelvic floor muscle training versus electrical stimulation
PFMT ES
Notes
Population 
type N Value N Value
Social Activity Index 
Bø 1999115 25 0.6 (1.02) 25 0.6 (1.02) Change in score (mean, SD) 1
PFMT, with or without BF, vs VC
Seven studies provided information on at least one 
of the specified primary outcomes.115,129,152,178–181 
Three of these studies, namely Bø and colleagues 
(1999),115 Cammu and colleagues (1998)181 and 
Peattie and colleagues (1988),180 provided intensive 
supervision (more than two sessions per month) 
for the PFMT group (with or without BF) but basic 
supervision (two or fewer sessions per month) for 
the VCs group. The other studies provided basic 
supervision for both groups.
Cure and improvement
There appeared to be no clear differences between 
PFMT, with or without BF, and VCs (Figures 23 
and 24). One study by Bø and colleagues (1999)115 
stands out, showing a relatively higher OR 
favouring PFMT. It is not clear why this is the case. 
One explanation may be a longer training duration 
and more supervisory sessions for the PFMT group 
relative to other studies.
Adverse events
Four studies115,129,179,181 reported adverse events 
(Table 33). The first study115 reported that 
62% (18/29) of participants in the VCs group 
experienced adverse events, compared with none 
in the PFMT group. The second study179 did 
not report any data but noted that PFMT was 
associated with difficulty remembering to use 
the technique, whereas participants using cones 
reported aesthetic dislike of the technique as well 
as difficulties associated with vaginal prolapse, 
resulting for some in discontinuation of the cone 
treatment. In the third study,129 there were two 
cases of urinary tract infection in both groups 
but no other side effects were reported by the 
participants. The fourth study181 reported that 47% 
(14/30) in the cones group experienced adverse 
events and subsequently discontinued treatment, 
compared with none in the PFMT-plus-BF group.
Quality of life
Two studies129,152 found no statistically significant 
differences between groups in condition-specific 
quality of life (Table 33).
PFMT, with or without BF, vs BT
Cure and improvement
Two studies182,183 compared PFMT (with or without 
BF) with BT (Table 34). The first study182 recruited 
women with SUI only (population type 1) and 
reported cure rates of 48% (19/40) for PFMT and 
26% (9/35) for BT immediately after the supervised 
treatment phase (OR 2.61, 95% CI 0.98 to 6.96). 
The difference was not statistically significant. 
The other study183 included women with other 
urinary incontinence symptoms (population 
type 2) and similarly found no clear difference 
between groups in cure and improvement at the 
end of the supervised treatment phase (Table 34: 
cure 13% vs 18%; improvement 76% vs 65%), and 
3 months after the end of the treatment phase 
(Appendix 17, Comparison 18: cure 20% vs 16%; 
improvement 70% vs 62%). In this second study,183 
a large proportion of participants from both groups 
appeared to have sought alternative treatments by Assessment of clinical effectiveness
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TABLE 33b  Quality of life: pelvic floor muscle training with or without biofeedback versus vaginal cones
PFMT ± BF VC
Reported 
p-value Notes
Population 
type N Value N Value
Social Activity Index – PFMT vs VC
Bø 1999115 25 0.6 (1.02) 27 0.1 (1.06) Change in score (mean, 
SD)
1
King’s Health Questionnaire – PFMT vs VC
Laycock 2001152 16 8.13 (9.06) 30 7.03 (7.74) NS Change in score (mean 
increase, SD)
1
King’s Health Questionnaire – PFMT + BF vs VC
Laycock 2001152 22 6.14 (6.2) 30 7.03 (7.74) NS Change in score (mean 
increase, SD)
1
The Leicester Impact Scale – PFMT vs VC
aWilliams 
2006129
77 2 (0.0 to 5.0) 79 2 (0.0 to 5.0) 0.729 Score (median interquartile 
range)
2
a  Lower scores reflect better quality of life.
TABLE 33a  Adverse events: pelvic floor muscle training with or without biofeedback versus vaginal cones
PFMT ± BF VC
Notes
Population 
type n/N % n/N %
PFMT vs VC
Bø 1999115 0/29 0 18/29 62 Abdominal pain, vaginitis, bleeding, 
motivation problems, trouble in using the 
cones
1
Haken 1991179 ND/33 ND/31 ‘Difficulty remembering to use the 
technique was a significant feature in the 
[PFMT] group which was not apparent in 
those using cones. Causes of withdrawal 
in the cones group were predominantly 
aesthetic dislike of the technique and 
difficulties associated with vaginal prolapse’; 
number lost to follow-up for PFMT = 3/33, 
for cones = 8/31
1
Williams 2006129 2/79 3 2/80 3 Urinary tract infection 2
PFMT + BF vs VC
Cammu 1998181 0/30 0 14/30 47 Unpleasant feeling (n = 5), time consuming 
(n = 3), inability to introduce the cone when 
too nervous or when in a hurry (n = 2), 
interference with menstrual cycle (n = 2), a 
certain cone held in the morning could not 
be held any longer in the evening (muscle 
fatigue) (n = 2)
1
ND, no data.DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
81
the end of the 3-year follow-up; of those who did 
not receive any additional treatment, cure rates 
were 9% (1/11) in the PFMT group and 18% (4/22) 
in the BT group (Appendix 17, Comparison 18).
Adverse events
No data were available on adverse events.
Quality of life
Condition-specific quality of life was better for 
women having PFMT with or without BF, compared 
with BT (Table 34). In one study182 that performed 
a statistical test, the difference was found to be 
statistically significant. General HRQoL scores 
[Assessment of Quality of Life (AQoL)] were similar 
for both groups in one study182 that reported this 
outcome (Appendix 17, Comparison 18).
PFMT vs SNRI (80 mg)
One study57 compared PFMT (with placebo drug) 
with SNRI (with imitation PFMT). The results 
showed greater improvement and better condition-
specific quality of life in the PFMT group, although 
the difference was not statistically significant  
(Table 35).
PFMT vs surgery
Data on cure and improvement from two 
studies184,185 comparing PFMT with surgery 
are shown in Figures 25 and 26. One of these 
studies184 compared PFMT with either Burch 
colposuspension, vaginal repair or combined 
procedures, whereas the other study185 compared 
PFMT with Burch colposuspension. The results 
for both cure and improvement favoured surgery 
(Figures 25 and 26: OR for cure 0.08, 95% CI 0.03 
to 0.23; OR for improvement 0.19, 95% CI 0.04 to 
0.77). However, no information was reported on 
adverse events or quality of life.
ES vs VC: cure and 
improvement
Figures 27 and 28 show pooled data from three 
studies115,187,188 reporting the number of women 
cured or improved after treatment with ES 
compared with VCs. No statistically significant 
difference between the groups was found (Figures 
27 and 28: OR for cure 1.00, 95% CI 0.26 to 3.91, 
OR for improvement 1.30, 95% CI 0.59 to 2.84).
One of these studies187 provided data at 6 months 
after the initial treatment phase had finished and 
found no statistically significant difference between 
the groups in terms of cure (OR 0.93, 95% CI 0.31 
to 2.78) or improvement (OR 0.54, 95% CI 0.17 to 
1.68) (Appendix 17, Comparison 19).
ES vs VC: adverse events
One study115 indicated that more participants 
experienced adverse events in the VC group 
(62%) than in the ES group (31%), although 
discontinuation due to adverse events was more 
common in the ES group (7/32) than in the VC 
group (1/29) (Table 36). Another study,187 which 
used cones to assess pelvic floor muscle strength in 
both groups, reported that nine women withdrew 
because of a failure to tolerate the cones during 
pretreatment assessment. In seven of these women, 
the vagina was too narrow and the cones ‘wedged’. 
The same study187 reported a further two adverse 
events (one psychiatric disorder and one death) 
in the cones group, which were considered by 
the study author to be unrelated to the study 
intervention.
ES vs VC: quality of life
The information on condition-specific quality of 
life was available from one study only.115 The results 
were similar for both groups (Table 36).
Comparison between 
different treatments: dual 
modality
The characteristics of included studies comparing a 
single intervention with an intervention combined 
with an adjunct treatment are summarised in Table 
37. Pelvic floor muscle training with sham ES was 
classified as being equivalent to PFMT. Where 
both PFMT and PFMT with sham ES were present 
within a trial, the dichotomous data were combined 
(added up).121,190 In two three-arm trials examining 
the addition of ES to PFMT plus BF,157,172 the trial 
arms involving different types of ES (PFMT plus 
BF and ES) were combined for dichotomous data.
PFMT (with or without BF) vs 
PFMT (with or without BF) and 
adjunct treatment
PFMT (with or without BF) vs PFMT 
(with or without BF) and ES
Cure and improvement
Pooled data on cure and improvement showed 
that all trial estimates overlapped, and there was 
significant statistical heterogeneity for the cure 
rate at the 10% level (Figures 29 and 30: OR for 
cure without BF 1.02, 95% CI 0.29 to 3.55; OR Assessment of clinical effectiveness
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TABLE 34a  Cure rates and improvement rates: pelvic floor muscle training, with or without biofeedback, versus bladder training
PFMT ± BF BT
OR (95% CI) Measure Population type n/N % n/N %
Cure rate
PFMT vs BT
Sherburn 2007182 19/40 48 9/35 26 2.61 (0.98 to 6.96), 
p = 0.055
2 1
PFMT + BF vs BT
Wyman 1998183 8/64 13 12/68 18 0.67 (0.25 to 1.76), 
p = 0.412
2 2
Improvement
PFMT + BF vs BT
Wyman 1998183 48/63 76 43/66 65 1.71 (0.79 to 3.70), 
p = 0.171
1 2
TABLE 34b  Quality of life: pelvic floor muscle training, with or without biofeedback, versus bladder training
PFMT ± BF BT
Reported 
p-value Notes
Population 
type N Value N Value
ICIQ-UI SF – PFMT vs BT
aSherburn 2007182 43 5 (4) 41 8 (7) 0.003 Score (median interquartile 
range)
1
Urogenital Distress Inventory – PFMT + BF vs BT
aWyman 1998183 45 81.2 (39.6) 47 99.2 (54.4) Score (mean, SD) 1
Incontinence Impact Questionnaire-Revised – PFMT + BF vs BT
aWyman 1998183 45 43.5 (47.4) 47 68.4 (69.7) Score (mean, SD) 1
ICIQ-UI SF, International Consultation on Incontinence Questionnaire – Urinary Incontinence Short Form.
a  Lower scores reflect better quality of life.
TABLE 35a  Improvement rate: pelvic floor muscle training versus serotonin–noradrenaline reuptake inhibitor (80 mg)
PFMT SNRI
OR (95% CI) Measure
Population 
type n/N % n/N %
Ghoniem 200557 32/49 65 27/50 54 1.60 (0.71 to 3.60), 
p = 0.253
1 1
TABLE 35b  Quality of life: pelvic floor muscle training versus serotonin–noradrenaline reuptake inhibitor (80 mg)
PFMT SNRI
Reported 
p-value Notes
Population 
type N Value N Value
I-QoL
Ghoniem 200557 49 7.8 50 8.3 0.979 Change in score (mean 
percentage score increase)
1DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
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TABLE 36a  Adverse events: electrical stimulation versus vaginal cone
ES VC
Notes
Population 
type n/N % n/N %
N experiencing AEs
Bø 1999115 10/32 31 18/29 62 ES: Smarting (tenderness, bleeding, 
discomfort), motivation problem, 
difficulty in using the stimulator
VC: Abdominal pain, vaginitis, bleeding, 
motivation problems, trouble in using the 
cones
1
Oláh 1990187 4/36 11 5/33 15 Unable to tolerate cones (used to assess 
pelvic floor muscle strength in both 
groups): the vagina was too narrow and 
the cones ‘wedged’; irregular uterine 
bleeding preventing cone use; discomfort 
experienced during use because of 
excessive scar tissue in the vagina
3
TABLE 36b  Quality of life: electrical stimulation versus vaginal cone
ES VC
Notes Population type N Value N Value
Social Activity Index
Bø 1999115 25 0.6 (1.02) 27 0.1 (1.06) Change in score (mean, 
SD)
1
for improvement without BF 0.84, 95% CI 0.34 to 
2.07; OR for improvement with BF 0.86, 95% CI 
0.36 to 2.08). The source of heterogeneity appears 
to be the study by Blowman and colleagues,189 
which suggested that adding ES to PFMT was 
significantly better than PFMT alone. The reason 
for this is unclear.
Two studies157,172 reported the improvement rate 
at 6 months after the end of the initial treatment 
phase (Appendix 17, Comparison 20). No 
differences between the treatment groups were 
found.
Adverse events
Only one study123 reported any adverse events 
(Table 38). The combined treatment group recorded 
four (6%) occurrences of vaginal irritation due to 
application of ES devices, compared with none in 
the PFMT group.
Quality of life
Condition-specific (Incontinence Impact 
Questionnaire) (Table 38) and general HRQoL (SF-
36) (Appendix 17, Comparison 20) was reported 
by one study only.123 The results did not differ by 
treatment group.
PFMT vs PFMT plus VC
One study192 reported cure and improvement rates 
for PFMT compared with PFMT with adjunct VCs 
(Table 39). The results were slightly better for the 
combined treatment group, but these differences 
were not statistically significant.
PFMT plus BF vs PFMT plus BF and BT
Cure and improvement
One study183 of 136 women with different types 
of incontinence reported cure and improvement 
at the end of the 3-month treatment phase, at 
6 months (3 months after the end of treatment) 
and at 3.2 years (Table 40). Both cure and 
improvement rates were consistently higher in the 
combined treatment group at 3 months (Table 40: 
cure OR 0.32, 95% CI 0.13 to 0.79; improvement 
OR 0.35, 95% CI 0.13 to 0.97) and 6 months 
(Appendix 17, Comparison 21: cure OR 0.69, 
95% CI 0.30 to 1.58; improvement OR 0.75, 
95% CI 0.34 to 1.69). However, the differences 
were not statistically significant at follow-up at 
6 months. The percentage of participants who Assessment of clinical effectiveness
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TABLE 37  Background characteristics of studies comparing different treatments (dual modality)
Study ID
Population 
type
Duration 
(month) Comparator
N 
randomised Age
Supervisory 
intensitya Notes
Bidmead 
2002121
1 3.5 PFMT 40? 46.2 Basic
PFMT + sham ES 42? 51.5 Basic
PFMT + ES 82? 50.4 Basic
Blowman 
1991189
1 ?1 PFMT 7 42.5 Basic With sham ES
PFMT + ES 7 45.0 Basic ES = neurotrophic 
stimulation
Ghoniem 
200557
1 3 PFMT 50 54.0 Basic
SNRI 52 53.0 Basic
PFMT + SNRI 52 54.0 Basic
Goode 
2003123
3 2 PFMT 66 57.7 Basic
PFMT + ES 67 54.9 Basic ES = biphasic 
pulses
Haig 
1995190
1 3 PFMT 20 55.0 Intensive
PFMT + sham ES 18 51.0 Intensive
PFMT + ES 20 51.0 Intensive
Hofbauer 
1990126
1 1.5 PFMT 11 51.0 Intensive
ES 11 59.7 Intensive Faradic
PFMT + ES 11 62.9 Intensive
Knight 
1998172
1 6 PFMT + BF 21 NR Intensive ES = maximal 
stimulation at 
clinic
PFMT + BF + ES 
(maximal)
24 NR Intensive
PFMT + BF + ES 
(low)
25 NR Intensive ES = overnight at 
low intensity at 
home
Pieber 
1995192
1 3 PFMT 25 44.3 Basic
PFMT + VC 21 41.7 Basic
Tapp 
1987191
1 3 PFMT 15 NR Intensive
PFMT + ES 14 NR Intensive
Tapp 
1989185
1 3 PFMT 27 NR Intensive
PFMT + ES 26 NR Intensive Faradic
Wilson 
1987157
1 1.5 PFMT + BF 15 46.8 Intensive
PFMT + BF + ES 
(faradism)
15 Intensive
PFMT + BF + ES 
(IFT)
15 Intensive
Wise 
1993188
1 3 PFMT + VC 21 NR Basic
VC 21 NR Basic
Wyman 
1998183
2 3 PFMT + BF 69 62.0 Basic
BT 68 60.0 Basic
PFMT + BF + BT 67 61.0 Basic
a  None, no clinic visit for training, treatment or supervision; basic, up to two clinic visits per month; intensive, more 
than two clinic visits per month.DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
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TABLE 38a  Number experiencing adverse effects: pelvic floor muscle training (PFMT) versus PFMT plus electrical stimulation
PFMT PFMT + ES
Notes Population type n/N % n/N %
Goode 2003123 0/66 0 4/67 6 Vaginal irritation 3
TABLE 38b  Quality of life: pelvic floor muscle training (PFMT) versus PFMT plus electrical stimulation
PFMT PFMT + ES
Notes Population type N Value N Value
Incontinence Impact Questionnaire
Goode 2003123 66 No difference 67 No difference Total score 3
TABLE 39  Cure and improvement rates: pelvic floor muscle training (PFMT) versus PFMT plus vaginal cone
PFMT PFMT + VC
OR (95% CI) Measure Population type n/N % n/N %
Cure rate
Pieber 1995192 3/25 12 5/21 24 0.44 (0.09 to 2.10), p = 0.300 1 1
Improvement rate
Pieber 1995192 12/25 48 11/21 52 0.84 (0.26 to 2.68), p = 0.767 1 1
TABLE 40a  Cure and improvement rates: pelvic floor muscle training (PFMT) plus biofeedback (BF) versus PFMT plus BF and bladder 
training
PFMT + BF PFMT + BF + BT
OR (95% CI) Measure
Population 
type n/N % n/N %
Cure rate
Wyman 1998183 8/64 13 19/61 31 0.32 (0.13 to 0.79), 
p = 0.014
2 2
Improvement rate
Wyman 1998183 48/63 76 55/61 90 0.35 (0.13 to 0.97), 
p = 0.044
1 2
remained cured at 3.2 years was 50% (8/16) for 
the combined treatment and 9% (1/11) for the 
comparator, although the number available for 
long-term assessment was very small (Appendix 17, 
Comparison 21).
Quality of life
The same study183 measured condition-specific 
quality of life using two instruments (Table 40). 
The data at the end of the 3-month treatment 
phase were reported separately for women with 
SUI alone: one instrument (Urogenital Distress 
Inventory) favoured the group with adjunct BT, 
and the other (Incontinence Impact Questionnaire 
Revised) favoured the group without BT. The data 
with longer follow-up were reported combined 
for all participants with SUI, UUI and MUI 
(Appendix 17, Comparison 21). The results were 
again contradictory according to the different 
instruments.
PFMT vs PFMT plus SNRI
One study57 reported improvement and condition-
specific quality of life for PFMT compared with DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
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TABLE 40b  Quality of life: pelvic floor muscle training (PFMT) plus biofeedback (BF) versus PFMT plus BF and bladder training
PFMT + BF PFMT + BF + BT
Notes Population type N Value N Value
Urogenital Distress Inventory
aWyman 1998183 45 81.2 
(39.6)
44 63.2 (49.2) Score (mean, SD) 1
Incontinence Impact Questionnaire-Revised
aWyman 1998183 45 43.5 
(47.4)
44 52.3 (73.4) Score (mean, SD) 1
a  Lower scores reflect better quality of life.
women having a combination of PFMT plus 
adjunct drug therapy (Table 41). The results were 
slightly better for the combined treatment, but 
these differences were not statistically significant. 
adverse events associated with SNRI (with PFMT 
or imitation PFMT) are reported separately in Table 
27.
PFMT plus adjunct treatment vs 
the adjunct treatment
PFMT plus ES vs ES
One study126 reported the number of women cured 
or improved for PFMT plus ES compared with 
ES alone (Table 42). The ORs (point estimate) 
favoured the combined treatment for both cure and 
improvement, but CIs were wide and included one 
(no difference).
PFMT plus VC vs VC
One study188 compared a combination of PFMT 
plus VCs with VCs alone (Table 43). Between 74% 
and 93% of participants improved after treatment 
but there was no clear difference between the 
groups.
PFMT plus BF and BT vs BT
Cure and improvement
One study183 of 135 women with different types 
of urinary incontinence reported cure and 
improvement at the end of the 3-month treatment 
phase, at 6 months (3 months after the end of 
treatment) and 3.2 years (Table 44). The results 
showed higher cure and improvement rates for 
the combined treatment group at the end of 
the initial treatment phase (Table 44: cure OR 
2.11, 95% CI 0.92 to 4.82; improvement OR 
4.90, 95% CI 1.84 to 13.10), and at 6 months 
(Appendix 17, Comparison 22; cure OR 1.89, 
TABLE 41a  Improvement rates: pelvic floor muscle training (PFMT) versus PFMT plus serotonin–noradrenaline reuptake inhibitor
PFMT PFMT + SNRI
OR (95% CI) Measure Population type n/N % n/N %
Ghoniem 200557 32/49 65 36/51 71 0.78 (0.34 to 1.82), 
p = 0.572
1 1
TABLE 41b  Quality of life: pelvic floor muscle training (PFMT) versus PFMT plus serotonin–noradrenaline reuptake inhibitor
PFMT PFMT + SNRI
Reported 
p-value Notes Population type N Value N Value
I-QoL
Ghoniem 200557 49 7.8 51 13.1 0.063 Mean percentage score 
increase
1Assessment of clinical effectiveness
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TABLE 42  Cure and improvement rates: pelvic floor muscle training plus electrical stimulation (ES) versus ES
PFMT + ES ES
OR (95% CI) Measure
Population 
type n/N % n/N %
Cure rate
Hofbauer 1990126 3/11 27 1/11 9 3.75 (0.33 to 43.31), 
p = 0.290
1 1
Improvement rate
Hofbauer 1990126 7/11 64 3/11 27 4.67 (0.77 to 28.47), 
p = 0.095
1 1
TABLE 43  Improvement rates: pelvic floor muscle training plus vaginal cone (VC) versus VC
PFMT + VC VC
OR (95% CI) Measure
Population 
type n/N % n/N %
Improvement rate
Wise 1993188 14/15 93 14/19 74 5.00 (0.52 to 48.46), 
p = 0.165
2 1
TABLE 44a  Cure and improvement rates: pelvic floor muscle training plus biofeedback and bladder training (BT) versus BT
PFMT + BF + BT BT
OR (95% CI) Measure
Population 
type n/N % n/N %
Cure rate
Wyman 1998183 19/61 31 12/68 18 2.11 (0.92 to 4.82), 
p = 0.076
2 2
Improvement rate
Wyman 1998183 55/61 90 43/66 65 4.90 (1.84 to 13.10), 
p = 0.002
1 2
TABLE 44b  Quality of life: pelvic floor muscle training plus biofeedback and bladder training (BT) versus BT
PFMT + BF + BT BT
Measure Population type N Value N Value
Urogenital Distress Inventory
aWyman 1998183 44 63.2 (49.2) 47 99.2 (54.4) Score (mean, SD) 1
Incontinence Impact Questionnaire-Revised
aWyman 1998183 44 52.3 (73.4) 47 68.4 (69.7) Score (mean, SD) 1
a  Lower scores reflect better quality of life.DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
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95% CI 0.78 to 4.59; improvement OR 1.95, 95% 
CI 0.88 to 4.33). The difference in improvement 
at 3 months reached statistical significance but 
the CIs were wide. At 3.2 years, 50% (8/16) of the 
women receiving the combined treatment and 
18% (4/22) receiving BT alone were continent 
(cured), although the number available for long-
term assessment was very small (Appendix 17, 
Comparison 22).
Quality of life
The same study183 measured condition-specific 
quality of life using two instruments. The data 
immediately after the 3-month treatment phase 
were reported separately for women with stress 
incontinence alone and suggested higher quality 
of life for the combined treatment compared with 
BT without PFMT and BF (Table 44). The data 
at 6 months (3 months after the end of 3-month 
treatment) were reported for all participants 
with SUI, UUI and MUI; the direction of effect 
remained in favour of the combined treatment 
(Appendix 17, Comparison 22). Among 38 women 
who did not seek additional treatment before the 
3.2 years’ follow-up, however, quality of life did not 
differ significantly between groups (Appendix 17, 
Comparison 22).
PFMT plus SNRI vs SNRI
One study57 compared PFMT plus drug therapy 
(SNRI) with drug therapy alone (Table 45). The 
apparent greater improvement and better quality 
of life in the combined therapy group was not 
statistically different from the group using drug 
therapy alone.
Summary
A summary of the effect sizes based on meta-
analyses of cure and improvement data are given 
in Tables 46 and 47. Overall, it appears that most 
standalone interventions had, on average, higher 
cure and improvement rates than no (active) 
treatment. In particular, PFMT with or without BF 
was more effective than no treatment.
There was insufficient evidence from direct 
comparisons to say whether PFMT was more 
effective than other modalities of treatment or 
which of the PFMT programmes was the most 
effective. Nevertheless, PFMT with additional 
supervisory sessions (or any face-to-face contacts 
with health-care professionals) appeared more 
effective than PFMT alone. PFMT augmented 
with BF was also associated with higher cure 
and improvement rates. With respect to PFMT 
combined with adjunct treatment (e.g. PFMT plus 
ES), it was not possible to draw firm conclusions 
due to the small number of studies identified from 
our searches.
Quality-of-life measures reported in included 
studies were highly variable, which made 
TABLE 45a  Improvement rates: pelvic floor muscle training plus serotonin–noradrenaline reuptake inhibitor (SNRI) versus SNRI
PFMT + SNRI SNRI
OR (95% CI) Measure
Population 
type n/N % n/N %
Ghoniem 200557 36/51 71 27/50 54 2.04 (0.90 to 4.64), p = 0.087 1 1
TABLE 45b  Quality of life: improvement rates: pelvic floor muscle training plus serotonin–noradrenaline reuptake inhibitors (SNRI) 
versus SNRI
PFMT + SNRI SNRI
Notes Population type N Value N Value
I-QoL
Ghoniem 200557 51 13.1 50 8.3 Change in score (mean 
percentage score increase)
1Assessment of clinical effectiveness
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TABLE 46  Summary table: odds ratio for cure rate
Intervention 1 Intervention 2
Number of 
trials in MA 
(total)
Number of 
participants in 
MA OR 95% CI p-value
Comparison with no treatment
PFMT NT 8 (14) 605 5.41 1.64 to 17.82 0.005
PFMT + BF NT 2 (2) 110 21.54 3.65 to 126.98 0.001
ES NT 6 (8) 288 1.10 0.41 to 2.94 0.849
VC NT 0 (2)
SNRI80 NT 3 (11) 1292 1.46 1.00 to 2.14 0.053
SNRI40 NT 1 (2) 255 1.81 0.96 to 3.39 0.065
SNRI30 NT 0 (1)
SNRI20 NT 1 (2) 260 1.10 0.56 to 2.14 0.781
BT NT 1 (1) 123 4.03 0.80 to 20.23 0.091
PFMT + ES NT 2 (3) 155 1.76 0.27 to 11.54 0.556
PFMT + SNRI NT 0 (1)
Single modality
PFMT ES 5 (7) 124 2.65 0.82 to 8.60 0.105
PFMT VC 3 (6) 245 0.61 0.09 to 3.95 0.606
PFMT + BF VC 1 (2) 46 0.86 0.25 to 2.93 0.806
PFMT BT 1 (1) 75 2.61 0.98 to 6.96 0.055
PFMT + BF BT 1 (1) 132 0.67 0.25 to 1.76 0.412
PFMT SNRI 0 (1)
PFMT Surgery 2 (2) 95 0.08 0.03 to 0.23 < 0.001
ES VC 2 (4) 106 1.00 0.26 to 3.91 0.998
Dual modality
PFMT PFMT + ES 4 (7) 133 1.02 0.29 to 3.55 0.976
PFMT + BF PFMT + BF + ES 0 (2)
PFMT PFMT + VC 1 (1) 46 0.44 0.09 to 2.10 0.300
PFMT + BF PFMT + BF + BT 1 (1) 125 0.32 0.13 to 0.79 0.014
PFMT PFMT + SNRI 0 (1)
PFMT + ES ES 1 (1) 22 3.75 0.33 to 43.31 0.290
PFMT + VC VC 0 (1)
PFMT + BF + BT  BT 1 (1) 129 2.11 0.92 to 4.82 0.076
PFMT + SNRI80 SNRI80 0 (1)
Variation within comparators
Fluid increase then 
decrease
Fluid, decrease then 
increase
0 (1)
PFMT PFMT + BF 8 (15) 370 0.48 0.30 to 0.77 0.002
PFMT PFMT with additional 
sessions
3 (4) 118 0.11 0.03 to 0.43 0.001
PFMT PFMT with audiotape 0 (2)
Strength and motor 
learning PFMT
Mortor learning 
PFMT alone
1 (1) 123 0.24 0.03 to 2.23 0.210
PFMT (in supine) + BF PFMT (in supine and 
upright) + BF
0 (1)
PFMT Modified pilates 0 (1)DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
93
Intervention 1 Intervention 2
Number of 
trials in MA 
(total)
Number of 
participants in 
MA OR 95% CI p-value
PFMT (maximal 
contraction) + BF
PFMT (submaximal 
contraction) + BF
1 (1) 32 1.80 0.39 to 8.22 0.448
PFMT + perineometer PFMT + urethral 
conductance
1 (1) 27 1.09 0.13 to 9.12 0.936
PFMT + BF (vaginal) PFMT + BF (vaginal 
and abdominal)
0 (1)
PFMT + BF PFMT + ES 0 (2)
PFMT + BF + ES 
(faradism)
PFMT + BF + ES 
(interferential)
0 (1)
PFMT + BF + ES 
(maximal)
PFMT + BF + ES (low) 0 (1)
VC passive VC active 0 (1)
SNRI 80 mg  SNRI 40 mg 1 (1) 246 0.71 0.39 to 1.32 0.279
SNRI 80 mg SNRI 20 mg 1 (1) 251 1.17 0.61 to 2.25 0.633
SNRI 40 mg SNRI 30 mg 0 (1)
SNRI 40 mg SNRI 20 mg 1 (2) 251 1.64 0.88 to 3.07 0.118
SNRI 30 mg SNRI 20 mg 0 (1)
MA, meta-analysis.
TABLE 46  Summary table: odds ratio for cure rate (continued)
TABLE 47  Summary table: odds ratio for improvement rate
Intervention 1 Intervention 2
Number of trials 
in meta-analysis 
(total)
Number of 
participants in 
meta-analysis OR 95% CI p-value
Comparison with no treatment
PFMT NT 11 (14) 689 11.75 3.49 to 39.55 < 0.001
PFMT + BF NT 2 (2) 110 24.20 2.02 to 290.58 0.012
ES NT 7 (8) 369 3.93 1.43 to 10.80 0.008
VC NT 2 (2) 212 5.43 0.07 to 396.77 0.439
SNRI80 NT 10 (11) 3672 2.02 1.67 to 2.44 < 0.001
SNRI40 NT 2 (2) 328 2.43 0.84 to 7.07 0.103
SNRI30 NT 1 (1) 60 2.58 0.73 to 9.11 0.142
SNRI20 NT 2 (2) 332 2.11 0.56 to 7.72 0.258
BT NT 1 (1) 123 9.60 4.22 to 21.87 < 0.001
PFMT + ES NT 2 (3) 108 8.69 1.87 to 40.32 0.006
PFMT + SNRI NT 1 (1) 96 3.28 1.41 to 7.64 0.006
Single modality
PFMT ES 6 (7) 190 2.18 0.76 to 6.28 0.148
PFMT VC 5 (6) 331 1.01 0.52 to 1.95 0.978
PFMT + BF VC 1 (2) 46 1.14 0.34 to 3.85 0.829
PFMT BT 0 (1)
continuedAssessment of clinical effectiveness
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Intervention 1 Intervention 2
Number of trials 
in meta-analysis 
(total)
Number of 
participants in 
meta-analysis OR 95% CI p-value
PFMT + BF BT 1 (1) 129 1.71 0.79 to 3.70 0.171
PFMT SNRI 1 (1) 99 1.60 0.71 to 3.60 0.253
PFMT Surgery 2 (2) 95 0.19 0.04 to 0.77 0.020
ES VC 3 (4) 141 1.30 0.59 to 2.84 0.514
Dual modality
PFMT PFMT + ES 3 (7) 160 0.84 0.34 to 2.07 0.699
PFMT + BF PFMT + BF + ES 2 (2) 102 0.86 0.36 to 2.08 0.743
PFMT PFMT + VC 1 (1) 46 0.84 0.26 to 2.68 0.767
PFMT + BF PFMT + BF + BT 1 (1) 124 0.35 0.13 to 0.97 0.044
PFMT PFMT + SNRI 1 (1) 100 0.78 0.34 to 1.82 0.572
PFMT + ES ES 1 (1) 22 4.67 0.77 to 28.47 0.095
PFMT + VC VC 1 (1) 34 5.00 0.52 to 48.46 0.165
PFMT + BF + BT  BT 1 (1) 127 4.90 1.84 to 13.10 0.002
PFMT + SNRI80 SNRI80 1 (1) 101 2.04 0.90 to 4.64 0.087
Variation within comparators
Fluid, increase 
then decrease
Fluid, decrease 
then increase
0 (1)
PFMT PFMT + BF 7 (15) 296 0.41 0.18 to 0.97 0.042
PFMT PFMT with 
additional sessions
2 (4) 74 0.05 0.01 to 0.28 0.001
PFMT PFMT with 
audiotape
0 (2)
Strength and 
motor learning 
PFMT
Motor learning 
PFMT alone
1 (1) 123 1.69 0.67 to 4.25 0.269
PFMT (in 
supine) + BF
PFMT (in supine 
and upright) + BF
0 (1)
PFMT Modified pilates 0 (1)
PFMT (maximal 
contraction) + BF
PFMT (submaximal 
contraction) + BF
0 (1)
PFMT +  
perineometer
PFMT + urethral 
conductance
1 (1) 20 1.17 0.26 to 5.29 0.842
PFMT + BF 
(vaginal)
PFMT + BF (vaginal 
and abdominal)
0 (1)
PFMT + BF PFMT + ES 0 (2)
PFMT + BF + ES 
(faradism)
PFMT + BF + ES 
(interferential)
1 (1) 30 1.38 0.29 to 6.60 0.691
PFMT + BF + ES 
(maximal)
PFMT + BF + ES 
(low)
1 (1) 39 4.44 1.08 to 18.36 0.039
VC passive VC active 1 (1) 61 0.59 0.21 to 1.71 0.334
SNRI 80 mg  SNRI 40 mg 1 (1) 259 1.32 0.80 to 2.17 0.277
SNRI 80 mg SNRI 20 mg 1 (1) 262 1.73 1.05 to 2.87 0.033
SNRI 40 mg SNRI 30 mg 1 (1) 59 1.88 0.64 to 5.51 0.253
SNRI 40 mg SNRI 20 mg 2 (2) 328 1.25 0.80 to 1.97 0.329
SNRI 30 mg SNRI 20 mg 1 (1) 60 0.56 0.19 to 1.65 0.294
TABLE 47  Summary table: odds ratio for improvement rate (continued)DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
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comparison across studies difficult. There were 
few major safety concerns for most non-surgical 
interventions, although some instances were 
reported which were related to the treatment device 
for BF, ES or weighted VCs. However, one notable 
exception was SNRI drug therapy, for which the 
majority of participants experienced adverse 
events and up to one-third of the participants 
discontinued treatment due to adverse events. It 
is unclear whether the potential mood-enhancing 
effect of SNRIs might or might not affect its 
measured effect on SUI. It is also worth mentioning 
the apparent placebo effects of the SNRI drug as 
noted above under SNRI drug therapy.
A key issue for all non-surgical interventions is 
their long-term performance. Data beyond the 
supervised treatment phase were sparse. The 
extent to which women continued to adhere to 
treatment after active supervision finished may 
also be an important confounding factor, although 
such data were poorly reported and could not be 
incorporated into the analysis.DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
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Introduction
The review of effectiveness data presented in 
the preceding chapters has revealed that several 
treatments are used for SUI, with many variations 
and combinations of them also being used. Mixed 
treatment comparison (MTC) models analyse 
all of the treatments in one model, allowing 
indirect evidence to supplement direct, head-to-
head evidence and thereby making comparison 
of treatments easier than via multiple head-to-
head analyses.113 The model produces estimates 
(from direct and indirect evidence) of the OR for 
each pair of treatments and then the cure and 
improvement rates of each individual treatment. 
Cure and improvement are defined in Chapter 
5 (see Types of outcome measures). The rest of 
this chapter describes the data used, discusses 
the technical issues surrounding the application 
of a MTC model to these data and gives some 
definitions of important terms in Bayesian statistics 
that are used in the chapter, followed by results, 
discussion and summary of the work.
The data
The cured and improved outcomes were analysed 
in separate models. The searches identified 61 
trials which have data on either or both of these 
outcomes. Fourteen treatments were included in 
the MTC analysis. The standard abbreviations for 
the treatments are used throughout this chapter 
(see List of abbreviations). Six trials (Table 48) were 
removed from the data set either because they 
compared one treatment on the list of treatments 
selected with one that was not, for example 
Klarskov and colleagues (1986),184 or because they 
compared two varieties of the same treatment and 
it was decided that separating treatments down 
to that level of detail was unhelpful, for example 
Burton (1993).173 Some trials included some 
treatments that did not meet the inclusion criteria 
of this review, for example Tapp and colleagues 
(1989),185 compares PFMT, PFMT plus ES, and 
surgery. In this case the surgery arm was not 
included in the analysis.
Removing these six trials resulted in 55 trials being 
used; of which eight reported cure results only, 17 
reported improved results only and 30 reported 
both. Therefore, 38 trials were included in the 
cured analysis and 47 in the improved analysis.
The success rates in each trial were assessed by 
either the patient or by a clinician, with some 
trials reporting both. As for the direct, head-
to-head meta-analyses, the patient-reported 
measure was used when it was available, with the 
clinician-reported measure being used as a proxy 
for it when the patient-reported measure was 
unavailable (see Model assumptions). The time 
between intervention and measurement of success 
varied across trials from 10 days to 6 months. 
Some trials also reported additional, long-term 
follow-up.150,157,172,183,187 Each trial appears once 
in the model, using the data collected at the first 
time that the outcome was measured. This assumes 
that the measurement was taken at the point in 
time when the trialists believed that the treatments 
would have their maximal effect.
Table 49 shows which treatments are compared 
in each trial and the number of patients in each 
arm. A MTC model requires all treatments of 
interest to be connected to each other, which was 
the case for both the cured and the improved data 
sets (i.e. if trial 1 compares treatments A and B, 
trial 2 compares treatments B and C, and trial 3 
compares treatments C and D, then A is connected 
to C through a path of trial 1, then trial 2 and A 
is connected to D through a path of trial 1, trial 2 
and trial 3; an MTC model can only be applied if 
all pairs of treatments in a model have a path of 
trials that connect them). A total of 6608 patients 
were involved in the 55 trials, with 3560 providing 
data for cure and 6140 for improvement. It should 
be noted that a large proportion of these patients 
(36.3%, 1292/3560 for cure and 61.4%, 3772/6140 
for improvement) come from the 10 trials testing 
SNRIs against a placebo (placebo being considered 
equivalent to ‘no treatment’). The cure model 
considered 13 treatments and the improvement 
model considered 14 treatments, as there were no 
cure data for the PFMT plus SNRI treatment.
Chapter 8  
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TABLE 48  Trials not used in the models, with reasons
Trial Reason
Burton 1993173 Comparison of ‘passive’ VC and ‘active’ VC
Hay-Smith 2003164 Comparison of ‘motor learning’ with and without PFMT
Johnson 2001167 Comparison of PFMT + BF with maximal contraction and submaximal contraction
Klarskov 1986184 Comparison of PFMT and surgery; surgery not included in the data set
Mayne 1998168 Comparison of PFMT with perineometer and PFMT with urethral conductance
Zinner 1998145 Comparison of no treatment with 20- and 40-mg doses of SNRI
An important difference between the MTC model 
and the head-to-head comparisons is that PFMT 
has been separated into two treatments: ‘PFMT 
basic’ and ‘PFMT extra sessions’, where ‘PFMT 
extra sessions’ is defined as having more than two 
supervised sessions per month (see Chapter 6, 
Characteristics of included studies).43 The models 
for each outcome were analysed twice, once with 
PFMT split into the two categories and once with 
it together as one treatment. This latter model 
is to facilitate comparison with the direct, head-
to-head analyses. However, three trials116,159,161 
are solely comparisons of the two intensities of 
PFMT, and as they provide no comparison with 
any other treatments they were removed from the 
data set when considering PFMT as one treatment. 
Hence, the former model, which considers the 
two intensities of PFMT separately, is taken as the 
base-case analysis and is presented in this chapter. 
The results from the models with PFMT considered 
as one treatment (regardless of the number of 
sessions) are shown in Appendix 23.
The model
The model used was developed by the Multi-
parameter Evidence Synthesis (MPES) Programme 
at the University of Bristol.202 The statistical 
theory behind the code can be found in Lu and 
Ades (2004),203 Caldwell and colleagues (2005),113 
Lu and Ades (2006),204 and Ades and colleagues 
(2006).205 Its main parameters are the log ORs of 
each treatment compared to a reference treatment, 
for which we used ‘no treatment’. A random effects 
model was adopted, and, as some of the trials 
involved had three or four arms that were relevant 
to the study, the multiarm version of the MTC 
model was used. This incorporates adjustments for 
the correlation between arms of the same trial. The 
model parameters are estimated within Bayesian 
methodology by the use of winbugs software.114 The 
model code, currently available from the MPES 
website,202 is given in Appendix 22, alongside the 
data used from the individual trials.
Model assumptions
The data that were available required the following 
two key additional assumptions to be made before 
using the model (as previously suggested – see The 
data):
1.  that the log OR of the success of any treatment 
compared to the no-treatment reference is 
the same when success is assessed using the 
clinician methods as when it is assessed by the 
patient
2.  that the log OR of the success of any treatment 
compared to the no-treatment reference is 
independent of the time period at which the 
outcome was assessed.
‘No-treatment’ cure rate and 
improvement rate
Although the main parameters of the model are 
the log ORs of pairs of treatments, other statistics 
can be calculated from the parameters. The cure 
and improvement rates for each treatment can be 
calculated from the ORs if the success rate for one 
treatment is known. The distribution of the success 
rate of the reference treatment was estimated by 
applying a normal distribution to the log odds 
of the probability of success, with its mean and 
variance being estimated from a random effects 
model of the no-treatment arms of the studies 
involved (see Appendix 22).
Technical information about the 
running of the model
Vague prior distributions are used on the necessary 
parameters: the log ORs of treatment to no 
treatment, the individual trial baselines and the 
random effects standard deviation – see Appendix 
22 for further details. The model was run on four 
different data sets; the cure and improvement 
data sets, with and without the PFMT treatment 
being split into basic and extra sessions. For the 
cure data set, a burn-in period of 20,000 iterations DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
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was used to ensure convergence, whereas for 
the improvement data set a burn-in period of 
10,000 iterations was sufficient for convergence. 
The results were sampled for a further 100,000 
iterations in both cases.
Bayesian terminology
For those who are unfamiliar with Bayesian 
methodology, a few terms used in the results 
section need to be explained. A good introduction 
to Bayesian methods can be found in O’Hagan and 
Luce’s primer for health economics.206
•  Distribution  The Bayesian method uses 
probability distributions to describe the 
uncertainty about a parameter, for example 
the OR between two treatments. The posterior 
distribution is the probability distribution gained 
from applying the data to the model. The 
posterior distribution is described through its 
summary statistics, such as the mean, median 
and percentiles. The phrase ‘the median odds 
ratio between …’ should be interpreted as ‘the 
median of the posterior distribution of the 
odds ratio between …’.
•  Ninety-five per cent central credible interval  A 95% 
credible interval is one where the probability 
that the true value for the parameter is within 
that interval is 95%. The interval is central 
if, in addition, the probability of being below 
the credible interval is 2.5% and being above 
it is 2.5%. Bayesian analyses report credible 
intervals for similar reasons to the reporting 
of CIs in frequentist analysis (e.g. the direct, 
pairwise, meta-analyses in this report are 
performed using frequentist statistical 
inference), i.e. to give an indication of the 
uncertainty surrounding the estimate. The 
abbreviation CrI is used for (central) credible 
interval.
Results
In this section we report the ORs between 
treatments. The posterior distributions of the ORs 
are generally skewed. Therefore, we report the 
median OR as the point estimate. As the log ORs 
are roughly symmetrical, Figures 31 and 32 are 
plotted on the log odds scale, although labelled 
with the ORs.
Table 50 shows the posterior distribution of the ORs 
for each treatment compared with no treatment for 
both the cure and the improvement models. These 
are shown graphically in Figures 31 and 32. Tables 
showing the distributions of the ORs for each pair 
of treatments are given in Appendix 23. For cure, 
all treatments when compared to no treatment 
have a median OR greater than one, indicating 
that on average they have higher cure rates than 
no treatment. PFMT extra sessions, PFMT plus 
BF, VCs, BT, PFMT plus ES and PFMT plus BT 
and BF all have their 2.5th percentile greater than 
one, indicating a benefit from the treatment. For 
improvement, the median ORs for all treatments 
compared with no treatment were greater than one, 
with all 2.5th percentiles being greater than one, 
except for PFMT plus VCs and BF, and PFMT plus 
SNRI. For both outcomes the treatment with the 
highest median OR is PFMT plus BT and BF. This 
treatment, however, appears in only one trial183 and 
has 61 participants in the PFMT-plus-BT-and-BF 
arm. Its success rate is high for both cure (19/61, 
31.1%) and improvement (55/61, 90.2%). Given 
that the data come from only one trial, further 
research is needed.
Splitting of PFMT into basic and 
extra sessions
The results show that the number of sessions of 
PFMT does have an effect. For cure, the combined 
PFMT has an OR of 4.56 (95% CrI 1.95 to12.4) 
against no treatment, but on splitting by number 
of sessions, PFMT basic (two or fewer sessions per 
month) has an OR of 1.28 (95% CrI 0.554 to 2.92), 
whereas PFMT with extra sessions (more than two 
sessions per month) has an OR of 10.7 (95% CrI 
5.03 to 26.2). The OR for PFMT with extra sessions 
compared with PFMT basic is 8.36 (95% CrI 3.74 
to 21.7). For improvement a similar relationship 
appears, with combined PFMT having an OR 
compared with no treatment of 8.97 (95% CrI 4.4 
to 20.8), whereas the model with PFMT separated 
into basic or with extra sessions has an OR for 
PFMT basic of 4.47 (95% CrI 2.03 to 10.9) and 
for PFMT extra sessions of 25.7 (95% CrI 10.3 to 
73.1). The OR between PFMT with extra sessions 
and PFMT basic is 5.75 (95% CrI 2.11 to 16.2). 
The results from the combined PFMT models are 
given in Appendix 23.
Treatment success rates
The cure and improvement rates for each 
individual treatment are shown in Table 51, 
and, graphically, in Figures 33 and 34. These 
are calculated by combining the treatment to 
no-treatment ORs with the success rate for no Mixed-treatment comparisons (direct and indirect)
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TABLE 49  List of trials showing which treatments each compares and the number of patients in each arm of the trial 
Trial ID Outcome NT
PFMT 
basic
PFMT 
extra
PFMT +  
BF ES VC SNRI BT
PFMT +  
ES
PFMT +  
ES + BF
PFMT +  
VC
PFMT +  
VC + BF
PFMT +  
BF + BT
PFMT +  
SNRI
Source of 
outcome
Number of 
patients in 
trial
Aksac 2003120 C/I 10 20 20 Clinician 50
Arvonen 2001178 C/I 19 18 Patient 37
Berghmans 1996147 C/I 20 20 Clinician 40
Bernardes 2000174 C 7 7 Patient 14
Blowman 1991189 C 6 7 Clinician 13
Bø 1990159 C/I 29 23 Patient 52
Bø 1999115 C/I 30 25 25 27 Patient 107
Bourcier 1994196 C 46 38 Patient 84
Brubaker 1997130 C 44 46 Clinician 90
I 60 61 Clinician 121
Burns 1993122 C/I 40 43 40 Clinician 123
Cammu 1998181 C/I 30 16 Clinician 46
Cardozo 2004137 I 52 51 Patient 103
Castro-Diaz 2007138 I 112 344 Patient 456
Dmochowski 2003139 C 322 286 Clinician 608
I 332 334 Patient 666
Fantl 1991135 C/I 63 60 Clinician 123
Ghoniem 200557 I 45 49 50 51 Patient 195
Glavind 1996150 C 15 19 Clinician 34
Goode 2003123 C 67 66 67 Clinician 200
I 40 47 47 Patient 134
Hahn 1991175 C/I 10 10 Patient 20
Haken 1991179 I 30 23 Clinician 53
Henalla 1989124 I 25 26 25 Clinician 76
Henalla 1990125 I 7 8 Clinician 15
Hofbaur 1990126 C/I 10 11 11 11 Patient 43
Kim 2007118 C 32 33 Patient 65
Kinchen 2005140 I 218 208 Patient 426
Klingler 1995151 C/I 21 20 Clinician (C) /
patient (I)
41
Knight 1998172 I 18 39 Patient 57
Konstantinidou 2007116 C/I 10 12 Clinician 22
Lagro-Janssen 1991127 C/I 33 33 Clinician 66
Laycock 1988176 I 11 18 Patient 29
Laycock Trial 1 1993132 C/I 23 16 Patient 39
Laycock Trial 2 1993132 C/I 11 15 Patient 26
Luber 1997133 C/I 24 20 Patient 44
Mah 2006141 I 57 56 Patient 113
Manning 2005142 I 311 306 Patient 617
Millard 2004143 C 229 200 Clinician 429
I 229 220 Patient 449
Mørkved 2002153 C 34 36 Patient 70
continuedDOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
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TABLE 49  List of trials showing which treatments each compares and the number of patients in each arm of the trial 
Trial ID Outcome NT
PFMT 
basic
PFMT 
extra
PFMT +  
BF ES VC SNRI BT
PFMT +  
ES
PFMT +  
ES + BF
PFMT +  
VC
PFMT +  
VC + BF
PFMT +  
BF + BT
PFMT +  
SNRI
Source of 
outcome
Number of 
patients in 
trial
Aksac 2003120 C/I 10 20 20 Clinician 50
Arvonen 2001178 C/I 19 18 Patient 37
Berghmans 1996147 C/I 20 20 Clinician 40
Bernardes 2000174 C 7 7 Patient 14
Blowman 1991189 C 6 7 Clinician 13
Bø 1990159 C/I 29 23 Patient 52
Bø 1999115 C/I 30 25 25 27 Patient 107
Bourcier 1994196 C 46 38 Patient 84
Brubaker 1997130 C 44 46 Clinician 90
I 60 61 Clinician 121
Burns 1993122 C/I 40 43 40 Clinician 123
Cammu 1998181 C/I 30 16 Clinician 46
Cardozo 2004137 I 52 51 Patient 103
Castro-Diaz 2007138 I 112 344 Patient 456
Dmochowski 2003139 C 322 286 Clinician 608
I 332 334 Patient 666
Fantl 1991135 C/I 63 60 Clinician 123
Ghoniem 200557 I 45 49 50 51 Patient 195
Glavind 1996150 C 15 19 Clinician 34
Goode 2003123 C 67 66 67 Clinician 200
I 40 47 47 Patient 134
Hahn 1991175 C/I 10 10 Patient 20
Haken 1991179 I 30 23 Clinician 53
Henalla 1989124 I 25 26 25 Clinician 76
Henalla 1990125 I 7 8 Clinician 15
Hofbaur 1990126 C/I 10 11 11 11 Patient 43
Kim 2007118 C 32 33 Patient 65
Kinchen 2005140 I 218 208 Patient 426
Klingler 1995151 C/I 21 20 Clinician (C) /
patient (I)
41
Knight 1998172 I 18 39 Patient 57
Konstantinidou 2007116 C/I 10 12 Clinician 22
Lagro-Janssen 1991127 C/I 33 33 Clinician 66
Laycock 1988176 I 11 18 Patient 29
Laycock Trial 1 1993132 C/I 23 16 Patient 39
Laycock Trial 2 1993132 C/I 11 15 Patient 26
Luber 1997133 C/I 24 20 Patient 44
Mah 2006141 I 57 56 Patient 113
Manning 2005142 I 311 306 Patient 617
Millard 2004143 C 229 200 Clinician 429
I 229 220 Patient 449
Mørkved 2002153 C 34 36 Patient 70
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Trial ID Outcome NT
PFMT 
basic
PFMT 
extra
PFMT +  
BF ES VC SNRI BT
PFMT +  
ES
PFMT +  
ES + BF
PFMT +  
VC
PFMT +  
VC + BF
PFMT +  
BF + BT
PFMT +  
SNRI
Source of 
outcome
Number of 
patients in 
trial
Norton 2002144 C 132 123 Clinician 255
I 132 130 Patient 262
Oláh 1990187 C/I 30 24 Patient 54
Pages 2001154 C/I 27 13 Patient 40
Peattie 1988180 I 16 17 Patient 33
Pieber 1995192 C/I 25 21 Patient 46
Ramsay 1990128 I 22 22 Patient 44
Sand 1995134 C/I 17 35 Clinician 52
Seo 2004195 I 60 60 Patient 120
Shepherd 2003155 C/I 11 11 Patient 22
Sherburn 2007182 C 40 35 Clinician 75
Smith 1996177 C/I 9 9 Clinician 18
Tapp 1989185 C/I 21 23 Clinician 44
van Kerrebroeck 2004117 I 245 240 Patient 485
Williams 2006129 C/I 75 77 79 Patient 231
Wilson 1987157 I 15 15 30 Patient 60
Wise 1993188 I 16 19 15 Clinician 50
Wyman 1998183 C 64 68 61 Clinician 193
I 63 66 61 Patient 190
Zanetti 2007161 C 21 23 Clinician 44
Totals C 1139 331 360 273 231 164 609 163 108 46 59 16 61 0 3560
I 2200 394 276 250 298 283 1939 126 81 129 36 16 61 51 6140
All 2259 455 413 306 305 283 1939 163 108 175 74 16 61 51 6608
C, cured; I, improvement.
Note:  The second column indicates whether a trial records the cure outcome (C), the improvement outcome (I) or 
both. In cases where both are reported, and the number of patients recording each outcome varies, the trial is recorded 
on two lines. The source of outcome (patient or clinician) is also recorded (see Chapter 5, Types of outcome measures). 
The total rows show the number of patients for each treatment that provided cure outcome data (C), improvement 
outcome data (I) and the number in total.
TABLE 49  List of trials showing which treatments each compares and the number of patients in each arm of the trial (continued)
treatment (obtained from modelling the no-
treatment arms). The width of the 95% CrIs 
suggests that there is still considerable uncertainty 
surrounding the success rates.
Nevertheless, PFMT extra sessions appears to have 
a higher cure rate than PFMT basic and a similar 
rate to PFMT plus BF. In fact, PFMT extra sessions, 
PFMT plus BF, and PFMT plus BT and BF appear 
to be the best treatments in terms of cure, bearing 
in mind that PFMT plus BT and BF is assessed in 
only one trial. These three treatments also have the 
highest median improvement rate.
Sensitivity analysis
In the cure model, two treatments, ‘PFMT plus 
VCs and BF’ and ‘PFMT plus BT and BF’, appear 
in only one trial. PFMT plus SNRI, which appears 
only in the improvement model, was also only 
reported in one trial. As a sensitivity analysis to the 
inclusion of these three treatments, the cure and 
improvement models were run without them. This 
resulted in one trial132 being removed from the 
data set. The log ORs between the treatments and 
no treatment and the individual treatment success 
rates were satisfactorily similar to those of the 
original models.DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
103
Trial ID Outcome NT
PFMT 
basic
PFMT 
extra
PFMT +  
BF ES VC SNRI BT
PFMT +  
ES
PFMT +  
ES + BF
PFMT +  
VC
PFMT +  
VC + BF
PFMT +  
BF + BT
PFMT +  
SNRI
Source of 
outcome
Number of 
patients in 
trial
Norton 2002144 C 132 123 Clinician 255
I 132 130 Patient 262
Oláh 1990187 C/I 30 24 Patient 54
Pages 2001154 C/I 27 13 Patient 40
Peattie 1988180 I 16 17 Patient 33
Pieber 1995192 C/I 25 21 Patient 46
Ramsay 1990128 I 22 22 Patient 44
Sand 1995134 C/I 17 35 Clinician 52
Seo 2004195 I 60 60 Patient 120
Shepherd 2003155 C/I 11 11 Patient 22
Sherburn 2007182 C 40 35 Clinician 75
Smith 1996177 C/I 9 9 Clinician 18
Tapp 1989185 C/I 21 23 Clinician 44
van Kerrebroeck 2004117 I 245 240 Patient 485
Williams 2006129 C/I 75 77 79 Patient 231
Wilson 1987157 I 15 15 30 Patient 60
Wise 1993188 I 16 19 15 Clinician 50
Wyman 1998183 C 64 68 61 Clinician 193
I 63 66 61 Patient 190
Zanetti 2007161 C 21 23 Clinician 44
Totals C 1139 331 360 273 231 164 609 163 108 46 59 16 61 0 3560
I 2200 394 276 250 298 283 1939 126 81 129 36 16 61 51 6140
All 2259 455 413 306 305 283 1939 163 108 175 74 16 61 51 6608
C, cured; I, improvement.
Note:  The second column indicates whether a trial records the cure outcome (C), the improvement outcome (I) or 
both. In cases where both are reported, and the number of patients recording each outcome varies, the trial is recorded 
on two lines. The source of outcome (patient or clinician) is also recorded (see Chapter 5, Types of outcome measures). 
The total rows show the number of patients for each treatment that provided cure outcome data (C), improvement 
outcome data (I) and the number in total.
Probability that each treatment 
is the most effective
Another measure that can be calculated from the 
results is the probability that each treatment is 
the best. In the cure model, ‘PFMT plus BT and 
BF’ has the highest probability (0.54) of being 
the best treatment, with ‘PFMT plus ES and BF’ 
(0.20) and ‘PFMT plus VCs and BF’ (0.17) the next 
highest. ‘PFMT plus BF’ (0.047) and ‘PFMT with 
extra sessions’ (0.025) come fourth and fifth in the 
ranking. For improvement, ‘PFMT plus BT and 
BF’ stands out as the treatment that is most likely 
to be the best (0.64), with ‘PFMT plus ES’ (0.092), 
‘PFMT plus ES and BF’ (0.083), ‘PFMT with extra 
sessions’ (0.060), ‘PFMT plus VCs’ (0.052) and 
‘PFMT plus BF’ (0.043) coming next.
These results need to be interpreted with caution, 
as ‘PFMT plus BT and BF’ appears in only one 
trial. In the models used in the sensitivity analysis 
(see Sensitivity analysis), excluding ‘PFMT plus 
VCs and BF’, ‘PFMT plus BT and BF’ and ‘PFMT 
plus SNRI’ (the interventions with only one trial) 
produces the following probabilities that each 
treatment is the most effective:Mixed-treatment comparisons (direct and indirect)
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TABLE 50  Posterior distribution of the odds ratio for each treatment compared to no treatment
Treatment Sample Mean SD Median
2.5th 
percentile
97.5th 
percentile
Cure
PFMT basic 331 1.4 0.627 1.28 0.554 2.92
PFMT extra 
sessions
360 12 5.7 10.7 5.03 26.2
PFMT + BF 273 14 7.38 12.3 5.35 32.7
ES 231 1.64 0.88 1.45 0.55 3.86
VC 164 4.18 2.62 3.55 1.23 10.9
SNRI 609 1.57 0.771 1.43 0.582 3.46
BT 163 9.34 7.17 7.53 2.34 27
PFMT + ES 108 3.78 2.84 3.05 1.09 10.7
PFMT + ES + BF 46 30.7 182 9.21 0.569 172
PFMT + VC 59 6.89 18 3.13 0.324 36
PFMT + VC + BF 16 86.4 2750 5.82 0.245 263
PFMT + BT + BF 61 37.8 55.1 25.2 4.94 146
Improvement
PFMT basic 394 4.97 2.37 4.47 2.03 10.9
PFMT extra 
sessions
276 29.8 17 25.7 10.3 73.1
PFMT + BF 250 31 21.8 25.4 8.68 86.9
ES 298 6.14 3 5.49 2.39 13.7
VC 283 7.86 4.65 6.77 2.6 19.4
SNRI 1939 2.29 0.87 2.14 1.06 4.4
BT 126 18.3 23.4 12 2.16 73.3
PFMT + ES 81 29.6 31 20.7 4.51 108
PFMT + ES + BF 129 31.2 35.3 21.6 4.5 116
PFMT + VC 36 21.7 35.6 12.2 1.83 99.2
PFMT + VC + BF 16 7.44 28.4 2.66 0.181 42
PFMT + BT + BF 61 160 401 69.8 6.59 852
PFMT + SNRI 51 7.37 11.8 4.42 0.646 31.8
Note: Each treatment is being compared to no treatment, so an OR of greater than one implies that the odds of success 
for the active treatment are better than the odds for no treatment. The no-treatment arms had a total of 1139 patients 
in the cure model and 2200 patients in the improvement model.
•  Cure  PFMT + ES + BF (0.384), PFMT + BF 
(0.354), PFMT extra (0.158)
•  Improvement  PFMT + ES (0.215), 
PFMT + ES + BF(0.212), PFMT extra (0.198), 
PFMT (0.186)
The results suggest that adding an adjunct (such 
as ES) or making PFMT more intensive in another 
way is likely to be the most effective. However, of 
the different options considered, several resulted in 
similar probabilities of being the most effective.
Discussion
Mixed-treatment comparison models are an 
effective method of handling evidence from many 
trials on several treatments in one analysis. Like 
all models, they require assumptions to be made 
that may or may not be reasonable. In this case, 
the assumptions used in this analysis indicate that 
the results should be interpreted with a degree of 
caution.DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
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FIGURE 31  Cure: odds ratio of each treatment versus no treatment. Note: posterior distribution median (circle) with 95% central 
credible intervals. The horizontal axis is plotted on the log scale.
FIGURE 32  Improvement: odds ratio of each treatment versus no treatment. Note: posterior distribution median (circle) with 95% 
central credible intervals. The horizontal axis is plotted on the log scale.Mixed-treatment comparisons (direct and indirect)
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The output from the MTC model shows wide 
credible intervals for some treatments. For 
example, the intervals for the cure rates for ‘PFMT 
plus ES and BF’ and ‘PFMT plus VCs and BF’ are 
so wide (on a bounded scale) that we know very 
little about the effectiveness of these treatments. 
This is due to there being very few data about the 
cure rates for these treatments; the data for each 
treatment come from only one trial, with ‘PFMT 
plus ES and BF’ having 46 participants in its arm 
and ‘PFMT plus VCs and BF’ having 16.
There are some results that are quite clear and 
useful. There is clear evidence that both ‘PFMT 
with extra sessions’ and ‘PFMT with BF’ are better 
at cure than the following: no treatment; PFMT 
basic; ES; VCs; SNRI; and PFMT plus ES. Both 
‘PFMT with extra sessions’ and ‘PFMT with BF’ 
are also better at improvement than: no treatment; 
PFMT basic; ES; VCs; and SNRI. The evidence 
also suggests that ‘PFMT plus BT and BF’ is better 
than each of the above listed treatments for cure 
and improvement, respectively, except for VCs, for 
which there is no clear evidence of a difference in 
improvement rates. However, conclusions about 
‘PFMT plus BT and BF’ must be considered with 
caution, as this appears as a treatment in only one 
trial.
The results of the model indicate where further 
research might be beneficial, for example ‘PFMT 
plus BT and BF’ had reasonable success in the one 
trial that is in the data set, and its comparisons with 
other treatments look promising.
Comparison of the results from the model with 
PFMT, separated into basic and extra sessions with 
the combined PFMT model, shows that the median 
ORs between the other treatments can be different. 
The nature of the MTC model is such that 
splitting a treatment into two has an effect on the 
comparisons between other treatments. However, 
the split PFMT models do include additional trials 
(three for cure and two for improvement) that 
compare the two PFMT intensities alone, which 
were not used in the combined PFMT model. This 
appears to account for most of the discrepancies 
between the results of the split PFMT model 
compared with the combined PFMT model.
Summary
PFMT appears to be more effective when delivered 
with extra sessions (more than two sessions per 
month). Using this format of PFMT or adding 
BF to PFMT appears to be more effective than 
the other standalone treatments that have been 
TABLE 51  Cure and improvement success rates for each treatment, as percentages
Cure Improvement
N Median 95% central CrI N Median 95% central CrI
NT 1139 5.8 3.3 9.9 2200 26.3 15.7 40.5
PFMT basic 331 7.3 2.8 17.8 394 61.5 36.4 82.7
PFMT extra 
sessions
360 39.9 20.2 65.8 276 90.2 74.9 96.9
PFMT + BF 273 43.3 21.5 70.2 250 90.1 72.0 97.3
ES 231 8.2 2.8 21.9 298 66.3 40.6 85.8
VC 164 18.0 6.1 43.5 283 70.8 43.1 89.3
SNRI 609 8.1 2.9 20.1 1939 43.3 22.7 66.7
BT 163 31.8 11.2 65.3 126 81.1 40.5 96.7
PFMT + ES 108 15.9 5.4 42.8 81 88.1 58.3 97.8
PFMT + ES + BF 46 36.1 3.2 91.8 129 88.5 58.5 97.9
PFMT + VC 59 16.1 1.8 70.3 36 81.4 36.7 97.5
PFMT + VC + BF 16 26.4 1.4 94.4 16 48.7 5.7 94.1
PFMT + BT 61 60.8 21.8 90.7 61 96.1 68.4 99.7
PFMT + SNRI 331 51 61.2 17.1 92.5DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
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FIGURE 33  Cure rate for each treatment. Note: posterior distribution median (circle) with 95% central credible intervals.
FIGURE 34  Improvement rate for each treatment. Note: posterior distribution median (circle) with 95% central credible intervals.Mixed-treatment comparisons (direct and indirect)
108
analysed: no treatment, PFMT basic, ES, VCs, 
and SNRIs. Adding ES as an adjunct may also be 
effective.
The strengths of this approach are that all of the 
treatments of interest are compared in one analysis, 
facilitating indirect evidence to support direct 
evidence.
The limitations of the models lie in the 
assumptions taken about the equivalence of 
patient- and clinician-assessed success, and that the 
different time intervals over which the outcome is 
assessed within the separate trials is unimportant. 
The credible intervals around the estimates are 
often wide, indicating that there is still considerable 
uncertainty about the values of some parameters.DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
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A 
formal systematic review of existing economic 
evaluations was not attempted, as initial 
scoping searches failed to identify any existing 
prior economic evaluations that considered all 
comparators from the perspective of the UK NHS. 
Therefore, this chapter focuses on presenting the 
methods and results of a de novo economic model.
The subsections ‘Model framework’ and ‘Summary 
of key assumptions made in the economic model’ 
(see Methods, below) describe the basics of the 
modelling approach and the key assumptions 
underpinning the estimates of cost-effectiveness 
results. The remainder of the Methods section 
describes, in detail, how parameter estimates for 
the economic model were derived and how these 
data were used to estimate cost-effectiveness. The 
results from the economic model are presented in 
three sections. In the first section, the results of the 
economic model are presented in terms of number 
of people cured, cured or improved (referred 
to in the text as ‘improvement’) or incontinent in 
the model at different time horizons (see Results 
of the model presented in terms of costs and 
consequences). In the second section the results are 
based upon patients being cured of incontinence 
(see Cost–utility analysis based upon cure rates). 
In the third section (see Results based upon 
improvement rates), results are presented when 
successful treatment is defined as being either 
cured or improved. The final section of this chapter 
provides a short summary of the results.
Methods
As explained in Chapter 3, the economic model 
described the pathways of care for alternative 
management strategies of SUI. The perspective 
adopted for the analysis is that of the NHS (the 
main health service provider within the UK).
Model framework
A Markov model portraying the temporal and 
logical sequence of the clinical decision problem 
was used to provide estimates of costs, effectiveness 
(measured in QALYs) and cost-effectiveness. The 
health states within the model are considered to 
reflect possible outcomes of therapy, for example 
successful treatment (i.e. cure or improvement), 
failure (i.e. incontinence) and recurrence of 
incontinence. Graduation in the severity of 
incontinence was otherwise not considered in 
the model due to paucity of the available data on 
effectiveness.
In the model, women receive an initial treatment 
and then move into one of three states: success, 
failure or death. If a woman considers herself cured 
(or sufficiently improved so that she no longer feels 
the need for further treatment) then the treatment 
is successful. If the treatment does not result in cure 
(or sufficient improvement) then the woman enters 
the failure state. There is always a chance that over 
any period of time that a woman would die. If this 
should happen, they then move into an absorbing 
state (a state from which they cannot move): 
death. Death takes into account that patients are 
exposed to a very small risk of death when they are 
undergo surgery as well as a chance of dying from 
other causes at any point in time, assumed to be 
equivalent to all-cause mortality.
In a Markov model, people stay in a state for a 
minimum period of time (called the cycle length). 
In this model the cycle length was 3 months. 
This cycle length was chosen as it represents the 
recommended/widely used duration of PFMT 
before reassessment. Women who enter into the 
success state, stay in that state for 3 months, 
after which time, if they are still alive, they either 
continue to stay in this state or suffer a recurrence 
and go to the next available treatment. If a woman 
becomes incontinent after previously being cured, 
or after a treatment has failed, she proceeds to the 
next treatment in the strategy.
Women can continue moving through states in the 
model for a maximum of 40 years (equivalent to 
160 cycles). This time horizon was chosen as it takes 
into account the average life expectancy of women 
who enter the model at the age of 45, which, as 
Figure 1 shows, is that age of peak incidence of 
SUI. Costs and benefits that occur in the future 
are discounted following standard practice. The 
discount rate used is the recommended rate of 
3.5% for both costs and benefits.105
Chapter 9  
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It is assumed that all women are initially given 
advice, if appropriate, about modifying their 
lifestyles. The interventions included in the 
management strategies are thus: lifestyle changes 
(LS); basic PFMT (PFMT basic); PFMT with extra 
sessions (PFMT extra sessions); PFMT plus BF; 
PFMT plus ES; ES; VCs; drug treatment (SNRI), 
surgery [tension-free vaginal tape (TVT) or other 
similar self-fixing sling, e.g. transvaginal obturator 
tape], and the second surgery. Once all of the 
treatments are exhausted, it is assumed that women 
have to manage their symptoms using containment 
products. Table 52 summarises the potential 
strategies that are considered in the model.
The difference between basic PFMT and PFMT 
with extra sessions was based upon the number of 
supervisory sessions that a woman had per month. 
For basic PFMT it was assumed that the woman 
would have six sessions in 3 months, whereas 
PFMT with extra sessions was defined as having 12 
sessions in 3 months.43
Pelvic floor muscle training with BF has not been 
explicitly included in this model, as its effectiveness 
is similar to the effectiveness of PFMT with extra 
sessions and it is plausible that the costs of the 
two types of therapy are similar. The impact of 
difference in costs for PFMT with BF is explored 
within a sensitivity analysis.
TABLE 52  Management strategies
Treatment sequence
First treatment
Second 
treatment
Third 
treatment
Fourth 
treatment
Fifth 
treatment
Sixth 
treatment
1 Lifestyle + PFMT basic TVT/TVT-O Second surgery Containment
2 Lifestyle + PFMT basic PFMT extra 
sessions
TVT/TVT-O Second surgery Containment
3 Lifestyle + PFMT basic PFMT extra 
sessions
SNRI TVT/TVT-O Second surgery Containment
4 Lifestyle + PFMT extra 
sessions
TVT/TVT-O Second surgery Containment
5 Lifestyle + PFMT extra 
sessions
SNRI TVT/TVT-O Second surgery Containment
6 Lifestyle TVT/TVT-O Second surgery Containment
7a Lifestyle + PFMT basic VC TVT/TVT-O Second surgery Containment
8a Lifestyle + PFMT basic ES TVT/TVT-O Second surgery Containment
TVT, tension-free vaginal tape; TVT-O, transvaginal obturator tape.
a  Two strategies reported in sensitivity analyses only.
Figure 35 depicts an example of one of the 
management strategies used in the model (a more 
detailed description of the model is provided in 
Appendix 24). A woman that is diagnosed with 
SUI is offered PFMT. If this treatment is successful 
then the patient stays in a success state. When 
a treatment fails the woman is offered the next 
available treatment in that particular strategy. 
In this example, if PFMT fails in the next cycle 
the woman is offered PFMT plus an adjunct. If 
this fails, the woman is offered the next available 
treatment, drug therapy, and so on. If necessary 
the woman will receive each treatment until 
the treatment options are exhausted and their 
incontinence has to be managed with containment 
products.
Summary of key assumptions 
made in the economic model
Outlined below are the key assumptions that are 
made within the economic model. Details about 
how these assumptions were arrived at and their 
justifications are provided in the remainder of this 
section.
Assumptions related to the structure of 
the model
1.  The age of the women considered in the model 
is 45 years. In sensitivity analysis, different 
starting ages were considered.DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
111
D
i
a
g
n
o
s
e
d
 
S
U
I
P
F
M
T
P
F
M
T
 
+
 
a
d
j
u
n
c
t
*
D
r
u
g
S
u
r
g
e
r
y
R
e
o
p
e
r
a
t
i
o
n
C
o
n
t
a
i
n
m
e
n
t
F
a
i
l
u
r
e
F
a
i
l
u
r
e
F
a
i
l
u
r
e
F
a
i
l
u
r
e
F
a
i
l
u
r
e
S
u
c
c
e
s
s
S
u
c
c
e
s
s
S
u
c
c
e
s
s
S
u
c
c
e
s
s
S
u
c
c
e
s
s
R
e
c
u
r
r
e
n
c
e
R
e
c
u
r
r
e
n
c
e
R
e
c
u
r
r
e
n
c
e
R
e
c
u
r
r
e
n
c
e
R
e
c
u
r
r
e
n
c
e
D
e
a
d
F
I
G
U
R
E
 
3
5
 
M
a
r
k
o
v
 
m
o
d
e
l
 
f
o
r
 
o
n
e
 
o
f
 
t
h
e
 
s
t
r
a
t
e
g
i
e
s
.
 
*
A
d
j
u
n
c
t
s
 
i
n
c
l
u
d
e
,
 
f
o
r
 
e
x
a
m
p
l
e
,
 
b
i
o
f
e
e
d
b
a
c
k
 
a
n
d
 
e
l
e
c
t
r
i
c
a
l
 
s
t
i
m
u
l
a
t
i
o
n
.Assessment of cost-effectiveness
112
2.  Cumulative costs and effectiveness were 
estimated for a 40-year time horizon. This 
would cover the average life expectancy of 
women aged 45 years. In sensitivity analyses 
the effect of shorter time horizons on costs, 
effects and cost-effectiveness was considered.
3.  Costs and effects that occur in the future are 
given less weight in the analysis than costs and 
effects that occur in the present, i.e. they are 
discounted. This is recommended practice for 
any economic evaluation. Different discount 
rates were considered in a sensitivity analysis.
4.  The cycle length of the model is 3 months. 
This cycle length determines the minimum 
period of time over which a woman’s 
continence status might change or over which 
treatments might change. This period was 
chosen as it represents the recommended/
widely used duration of PFMT before 
reassessment.
5.  Within the model, women can either be cured 
(or improved in the version of the model based 
on improvement rates) or be incontinent. 
Severity of disease is not otherwise considered 
in the model because of lack of data.
Assumptions related to the treatment 
strategies compared
1.  The treatment strategies compared consist of a 
finite number of treatments. In reality women 
whose symptoms are not controlled to their 
satisfaction could continue seeking treatment 
until they have what they consider adequate 
control of their symptoms.
2.  All women are initially given advice, if 
appropriate, about modifying their lifestyles.
3.  If a woman becomes incontinent after 
previously been cured, or after a treatment 
failed, she would proceed to the next treatment 
in the strategy. Sensitivity analysis was 
performed to explore the relaxation of this 
assumption.
4.  In the cure model analysis women were 
assumed not to use containment products 
until they had exhausted all treatments in a 
treatment strategy. Sensitivity analysis was 
performed to explore the relaxation of this 
assumption.
5.  In the improvement model all women were 
assumed to use containment products. 
Those women who were improved used less 
containment products than those who were not 
improved. Sensitivity analysis was performed to 
explore the relaxation of this assumption.
6.  The probability of drug therapy being 
successful after suffering an adverse event was 
assumed to be zero as we expected the woman 
to stop taking the drug when she suffered an 
adverse event.
Assumptions relating to effectiveness
1.  The median values of cure and improvement 
rates were used in the economic model, as the 
data were highly skewed and the median was 
believed to provide a better representation of 
the actual difference.
2.  Long-term cure rates of all interventions were 
based on extrapolation of available data.
3.  When making an extrapolation from these 
data, it was assumed, for drug therapy, that at 
12 months only 5.8% of those initially cured 
remain cured, which is equivalent to the 
spontaneous cure estimated for no treatment.
4.  The estimates of cure and improvement rates 
for all treatments were assigned log-normal or 
normal distributions, based on the assumptions 
made for the mixed-treatment model in 
Chapter 8.
Assumptions relating to costs
1.  The difference between basic PFMT and PFMT 
with extra sessions was based upon the number 
of sessions that a woman had per month.
2.  The resources used in PFMT plus BF were 
based on the assumption that the staff 
providing the service was the same as those 
providing PFMT and that the number of 
sessions were the same as those for PFMT.
3.  The costs of VCs were based on the assumption 
that the labour costs were one-third of those for 
PFMT (i.e. two visits with the physiotherapist).
4.  The costs of exercise dairies and leaflets were 
considered to be negligible and it was also 
assumed that all patients would receive them. 
Therefore, their costs were not included.
5.  All treatment costs were assigned log-normal 
distributions, as this distribution appeared to 
best fit the data that have skewed or symmetric 
ranges.
Estimation of model 
probabilities
The main probabilities for the model are the cure 
rates, improvement rates and recurrence rates of 
different interventions and mortality rates.
Relative differences in cure and 
improvement rates
The estimates of cure and improvement rates 
for the interventions considered in the model 
are based on the results of the mixed-treatment 
model reported in Chapter 8. Table 53 describes 
the median ORs for the comparison with either no DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
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TABLE 53  Odds ratios of intervention compared with no treatment or basic pelvic floor muscle training
Intervention vs comparison
Cure rates Improvement rates
Median 95% CrI Median 95% CrI
Used in base-case analysis
PFMT basic vs NT 1.28 0.55 to 2.92 4.47 2.03 to 10.9
PFMT extra sessions vs NT 10.7 5.03 to 26.2 25.7 10.3 to 73.1
SNRI vs NT 1.43 0.58 to 3.46 2.14 1.06 to 4.4
Used only in sensitivity analysis
ES vs NT 1.45 0.55 to 3.86 5.49 2.39 to 13.7
VC vs NT 3.55 1.23 to 10.9 6.77 2.6 to 19.4
ES vs PFMT basic 1.13 0.39 to 3.32 1.23 0.45 to 3.25
VC vs PFMTbasic 2.77 0.98 to 8.51 1.52 0.58 to 3.97
CrI, credible interval.
treatment or PFMT. The median values were used 
in the economic model, as the data were highly 
skewed and the median was believed to provide a 
better representation of the actual difference.
Absolute cure and improvement rates
As mentioned in Chapter 8, while the main 
parameters of the model are the log ORs of the 
treatments, the absolute success rate for each 
treatment can be calculated from the relative 
success rates, if the absolute success rate for 
one treatment is known. The absolute cure and 
improvement rates were calculated in the model 
by combining the information on relative cure and 
improvement rates described in Table 53, above, 
with the absolute cure and improvement rates for 
no treatment which was taken to be the reference 
treatment. The absolute cure rate at 3 months for 
no treatment was median 5.8% (95% CrI: 3.3% to 
9.9%) and the improvement rate at 3 months was 
26.3% (95% CrI: 15.7% to 40.5%) (Chapter 8).
Transition probabilities
Recurrence rates of PFMT
Despite extensive searching, few data were 
identified on the long-term effectiveness (greater 
than 1 year) for any of the interventions. 
Therefore, estimates used in the model were based 
on extrapolations of the available data.
Only four reports159,207–209 provided long-term 
follow-up of women who had received PFMT. One 
report209 indicated that at 6 years no significant 
differences were found in urinary incontinence 
prevalence, severity or leakage episodes in the 
women who responded to the questionnaire 
between groups for PFMT with extra sessions 
and basic PFMT. However, this study was based 
on postnatal women, whom we regarded as not 
being representative of women with SUI. A further 
three reports published by other authors provided 
outcome data at 5 years207 and 15 years208 after 
receiving PFMT were identified. One report208 
looked at two different intensities of pelvic floor 
muscle exercises over a period of 15 years. Hence, 
data from these three reports have been used in 
the model, although the sample sizes were small. 
Details of the values taken from these papers are 
described in Table 54.
Extrapolation of the long-term cure rates used 
in the model was generated from Kaplan–Meier 
survival curves, using a linear exponential 
distribution that manipulated by adjusting the two 
parameters (defined below). Using this process it 
is possible to estimate a hazard function using the 
values reported in Table 55.
The formula used to extrapolate the survival 
function [S(t)] is:
S(t) = exp(–(λt + γt2/2))
λ = 0.001372, γ = 0.006308
where:
•  S(t) is the probability of cure at any given time t
•  t is time (measured in terms of the number 
of cycles, where each cycle is equivalent to 
12 weeks)Assessment of cost-effectiveness
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TABLE 54  Values used in the estimation of long-term recurrence rates of pelvic floor muscle traininga
Values
Number of patients
PFMT basic PFMT extra sessions
Randomised 31 26
At 6 months 29 23
At 5 years NR 20
At 15 years 26 21
Surgical interventions at 5 years 9 3 (3/23)
Surgical interventions at 15 years 4 8 (8/21)
Pad test < 2 g (cure) at 5 years NR 6 (6/20)
No visible leakage on stress pad test at 6 months NR 17 (17/20)
No visible leakage on stress pad test at 5 years NR 15 (15/20)
Dry on severity index at 15 years 4 (4/25) 6 (6/20)
a  PFMT follow-up rates (home vs intensive) – Bø and colleagues (1990);159 (1996);207 (2005).208
TABLE 55  Values used in the estimation of long-term cure rate 
after receiving pelvic floor muscle training
Time 
(years)
Probability of cure for:
PFMT basic PFMT extra sessions
0 1 1
5 0.67a 0.75b
15 0.16b 0.30b
a  Value based on Lagro-Janssen and van Weel (1998).210
b  Value based on results of Bø and colleagues (2005).208
•  λ is the scale parameter, which describes the 
probability that a woman will remain/become 
incontinent during the next time period, given 
that she was continent in the current period
•  γ is the shape parameter, which, in simple 
terms, describes the rate of change in 
the probability that a woman will become 
incontinent over time.
Appendix 25 described how the transition 
probabilities (i.e. the chance or remaining cured 
or suffering a recurrence of symptoms) were 
calculated using the above formula. Figure 36 shows 
the shape of the linear exponential curve that was 
fitted to the data reported in Table 55.
Recurrence rates for other physical 
therapies
The recurrence rate for physical therapies was 
generated by multiplying the failure of PFMT 
by the relative effect sizes derived in the MTC 
reported in Chapter 8 and summarised in Table 50.
Recurrence rates for drug (SNRI) 
therapy
As with the PFMT, there were very few studies that 
had long-term follow-up of women who were using 
drugs to treat their incontinence. Four relevant 
studies were identified as part of the systematic 
review studies57,136–138 and an unpublished study 
from Eli Lilly and Company.211 These studies had 
an unclear length of follow-up, a follow-up of 
less than 1 year or were unpublished. One study 
was identified that reported recurrence rates for 
a cohort of women at different time points after 
the initiation of drug treatment.212 In making 
an extrapolation from these data it was assumed 
that at 12 months only 5.8% of those initially 
cured remain cured, which is equivalent to the 
spontaneous cure estimated for no treatment. This 
rate is lower than the 9% cure rate reported by 
Vella and colleagues.212
Extrapolation of cure rate (disease free) was 
estimated from a Kaplan–Meier curve using a 
Weibull survival model from the data reported in 
Table 56. The Weibull distribution was chosen for 
this extrapolation as it was felt to have a suitable 
functional form to estimate a survival. The Weibull 
distribution is defined by two parameters: the 
scale parameter (λ) and the shape parameter (γ). 
The scale parameter describes the probability that 
the woman becomes incontinent during the next 
time period, given that she is continent during 
the current time period. The shape parameter 
describes the hazard function of Weibull function 
for the survival time. The hazard function for 
Weibull survival time could be increasing or DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
115
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0 20 40 60 80 100 120 140 160
Time (cycle)
PFMT basic based on Lagro–Janssen 1998210 and Bø 2005208
PFMT extra sessions based on Bø 2005208
P
r
o
b
a
b
i
l
i
t
y
 
o
f
 
c
u
r
e
0.0
FIGURE 36  Extrapolated cure rates after pelvic floor muscle training. Note that each cycle is 3 months long. Based on Lagro-Janssen 
and van Weel (1998)210 and Bø and colleagues (2005).208
decreasing with time, depending on the value 
of parameter γ. If the value is greater than 1, 
the hazard rate increases with time. If the shape 
parameter is less than 1, the hazard decreases with 
time. If the shape parameter is equal to 1, then the 
Weibull distribution is equivalent to an exponential 
distribution. Figure 37 describes the curve fitted 
to the data reported in Table 56. An approximate 
hazard function for the curve is given by:
S t t ( ) exp(– ): . , . = = = λ λ γ
γ where 1 73459 0 36
where:
•  S(t) is the probability of cure in any given cycle
•  t is time (measured in terms of the number 
of cycles, where each cycle is equivalent to 
12 weeks)
•  λ is the scale parameter that describes 
the probability that the woman becomes 
incontinent during the next time period, given 
that she is continent during the current time 
period
•  γ is the shape parameter, which describes the 
hazard function of Weibull function for the 
survival time.
Appendix 25 describes how the above equation 
was used to calculate the transition probabilities 
required for the model (e.g. the probability 
of a woman who is currently cured suffering a 
recurrence in the next cycle and the probability of 
remaining cured).
Recurrence rates of TVT
The long-term recurrence rates of TVT were 
derived using the long-term cure rates of a recent 
trial conducted in the UK, comparing TVT with 
Burch colposuspension.213 The data from reported 
cure rates for up to 5 years were used to estimate 
longer-term recurrence rates using a Weibull 
survival model (Figure 38), from the data reported 
in Table 57. As was the case for drug treatment, this 
model was chosen because it was felt to provide a 
reasonable representation of the estimated long-
term recurrence rates.
TABLE 56  Values used in the estimation of long-term cure rates 
after drug therapy
Time (months) Cure rate
0 1
1 0.31
4 0.12
6 0.1
12 0.09a
a  Value from Vella and colleagues (2008).212Assessment of cost-effectiveness
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FIGURE 37  Extrapolated long-term cure rates after drug therapy. Note that each cycle is 3 months long. Based on Vella and 
colleagues (2008).212
TABLE 57  Values used in the estimation of long-term cure rates 
after being treated with tension-free vaginal tape
Time (years) Rate of continence
0 1
0.5 0.85
2 0.80
In this trial the cure rate at 5 years was 0.81, which 
is 0.01 higher than it was at 2 years, which is likely 
to be caused by women being lost to follow-up. 
Therefore, the reported data at 5 years were not 
used in the extrapolation, although it did help 
inform assumptions about what proportion of 
women might remain cured at 5 years.
The following survival hazard formula was defined:
S t t ( ) exp(– ): . , . = = = λ λ γ
γ 0 138696 0 228682
where:
•  S(t) is the probability of cure
•  t is time (measured in terms of the number 
of cycles, where each cycle is equivalent to 
12 weeks)
•  λ is the scale parameter, which describes 
the probability that the woman becomes 
incontinent during the next time period, given 
that she is continent during the current time 
period
•  γ is the shape parameter, which describes the 
hazard function of Weibull function for the 
survival time.
The transition probabilities used in the model  
were calculated using the formula shown in  
Appendix 25.
Other parameters
The other parameters (Table 58) considered in the 
model were:
•  The probability of adverse events (drugs only). 
The estimate used in the model was generated 
from the systematic review reported in Chapter 
7 (see SNRI drug therapy).
•  The chance that women may still need to use 
containment products when undergoing any 
of the interventions. In the base-case analysis 
it was assumed that if women were cured then 
they did not need to use containment products. 
This assumption was tested in a sensitivity 
analysis. In the improvement model all women 
were assumed to use containment products. 
The cost of the containment product used by 
those who were improved was based on the DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
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FIGURE 38  Extrapolated long-term cure rates after tension-free vaginal tape surgery. Note that each cycle is 3 months long. Based 
on Hilton and colleagues (2008),214 which summarises data reported in Ward and colleagues (2002);213 (2004);215 (2008).216
least expensive type of containment product 
used (menstrual pads).84
•  Risk of death attached to surgery. This 
information was taken from a previous 
systematic review that reported the risk of 
death from open colposuspension surgery.80
All-cause mortality rates in the UK
As a woman moves through the model there 
will be some chance of that the woman might 
die. The likelihood that a woman might die was 
based upon the annual rates of age-specific all-
cause mortality for women [based on the Office 
for National Statistics (ONS) interim life tables 
2004–06 (database on the Internet)].217 Figure 39 
shows the survival curve for females for the UK and 
Appendix 25 reports the rates of all-cause mortality 
used in the model.
Resource utilisation and cost 
estimation
Resource use data was identified from existing 
studies,43 relevant literature (e.g. reports from 
manufacturers) and advice from experts in this 
field. The resources used to provide the non-
surgical interventions included:
•  the number of visits to the practitioners for the 
sessions of therapy
•  the staff time, the appropriate grade and 
direct overheads associated with delivering 
health care, such as clerical support and 
administration of the sessions of therapy
•  the consumables required to provide service
•  the reusable equipment used.
The costs of exercise dairies and leaflets were 
considered to be negligible and it was also assumed 
that all patients would receive them. Therefore, 
their costs were not included.
Lifestyle changes
The cost of lifestyle changes were based on the cost 
of a single visit to the GP.
PFMT basic
As indicated in the recent NICE guidance,43 it 
was assumed that PFMT comprised six sessions. 
As acknowledged in the guidance, it is difficult 
to define a ‘standard’ or ‘typical’ PFMT session, 
and, hence, in reality, costs will vary according to 
the actual care provided. Within the model it was 
assumed that the first session of PFMT would last 
for 1 hour and the other five sessions would last for 
30 minutes each. Each session would be conducted 
by a senior grade 1 women’s health physiotherapist 
in a hospital physiotherapy department. The 
consumables that would be required per session 
would be: gloves, KY Jelly, wipes and paper towels.Assessment of cost-effectiveness
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TABLE 58  Other parameters used in the economic model
Probability Value Source
Probability of adverse event while on drug therapy 0.45 Estimated from 
systematic reviewa
Probability that women who failed PFMT, or for whom symptoms recurred, managed 
their symptoms thereafter with containment products
0 Assumption
Probability of continuing to use containment products after PFMT has failed or 
symptoms have recurred
0 Assumption
Probability that women who failed PFMT + adjunct, or for whom symptoms recurred, 
managed their symptoms thereafter with containment products
0 Assumption
Probability of continuing to use containment products after PFMT + adjunct has failed 
or symptoms have recurred
0 Assumption
Probability that women who failed PFMT, etc., or for whom symptoms recurred, 
managed their symptoms thereafter with containment products
0 Assumption
Probability of continuing to use containment management after PFMT, etc. has failed 
or symptoms have recurred
0 Assumption
Probability that women who failed with drugs, or for whom symptoms recurred, 
managed their symptoms thereafter with containment products
0 Assumption
Probability of continuing to use containment products after drugs have failed or 
symptoms have recurred
0 Assumption
Probability that women who failed following surgery, or for whom symptoms 
recurred, managed their symptoms thereafter with containment products
0 Assumption
Probability of continuing to use containment products after surgery has failed or 
symptoms have recurred
0 Assumption
Probability of the first surgery being successful 0.87 Estimated in the 
model
Probability of a second surgery being successful 0.85 Estimated in the 
model
Probability of drug therapy being successful after suffering an adverse event 0 Urinary incontinence 
guideline, 200643
Mortality rates of surgery 0.0005 Cody 200380
a  See Chapter 7.
PFMT with extra sessions
The costs of PFMT with extra sessions were derived 
in the same way as those of basic PFMT described 
above, but the number of sessions was increased 
from six to 12.
PFMT plus BF
The resources used for PFMT plus BF were based 
on the assumption that the staff providing the 
service was the same as those providing PFMT 
alone, and that the number of sessions were the 
same as those for PFMT. Additional resources 
required for the BF were the equipment used, 
for example the hand-held single-channel EMG 
channel, the Neen Educator and Neen Periform 
vaginal probe. The educators and the probes were 
treated as consumables, as they were used by only 
one woman over all of the sessions. However, 
the NeuroTrac device™ was loaned to women 
for 3 months. Based upon information from 
manufacturers and from NHS users, this piece 
of equipment was considered to have a lifespan 
of 5 years, the equivalent annual cost of the 
equipment was calculated (using a 3.5% discount 
rate as recommended by the UK Treasury) and 
the cost per woman took into account that the 
equipment was used by four women per year. These 
data were used to help interpret the results of 
‘PFMT with extra sessions’ only when it was used 
in the model. This is because the effectiveness of 
PFMT with extra sessions was similar to PFMT plus 
BF, and it is plausible that the costs of the two types 
of therapy were similar.DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
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FIGURE 39  Age-adjusted survival Kaplan–Meier curve for females in the UK.
Vaginal cones
Although VCs are recommended as a first-line 
treatment, they are not routinely provided by the 
NHS. Cones are often bought over the counter 
after GP advice. The cost of VCs was based on 
the assumption that the labour costs were one-
third of those for PFMT (i.e. two visits with the 
physiotherapist). Although VCs are not currently 
provided by the NHS, the women using VCs would 
still have two visits with the physiotherapist. The 
consumables required and consumables used were 
cones, gloves, paper towels and KY Jelly.
Electrical stimulation
Electrical stimulation can be provided either at 
home or in a clinic. The difference between the 
two ways of providing the therapy relates to the 
number of sessions that the woman receives. 
Home-based ES has three sessions, whereas the 
clinic-based therapy has 13 sessions (although this 
may vary in practice), with the first session lasting 
1 hour and the remainder lasting 30 minutes. For 
the home-based ES, the woman has a 1-hour-long 
session in the hospital physiotherapy department 
to determine an appropriate programme and 
then two follow-up sessions. The Neen Pericalm 
device is loaned to women for home use for 
3 months. In this analysis it was assumed that 13 
sessions would be provided by a physiotherapist 
in a hospital department. The resources used 
included a Neen Periform vaginal electrode and 
data-reading clinical equipment, along with the 
same consumables that were used in the provision 
of PFMT (gloves, KY Jelly, couch roll, wipes and 
paper towels). Based upon information from 
manufacturers and from NHS users, the equipment 
was assumed to have a lifespan of 5 years and 
an equivalent annual cost of the equipment 
was calculated (using a 3.5% discount rate as 
recommended by the UK Treasury). A total of 
200 women would be able to use it each year in a 
clinical setting.
Medical therapy
The cost of drug treatment was based on two 
consultations (an initial consultation and a review 
consultation) with the GP, and the drug costs for 
each cycle (3 months).
Surgical interventions
Surgical costs were based on the average costs of 
an elective minor lower urinary tract procedure 
without complications.54
Containment products
The costs of containment products (such as 
disposable insert and menstrual pads, and 
washable pants with and without insert pads) were 
based on information reported in a systematic 
review of containment products.84 The cost of other 
containment products, such as urethral plugs, were 
not included in the base analysis.Assessment of cost-effectiveness
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Cost estimation
As described above, costs focused on the direct 
health service costs that were associated with each 
treatment. Unit cost data were extracted from 
the literature or from relevant sources, such as 
manufacturer price lists and NHS reference costs. 
The year of the cost data is 2008 and the currency 
is pounds sterling (£). Table 59 provides a summary 
of the costs for each intervention.
Quality of life
Summary of a structured review of 
reports on health-state utilities
The primary outcome for the economic analysis 
was QALYs. The QALY estimates within the model 
analysis are mainly determined by whether a 
woman was continent or not, as the risk of death 
from SUI or any of the treatment options is very 
low. Although there is considerable evidence about 
the quality of life of women with SUI, this tends 
to be measured using condition-specific tools, 
such as the I-QoL. Such data are not ideal for 
incorporation into an economic evaluation. As an 
economic evaluation seeks to inform choices about 
how best to allocate society’s scarce resources, it 
has been argued that changes in quality of life 
should reflect society’s valuation. One quality-of-life 
instrument that has a scoring system based on the 
preferences of the UK population is the EQ-5D. 
This method is the approach preferred by NICE105 
in HTAs, although there may be some concerns 
that it is not sufficiently sensitive to changes in the 
symptoms of incontinence.
Estimates of the EQ-5D scores for a sample of 
women suffering from SUI were reported in 
Chapter 4. Further data were identified from 
the literature search that was performed for the 
effectiveness review and these were supplemented 
by information from NHS Economic Evaluation 
Database (EED) and the Cost-Effectiveness 
Analysis (CEA) Registry at Tufts Medical Center.218 
From this search, only three published studies 
TABLE 59  Cost of each intervention
Intervention Cost per cycle (£)a Range (£) Notes and comments
Lifestyle changes
Cost per visit 27 13–40 Range based on 1 or 3 visits to GP (Curtis 2008)46
PFMT
PFMT basic 189 135–243 Range based on 4 and 8 sessions
PFMT + BF 224 175–388 Range based on 4 and 8 sessions
ES 398 206–481 Range based on 8 and 16 sessions
VCs 93 83–103 Assumed provided at the hospital
PFMT extra sessions 351 243–459 Based on 8 and 16 sessions
Drug therapy (SNRI)
Appointments and drugs 
for 12 weeks
164 128–200 Initial cost based on 2 appointments (initial and 
review) and the range is based on 1 or 3 visits to 
GP
Surgical therapy
TVT/TVT-O 1135 741–1357 Based on lower and upper interquartile range 
of reference costs (2008) for elective surgery 
on lower-tract minor procedures without 
complications
Colposuspension 1396 1002–1618 Range estimation based on TVT range
Containment products
Washable inserts 39 9–75 Initial cost based on cost per month for washable 
insert pants; range based on the minimum 
(menstrual pads) and maximum (disposable insert 
pants) cost of containment
a  Log-normal probability distribution was attached to all these costs.DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
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TABLE 60  EQ-5D values used in the model
EQ-5D score Value Source
The baseline of SUI (pretreatment) 0.78 Manca and colleagues (2003)220
The failure of treatment 0.74 Haywood and colleagues (2008)219
The success of treatment 0.85 Haywood and colleagues (2008)219
were identified.219–221 The first study221 was a 
pan-European study of women with urinary 
incontinence, who sought treatment, the second 
study219 was a clinical trial of group versus 
individual physiotherapy for women with SUI 
and the final study220 was an economic evaluation 
alongside an RCT, conducted in the UK, of TVT 
compared with Burch colposuspension.
In the first study, conducted in 14 European 
countries, the median EQ-5D score of women with 
urinary incontinence that sought treatment was 
0.85. The mean score for women in the UK was 
0.73 and the median 0.85.221 Another study on the 
same population of women reported 0.76 as the 
adjusted OR for EQ-5D health-state index score.222
Haywood and colleagues219 reported EQ-5D scores 
for women based on the number of incontinence 
episodes at baseline. Those with no episodes has a 
mean score of 0.85 (SD 0.24). When incontinence 
was suffered on a few days the mean score was 0.85 
(SD 0.16). As would be anticipated, the mean score 
declined as severity of incontinence increased. 
For example, when incontinence was suffered for 
‘about half the week’ the mean score was 0.81 
(SD 0.20); for ‘most days’ the mean score was 
0.79 (SD 0.23) and for ‘everyday’ the mean score 
was 0.75 (SD 0.32).219 This study219 also reported 
EQ-5D scores based upon the perceived benefit 
from physiotherapy at 6 weeks and 5 months. At 
6 weeks the mean score from those who said they 
had benefited was 0.85 (SD 0.23) and for those who 
said that they had no benefit was 0.73 (SD 0.31). At 
5 months the mean scores were 0.85 (SD 0.24) and 
0.74 (SD 0.38) for those who said they did and did 
not benefit from physiotherapy, respectively.
The third study published on women who were 
receiving surgery for SUI reported quality of life 
at baseline and at trial follow-up.220 These data 
were subsequently manipulated in an HTA trial 
comparing different surgical treatments.80 The 
EQ-5D score for women prior to surgery was 0.778 
for women randomised to TVT, and 0.785 for 
women randomised to colposuspension.220 Finally, 
as reported in Chapter 4, the survey of members of 
InContact previously identified as suffering from 
SUI reported a mean EQ-5D score of 0.598 (SD 
0.339). The mean age for the women involved in 
this sample was 57 years (range 28–89).
Derivation of values used in the model
It was thought possible that the women involved in 
the survey reported in Chapter 4 might be atypical 
of the average woman with SUI, as they were part 
of a self-selected patient group. Therefore, in 
the economic model the utility score was based 
on the study by Manca and colleagues,220 and 
failure after treatment was based on the study by 
Haywood and colleagues.219 This value was that 
of women who perceived that they did not benefit 
from physiotherapy treatment, thus indicating 
that it had failed. The utility assigned to successful 
treatment was taken as 0.85. This value was based 
on the women who perceived that they benefited 
from physiotherapy treatment at 6 months after 
treatment (Table 60).
Data analysis
Cost–utility analysis
As women with SUI might be either cured or 
‘cured or improved’ (i.e. not requiring further 
treatment but possibly still having some degree 
of incontinence), two separate analyses were 
conducted. One analysis was based upon the 
reported cure rates (see Cost–utility analysis based 
upon cure rates, below) and a second analysis based 
upon improvement rates (see Results based upon 
improvement rates, below).
The estimation of the costs and consequences 
of the different management strategies was 
performed using a hypothetical cohort of 1000 
women, starting at age of 45 years (the identified 
prevalence average age of women with SUI in 
Chapter 1) over a 40-year horizon. Results are 
presented as incremental cost per QALY. These are 
ratios of the differences in costs of the interventions 
divided by the differences in effectiveness between 
the different strategies. These data show the rate of 
return (in QALYs) to the quantity of resources used 
(measured in monetary terms). If for any given Assessment of cost-effectiveness
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incremental cost-effectiveness ratio (ICER) it is 
judged that a treatment is efficient then it implies 
that society is willing to pay at least that amount 
to obtain an additional QALY. The value society is 
willing to pay for a QALY is unclear, but, typically, 
NICE, within the UK, recommends interventions 
when the incremental cost per QALY is less than 
£20,000–30,000.105
Sensitivity analyses
With all parameter estimates there are elements 
of uncertainty owing to the lack of available 
information. In order to explore the importance 
of such uncertainties and assumptions, various 
sensitivity analyses were conducted by varying 
some of the assumptions or parameters made in 
the model. Two types of sensitivity analyses were 
performed: a probabilistic sensitivity analysis and a 
deterministic sensitivity analysis.
Probabilistic sensitivity analysis
One area of uncertainty within the economic model 
is precision of the parameter estimates used. Many 
of the parameters are not precisely known but the 
uncertainty surrounding a point estimate can be 
described using a statistical distribution. Probability 
distributions were applied to the specific ranges 
of the key parameters (Table 61), such as costs and 
samples drawn at random from these distributions 
to generate an empirical distribution of the 
cost-effectiveness ratios. All treatment costs 
were assigned log-normal distributions, as this 
distribution appeared to best fit the data that 
have skewed or symmetric ranges. There was 
no distribution to be assigned for probabilities 
of recurrence of all treatment (PFMT, drug and 
TVT surgery) due to the paucity of data. There 
was also no distribution to all-cause mortality rate 
as the number of observation used to calculate 
the risk was very large. The estimates of cure and 
improvement rates for all treatments were assigned 
log-normal or normal distributions based on the 
assumptions made in the mixed-treatment model 
in Chapter 8.
Deterministic sensitivity analysis
The second type of analysis undertaken to handle 
parameter uncertainty was to consider changes in 
one or more parameter value at the same time. 
This was used to explore structural uncertainty, 
extrapolations, methodological uncertainty, etc. 
This deterministic sensitivity analysis had been 
combined with probabilistic sensitivity analysis 
so that the joint effect of using different values 
(and distributions) and statistical imprecision 
surrounding estimates is explored. Outlined below 
are the details of the specific sensitivity analyses 
performed.
Recurrence rates of PFMT
As there were limited data relating to the long-term 
follow-up of PFMT, the long-term recurrence rates 
of PFMT in the base-case analysis were produced 
based on the values at 5 years210 and 15 years.208 
However, the identified data at 15 years in the 
study by Bø and colleagues208 was varied as in Table 
55. Changes to the recurrence rates of PFMT are 
likely to alter cost-effectiveness of the strategies 
related to PFMT. Figure 40 describes the alternative 
long-term recurrence rates considered in the 
sensitivity analysis.
As described in the section Estimation of model 
probabilities, data on the long-term effectiveness of 
all physical interventions were not readily available. 
In the base-case model it was assumed that the 
recurrence rates for physical therapies could be 
derived by multiplying the recurrence of PFMT 
by the relative effect sizes derived in the MTC, 
reported in Chapter 8 and summarised in Table 
50. The recurrence rates for PFMT came from Bø 
and colleagues.208 Bø and colleagues208 reported 
that there was no difference at 15 years in the 
effectiveness of the two forms of PFMT compared. 
Therefore, in this sensitivity analysis it was assumed 
that the recurrence rates for all different physical 
treatments (PFMT plus BF, VCs and ES) had the 
same recurrence rate as PFMT.
Recurrence rates of TVT
As explained in Estimation of model probabilities, 
there was no reliable evidence related to the long-
term follow-up of recurrence rate of TVT surgery. 
The trial by Ward and colleagues,213 which reported 
recurrence rates for up to 5 years’ follow-up, was 
used to estimate the recurrence rates of TVT 
surgery in the base-case analysis. This sensitivity 
analysis used the recurrence rates estimated in an 
earlier HTA that compared TVT surgery with other 
surgical treatments.80 In the sensitivity analysis 
the long-term cure rates for TVT surgery were 
increased to 81% and reduced to 65% in the first 
year and 61% in the second year.
Starting age and time horizon
The incidence rate of SUI is likely to increase as 
age increases. The mean age of women with SUI in 
the UK is 45 years and this was taken to be the age 
of women in the cohort modelled. Women included 
in the trials included in the systematic review 
of effectiveness tended to be slightly older, with DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
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FIGURE 40  Linear exponential curves with variation of recurrence rates of pelvic floor muscle training. Note that each cycle is 3 
months long.
average ages varying from 50 to 60 years. The costs 
and effects in the model were estimated for a 40-
year time horizon. This time horizon was chosen 
as it was felt to cover the expected life expectancy 
of women aged 45. However, few robust data are 
available for such a long follow-up.
In this sensitivity analysis the implications of 
varying the age of women at the start of treatment 
and the impact of adopting a shorter time horizon 
were explored. Therefore, the starting age of 
women was changed to 50, 55, and 60 years in the 
sensitivity analyses. The time horizons were likewise 
reduced to 10, 20 and 30 years.
Quality of life
As mentioned previously (see Quality of life), data 
from Manca and colleagues220 and Haywood and 
colleagues219 were used in the base-case analysis. 
Sensitivity analysis was performed using the EQ-5D 
scores derived in the survey reported in Chapter 4 
to weight the utility scores taken from the study by 
Haywood and colleagues219 (Table 61).
The impact of the natural decline in quality of life 
over time was also considered in further sensitivity 
analysis. The values for the age-related reduction 
was derived based on published values for age-
related quality of life.223 The extrapolated values 
are illustrated in Figure 41 and Appendix 25.
Discount rate
As recommended in the NICE guidelines, an 
annual discount rate of 3.5% for costs and benefits 
was used in the base-case analyses.105 A range of 
1–6% for discount rate was considered in this 
sensitivity analysis.
Probability of moving to the next 
treatment following failure of prior 
treatment
Considerable efforts were made to identify the 
estimates for a probability that women would 
not seek further treatment should a treatment 
fail or symptoms recur, and would manage their 
incontinence using containment products, but few 
data are available. In the base-case analyses it was 
assumed that the women would go immediately 
to the next treatment after failure or recurrence. 
In this sensitivity analysis, the impact of allowing 
between 10% and 50% of women who experience a 
treatment failure or recurrence of symptoms not to 
seek further treatment was explored.
Use of containment products
Although there is anecdotal evidence that women 
use containment even when they are undergoing 
treatment, there were no data to inform what 
proportion of the women use containment products Assessment of cost-effectiveness
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TABLE 61  EQ-5D values weighted by the utilities reported in Chapter 4
EQ-5D score Value Source
The baseline of SUI (pretreatment) 0.60 Chapter 4
The failure of treatment 0.57 Haywood and colleagues (2008),219 weighted by utilities reported in 
Chapter 4
The success of treatment 0.65 Haywood and colleagues (2008),219 weighted by utilities reported in 
Chapter 4
and what type of products they use. Therefore, in 
the cure and improvement model it was assumed 
all women used containment products, although 
the quantity/type used varied according to 
symptoms. 
Mortality and success rate of TVT
Further sensitivity analyses were conducted by 
varying the mortality risk and success rates related 
to TVT in base case. In the base-case analysis a 
mortality risk based on the risk of undergoing 
open surgery (0.0005) was attached to TVT. In 
the sensitivity analysis this was reduced to zero. 
Sensitivity analysis was also performed to estimate 
the impact of an increase in the success rate of TVT 
by 5%.
Costs
As indicated earlier, it is difficult to define a 
‘standard’ intervention, as practice varies greatly. 
The costs of interventions are dependent on the 
assumptions made about the number of sessions 
of therapy a woman could get. Maximum and 
minimum costs were derived by increasing and 
reducing the number of sessions. For example, 
the minimum cost of basic PFMT was derived 
by reducing the number of sessions to four and 
the maximum cost was derived by increasing the 
number of sessions to eight. Distributions were 
used in the analysis to incorporate the minimum 
and maximum values attached to the costs.
Results of the model 
presented in terms of costs 
and consequences
The results of the base-case deterministic analyses 
for 1000 women are presented in terms of 
summaries of the time spent cured (or improved 
for the improvement model), with incontinence 
and also the cumulative number of women 
who have received surgery. The results are also 
presented in terms of the cumulative QALYs and 
cost.
Analysis based on cure rates
For the analyses based on the cure rates, the 
strategy that used lifestyle changes and PFMT 
basic followed by PFMT with extra sessions 
followed by TVT surgery (LS–PFMT basic–PFMT 
extra sessions–TVT) had the best performance 
in terms of the highest number of successes (939 
and 953) and lowest number of failures (59 and 
36) at the 1- and 10-year time horizons, whereas 
the strategy that used lifestyle changes and PFMT 
basic followed by TVT surgery (LS–PMT basic–
TVT) had the highest number of success at the 
40-year time horizon (398). The strategy that 
had the least number of failures (28) was the one 
that used the lifestyle changes and PFMT basic 
followed by PFMT with extra sessions followed by 
SNRI followed by TVT surgery (LS–PFMT basic–
PFMT extra sessions–SNRI–TVT). The strategy 
of lifestyle change and TVT surgery (LS–TVT) 
has the worst performance in terms of the lowest 
number of successes (726, 907 and 363) and the 
highest number of failures (272, 82 and 57) at 
all three time horizons. This strategy had the 
highest number of patients (998 and 989) receiving 
surgery at 1- and 10-year time horizons, and the 
strategy that used lifestyle changes and PFMT basic 
followed by TVT surgery (LS–PFMT basic–TVT) 
had the highest number (443) of patients receiving 
surgery at the 40-year time horizon (Table 62).
Analysis based on improvement 
rates
For the analysis based on improvement rates, the 
strategy that used LS–PFMT with extra sessions 
followed by TVT surgery had the best performance 
in terms of the highest number of successes (985, 
951 and 410) at all the three time horizons and 
the lowest number of failures (13 and 22) at 1 
and 10 years (Table 63). The strategy that used 
lifestyle changes and PFMT basic followed by 
PFMT with extra sessions followed by drug therapy 
followed by TVT surgery (LS–PFMT basic–PFMT 
extra sessions–SNRI–TVT) had the least number DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
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FIGURE 41  Linear extrapolation of EQ-5D score using EQ-5D adjusted by age. Note that extracted data refers to data taken from 
Kind and colleagues (1999).223
of failures (8). The strategy of lifestyle changes 
followed by TVT surgery (LS–TVT) had the worst 
performance in terms of the lowest number of 
successes (793, 913 and 382) and the highest 
number of failures (205, 60 and 40) at all three 
time horizons. This strategy also had the highest 
number of patients (998, 973 and 422) having had 
surgery at all three time horizons.
Cost–utility analysis based 
upon cure rates
Deterministic results
Table 64 details the results of the mean cost and 
treatment effects of the model using cure rates 
from the mixed-treatment model in a hypothetical 
cohort with 1000 samples. The table reports 
performance of the strategies from the least to the 
most costly. The lower part of the table reports 
the ICERs when dominated and extendedly 
dominated strategies are omitted. The strategy 
that used lifestyle changes and PFMT with extra 
sessions followed by TVT surgery (LS–PFMT extra 
sessions–TVT) was the least costly (£1644) and the 
most effective (16.20 QALYs). The strategy that 
had lifestyle changes followed by TVT surgery 
(LS–TVT) was the most costly (£1973), and the 
strategy that used lifestyle changes and PFMT basic 
followed by PFMT with extra sessions followed by 
SNRI and then TVT surgery (LS–PFMT basic–
PFMT extra sessions–SNRI–TVT) was the least 
effective (15.89 QALYs).
Probabilistic results
As the cost-effectiveness point estimates do 
not provide any information of uncertainty 
surrounding the model parameters, probabilistic 
sensitivity analysis using Monte Carlo simulations 
was also performed using these strategies. The 
results of the probabilistic analysis are presented in 
the form of cost-effectiveness acceptability curves in 
Figure 42. The strategy employing lifestyle changes 
and PFMT with extra sessions followed by TVT 
surgery (LS-PFMT extra sessions-TVT) has a more 
than 70% probability of being considered cost-
effective for all threshold values for willingness to 
pay for a QALY presented. The other five strategies 
each have a probability of less than 20% of being 
considered cost-effective.
Sensitivity analyses
Changes to the effectiveness and cost 
of PFMT basic and PFMT with extra 
sessions
Change in the long-term recurrence 
rates of PFMT basic and PFMT with 
extra sessions
As mentioned previously (under Summary of key 
assumptions made in the economic model), the Assessment of cost-effectiveness
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TABLE 62  Results of the deterministic model based on cure rates for 1-, 10- and 40-year time horizonsa
Year Strategy
Success performance
Receiving 
surgery Population
QALYs/costs
Success Failure QALYs Costs (£)
1 LS–PFMT extra sessions–
TVT
927 71 393 1000 0.8 821
LS–PFMT extra sessions–
SNRI–TVT
927 71 375 1000 0.79 855
LS–PFMT basic–PFMT extra 
sessions–TVT
939 59 357 1000 0.78 930
LS–PFMT basic–PFMT extra 
sessions–SNRI–TVT
936 62 333 1000 0.77 954
LS–PFMT basic–TVT 845 153 926 1000 0.78 1261
LS–TVT 726 272 998 1000 0.8 1186
10 LS–PFMT extra sessions–
TVT
950 39 512 1000 6.97 1290
LS–PFMT extra sessions–
SNRI–TVT
946 43 500 1000 6.93 1349
LS–PFMT basic–PFMT extra 
sessions–TVT
953 36 478 1000 6.90 1391
LS–PFMT basic–PFMT extra 
sessions–SNRI–TVT
947 42 466 1000 6.86 1449
LS–PFMT basic–TVT 932 57 937 1000 6.89 1676
LS–TVT 907 82 989 1000 6.91 1733
40 LS–PFMT extra sessions–
TVT
386 31 416 1000 16.2 1644
LS–PFMT extra sessions–
SNRI–TVT
380 28 406 1000 16.06 1727
LS–PFMT basic–PFMT extra 
sessions–TVT
379 29 407 1000 16.02 1758
LS–PFMT basic–PFMT extra 
sessions–SNRI–TVT
373 27 398 1000 15.89 1842
LS–PFMT basic–TVT 398 45 443 1000 16.03 1886
LS–TVT 363 57 420 1000 16.08 1973
a  The addition of success and failure rates does not equal 1000, as in any given year some women in the original cohort 
will have died.
recurrence rates of PFMT basic and PFMT with 
extra sessions were estimated from the study by Bø 
and colleagues208 and it is possible that this value 
is overestimated. As long-term cure rates of PFMT 
basic and PFMT with extra sessions decreased, 
the costs of the strategies associated with long-
term PFMT basic and PFMT with extra sessions 
are increased because the long-term recurrence 
estimation for PFMT basic and PFMT with extra 
sessions is increased. However, the outcomes 
associated with long-term PFMT basic and PFMT 
with extra sessions are decreased. The results of 
the sensitivity analyses of variations of long-term 
of recurrence rates for PFMT basic and PFMT 
with extra sessions are presented in Table 65. 
The probability that society is willing to pay for 
an additional QALY for the strategies associated 
with PFMT basic and PFMT with extra sessions 
generally decreases as the long-term cure rate of 
PFMT decreases.
Changes to the ORs of PFMT basic and 
PFMT with extra sessions compared 
with no treatment
The results of the sensitivity analysis performed 
using different point estimates in clinical 
effectiveness for cure rates of PFMT with extra 
sessions and PFMT basic are reported in Table 
66. When the ORs of PFMT with extra sessions 
were compared with no treatment decreased, DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
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TABLE 63  Results of the deterministic model in terms based on improvement rates for 1-, 10- and 40-year time horizonsa
Year Strategy
Success performance
Receiving 
surgery Population
QALYs/costs
Success Failure QALYs Costs (£)
1 LS–PFMT extra sessions–
TVT
985 13 23 1000 0.82 430
LS–PFMT extra sessions–
SNRI–TVT
977 21 8 1000 0.81 416
LS–PFMT basic–PFMT 
extra sessions–TVT
983 15 0 1000 0.81 252
LS–PFMT basic–PFMT 
extra sessions–SNRI–TVT
983 15 0 1000 0.81 252
LS–PFMT basic–TVT 981 17 30 1000 0.81 275
LS–TVT 793 205 998 1000 0.8 1200
10 LS–PFMT extra sessions–
TVT
951 22 462 1000 7.04 1159
LS–PFMT extra sessions–
SNRI–TVT
942 31 401 1000 7.02 1145
LS–PFMT basic–PFMT 
extra sessions–TVT
947 26 162 1000 7.03 833
LS–PFMT basic–PFMT 
extra sessions–SNRI–TVT
940 33 127 1000 7.03 818
LS–PFMT basic–TVT 947 26 593 1000 7.03 1139
LS–TVT 913 60 973 1000 6.96 1883
40 LS–PFMT extra sessions–
TVT
410 12 420 1000 16.37 1938
LS–PFMT extra sessions–
SNRI–TVT
403 11 404 1000 16.27 1965
LS–PFMT basic–PFMT 
extra sessions–TVT
406 9 410 1000 16.31 1795
LS–PFMT basic–PFMT 
extra sessions–SNRI–TVT
400 8 386 1000 16.24 1803
LS–PFMT basic–TVT 408 13 421 1000 16.34 1873
LS–TVT 382 40 422 1000 16.2 2425
a  The addition of success and failure rates does not equal 1000, as in any given year some women in the original cohort 
will have died.
the probability that the strategies associated with 
PFMT with extra sessions were cost-effective was 
also reduced. When the ORs compared with no 
treatment reduced to four (the value used in 
base case was 10.7), the likelihood that lifestyles 
followed by PFMT with extra sessions followed by 
TVT surgery (LS–PFMT extra sessions–TVT) was 
cost-effective fell to approximately 40%. The main 
strategy that gained was ‘lifestyles’, followed by 
‘TVT surgery’, which has a 50% chance of being 
considered cost-effective over the range of values 
for a cost per QALY considered.
When the OR of PFMT basic compared with no 
treatment varied (Table 67), the results were broadly 
similar to the best case analysis.
Changes to the cost of PFMT with extra 
sessions
As indicated in Resource utilisation and cost 
estimation, the cost of PFMT with extra sessions 
may be underestimated. As shown in Table 68, the 
probability that lifestyle–PFMT extra sessions–
TVT was most cost-effective decreased and 
the probability that LV–TVT was cost-effective 
increased. However, PFMT with extra sessions 
would need to increase in cost by more than £400 
before the base-case conclusions would substantially 
change.Assessment of cost-effectiveness
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TABLE 64  Base-case results of costs and effects using cure rates from the mixed-treatment model
Strategy Cost (£) Incremental cost (£) QALYS Incremental QALY ICER
LS–PFMT extra sessions–TVT 1644 16.20
LS–PFMT extra sessions–
SNRI–TVT
1727 82 16.06 –0.13 Dominated
LS–PFMT basic–PFMT extra 
sessions –TVT
1758 113 16.02 –0.17 Dominated
LS–PFMT basic –PFMT extra 
sessions–SNRI –TVT
1842 197 15.89 –0.3 Dominated
LS–PFMT basic–TVT 1886 242 16.03 –0.17 Dominated
LS–TVT 1973 328 16.08 –0.12 Dominated
Results without dominated and extendedly dominated options
LS–PFMT extra sessions–TVT 1644 16.20
FIGURE 42  Cost-effectiveness acceptability curves determined by society’s willingness to pay for a quality-adjusted life-year for the six 
strategies.
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Changes to the effectiveness of surgery
Changes to the recurrence rates of TVT 
surgery
As indicated in Estimation of model probabilities, 
the long-term recurrence rates of incontinence 
after TVT surgery were estimated from the trial 
by Hilton and colleagues (2008).214 There is some 
uncertainty attached to this estimate and it is 
probable that this value could be either an over- or 
underestimate. As long-term cure rates of TVT 
surgery increases, the costs for each strategy are 
decreased and QALYs increase, as women spend 
more time continent over the 40-year time horizon. 
When the probability of recurrence of TVT surgery 
was increased to 81%, the probability that LS–
PFMT extra sessions–TVT would be considered to 
be cost-effective was reduced, and the probability 
that lifestyle changes followed by TVT surgery 
(LS–TVT) was cost-effective increases. When the 
TVT surgery cure rate was reduced to 65%, the 
probability that the strategy that uses lifestyle 
changes followed by TVT surgery (LS–TVT), was 
considered to be cost-effective was also reduced 
(Table 69).DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
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Mortality and success rate of TVT 
surgery
These results did not change to any extent when 
the mortality risk of surgery was reduced to zero 
or the success rate of TVT surgery was increased 
by 5%. The results of this analysis are shown in 
Appendices 26–27.
Changes to the structure of the model
Probability of containment after 
failure or recurrence for non-surgical 
treatment
The likelihood that the strategies would be 
considered cost-effective in cure rate base case 
did not largely change, although the costs for the 
strategy associated with no surgical treatments 
were increased, and the outcomes (QALYs) were 
decreased when the proportion of women using 
containment products increased (Table 70).
Probability of containment after 
failure or recurrence for first surgical 
treatment
For the model based on cure rates, the likelihood 
that the different strategies would be considered 
cost-effective did not change when the probability 
of using containment products after failure or 
recurrence was applied, although costs for each 
given strategy increased and the outcomes (QALYs) 
decreased when the proportion of women using 
containment products increased (Table 71).
Adding strategies that use VCs and ES
As indicated in Model framework, strategies using 
VC and ES were to be considered in sensitivity 
analyses. The results of the deterministic analysis 
are reported in Table 72. The strategy that 
employed lifestyle changes and PFMT basic 
followed by ES followed by TVT surgery (LS–PFMT 
basic–ES–TVT) was dominated (more costly and 
less effective than another strategy). The strategy 
that employed lifestyle changes and PFMT 
basic followed by VCs followed by TVT surgery 
(LS–PFMT basic–VC–TVT) was dominated. The 
addition of strategies involving VCs and ES had a 
small probability of being considered cost-effective 
(less than 12%) and did not greatly influence the 
results.
Other sensitivity analyses
Changes to starting ages, time horizon, quality of 
life and discount rates all had no substantial effect 
on the results. As the starting age was increased 
the costs and outcomes for each strategy were 
reduced because of the increase in mortality as age 
increased. As the time horizon reduced there was 
less opportunity for women who had undergone 
the relatively costly surgery to accrue much 
benefit. Reducing the discount rate meant that 
the sustained benefits of surgery were given more 
weight in the analysis as were the costs of using 
containment products. Therefore, the LS–TVT 
strategy increased in its likelihood of being cost-
effective. The results of these sensitivity analyses 
are reported in Appendix 26.
Results based upon 
improvement rates
Deterministic results
In these analyses the costs were lower and the 
QALYs were higher than those reported in analyses 
based on cure rates (Table 73). The strategy that 
used lifestyle changes and PFMT basic followed by 
PFMT with extra sessions followed by TVT surgery 
(LS–PFMT basic–PFMT extra sessions–TVT) was 
the least costly (£1795) and the strategy that had 
lifestyle and PFMT with extra sessions followed by 
TVT surgery (LS–PFMT extra sessions–TVT) was 
the most effective (16.37 QALYs). The strategy 
that had lifestyle changes followed by TVT surgery 
(LS–TVT) was the most costly (£2425) and the least 
effective (16.2 QALYs).
Probabilistic results
Probabilistic analysis was performed comparing 
all these strategies. As illustrated in Figure 43, the 
strategy that used lifestyle and PFMT with extra 
sessions followed by TVT surgery (LS–PFMT extra 
sessions–TVT) has more than a 50% probability 
of being considered cost-effective when society’s 
willingness to pay for an additional QALY is more 
than £10,000. The other strategies have a less than 
20% chance of being considered cost-effective, as 
society’s willingness to pay more for additional 
QALYs increases. The strategy that had the least 
probability of being considered cost-effective was 
the one that used lifestyle changes followed by TVT 
surgery.
Sensitivity analyses
Changes to the effectiveness and cost of 
PFMT basic and PFMT extra sessions
Change in the long-term recurrence 
rates of PFMT basic and PFMT extra 
sessions
When the long-term cure rates of PFMT with extra 
sessions were the same as PFMT basic, then the 
strategy that had the highest probability of being 
cost-effective changed from lifestyle and PFMT Assessment of cost-effectiveness
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TABLE 73  Base-case results using on the improvement rates of the mixed-treatment model
Strategy Cost (£)
Incremental 
cost (£) QALYs
Incremental 
QALYs ICER
LS–PFMT basic–PFMT extra sessions–TVT 1795 16.31
LS–PFMT basic–PFMT extra sessions–SNRI–TVT 1803 8 16.24 –0.07 Dominated
LS–PFMT basic–TVT 1873 78 16.34 0.04 Extendedly 
dominated
LS–PFMT extra sessions–TVT 1938 143 16.37 0.07 £2147
LS–PFMT extra sessions–SNRI–TVT 1965 27 16.27 –0.10 Dominated
LS–TVT 2425 487 16.20 –0.17 Dominated
Results without dominated and extendedly dominated options
LS–PFMT basic–PFMT extra sessions–TVT 1795 16.31
LS–PFMT extra sessions–TVT 1938 143 16.37 0.07 £2147
with extra sessions followed by TVT surgery (LS–
PFMT extra sessions–TVT) to lifestyle and PFMT 
basic followed by TVT surgery (LS–PFMT basic–
TVT) (Table 74). Similarly, reducing the cure rates 
of both PFMT basic and PFMT with extra sessions 
also meant that lifestyle and PFMT basic followed 
by TVT surgery (LS–PFMT basic–TVT) was most 
likely to be cost-effective.
Changes to the ORs of PFMT basic and 
PFMT extra sessions compared with no 
treatment
The results of the sensitivity analysis performed 
using different point estimates in clinical 
effectiveness for improvement rates of PFMT 
extra sessions and PFMT basic are reported 
in Table 75. When the OR of PFMT with extra 
sessions compared with no treatment falls, 
strategies involving this treatment are less likely 
to be considered cost-effective. The strategy that 
increased more in terms of the likelihood of being 
cost-effective was lifestyle changes and PFMT basic 
followed by TVT surgery (LS–PFMT basic–TVT).
Changes to the cost of PFMT with extra 
sessions
As indicated in Resource utilisation and cost 
estimation, the cost of PFMT with extra sessions 
may be underestimated. When the cost of PFMT 
with extra sessions increases, the strategies 
containing this treatment became less likely to 
be considered cost-effective (Table 76). When the 
cost of PFMT increased beyond £200 there was an 
increasing chance that lifestyle changes and PFMT 
basic followed by TVT surgery (LS–PFMT basic–
TVT) would be considered cost-effective.
Changes to the effectiveness of surgery
Change in the recurrence rates of TVT
As indicated in Estimation of model probabilities, 
the long-term recurrence rates of incontinence 
after TVT surgery were estimated from the trial by 
Ward and colleagues.213 There is some uncertainty 
attached to this estimate and it is probable that this 
value could be either an over- or underestimate. 
As long-term cure rates of TVT surgery decreased, 
the costs associated with long-term TVT surgery 
for each strategy were increased because the long-
term recurrence of TVT surgery was also increased 
leading to a decrease in long-term benefits. Table 
77 describes the results of the sensitivity analyses 
for changes in the long-term cure rates for TVT 
surgery. When the probability was increased to 
81%, the likelihood that lifestyle changes and 
PFMT with extra sessions followed by TVT (LS–
PFMT extra sessions–TVT) was cost-effective fell 
to approximately 60%. The main gainer was the 
strategy of lifestyle changes followed by TVT (LS–
TVT), which had a 30% chance of being considered 
cost-effective over the range of values considered. 
When the probability was reduced to 65%, the 
likelihood that the strategy lifestyle changes 
and PFMT with extra sessions followed by TVT 
(LS–PFMT extra sessions-TVT) was considered to 
be cost-effective is increased to 80% and that of 
lifestyle changes followed by TVT is reduced to 1% 
(Table 78).
Mortality and success rate of TVT
The results did not change to any extent when the 
mortality risk was reduced to zero or the success 
rate of TVT was increased to 5%. The results of 
these analyses are shown in Appendix 27.Assessment of cost-effectiveness
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FIGURE 43  Cost-effectiveness acceptability curves determined by society’s willingness to pay for a quality-adjusted life-year for the six 
strategies.
Changes to the structure of the model
Probability of containment after 
failure or recurrence for non-surgical 
treatment
The likelihood that the strategies would be 
considered cost-effective in the improvement 
model hardly changed when the probability that 
women might use containment products rather 
than progress to the next active treatment was 
increased to 30% and 60% (Table 78).
Probability of containment after 
failure or recurrence for first surgical 
treatment
When women might use containment products 
rather than resort to a second operation (if one was 
necessary) the likelihood of the strategy lifestyle 
changes and basic PFMT followed by PFMT with 
extra sessions followed by tension-free tape (LS-
PFMT basic-PFMT extra sessions-TVT) would be 
considered cost-effective reduced (Table 79).
Adding strategies using VCs and ES
For the sensitivity analysis the only difference was 
that the likelihood of the strategy involving the 
use of VCs (LS–PFMT basic–VC–TVT) was more 
likely to be considered cost-effective instead of the 
lifestyle changes and basic PFMT followed by TVT 
(LS–PFMT basic–TVT) (Table 80).
Other sensitivity analysis
Changes to starting ages, quality of life and 
discount rates had no substantial effect on 
the results. As the starting age was increased, 
the costs and outcomes for each strategy were 
reduced because of the increase in mortality as 
age increased. However, as the time horizon was 
reduced in the analysis using the improvement 
rates, the non-dominated strategy of lifestyle-
PFMT basic-PFMT with extra sessions followed 
by TVT (LS–PFMT basic–PFMT extra sessions–
TVT) had a slightly increased likelihood of being 
considered cost-effective. Reducing the discount 
rate meant that the sustained benefits of surgery 
were given more weight in the analysis as were the 
costs of containment products. The results of these 
sensitivity analyses are reported in Appendix 27.
Summary of results
The economic model presented in this chapter 
considered some of the management strategies 
that have the potential to be, or are currently 
being, used in managing women with SUI. These 
strategies included the following interventions: 
lifestyle changes, physical therapies, medical 
therapies and surgery. The effectiveness data for 
non-surgical treatments came from the results of 
mixed-treatment model. This was because the data Assessment of cost-effectiveness
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of direct comparison were not adequate, as they 
were based on very few and very small studies.
There were no data on the clinical effectiveness of 
lifestyle modification interventions. It was therefore 
assumed in the model that all women have 
received lifestyle change advice in each strategy 
and then go to the next treatment. There were no 
reliable data on the long-term clinical effectiveness 
of PFMT, drug therapy and TVT surgery. 
Long-term recurrence rates for PFMT, drug 
therapy and TVT were estimated by parametric 
extrapolation methods of the limited evidence 
base. Furthermore, there was also no information 
associated with long-term clinical effectiveness of 
other non-surgical treatments.
The cost–utility analyses were conducted using 
EQ-5D scores to value health effects in the two 
base-case analyses. Broadly speaking, the results 
that were based on cure rates were similar to those 
based on improvement rates.
In the cure-rate base-case analysis there was only 
one non-dominated or non-extendedly dominated 
strategy (i.e. it provided more benefits than a less 
costly strategy or more benefits than could be 
provided should a combination of a less and more 
costly strategies be used):
•  lifestyle changes and PFMT with extra sessions 
followed by TVT (LS–PFMT extra sessions–
TVT).
In the analysis based on improvement rates there 
were two strategies that were not dominated or 
extendedly dominated:
•  lifestyle changes and PFMT with extra sessions 
followed by TVT surgery (LS–PFMT extra 
sessions–TVT) and
•  lifestyle changes and PFMT basic followed by 
PFMT with extra sessions then TVT surgery 
(LS–PFMT basic–PFMT extra sessions–TVT).
For the cure-rate base-case analysis, the strategy 
‘lifestyle changes and PFMT extra session followed 
by TVT (LS–PFMT extra sessions–TVT)’ was the 
least costly (£1644) and the most effective (16.20 
QALYs) strategy. For the improvement-rate base-
case analysis, the strategy ‘lifestyle changes and 
PFMT basic followed by PFMT with extra sessions 
followed by TVT surgery (LS–PFMT basic–PFMT 
extra sessions–TVT)’ was the least costly (£1795) 
and provided 16.31 QALYs. For both base-case 
analyses the strategy of ‘lifestyle changes followed 
by TVT surgery (LS–TVT)’ (mean cost = £1793 for 
cure rates and £2524 for improvement rates) was 
the most costly.
In the cure-rate base case, the strategy of ‘lifestyle 
changes and PFMT basic followed by PFMT 
with extra sessions followed by SNRI and then 
TVT surgery’ was the least effective (providing 
15.89 QALYs) strategy. In the improvement-rate 
base-case analysis the strategy that used ‘lifestyle 
changes followed by TVT surgery’ was the least 
effective.
Although the differences between strategies in 
terms of costs and effects in both base-case analyses 
appear not to be large, the important issue is 
whether society is willing to pay for any additional 
gain. Only two strategies have a likelihood of 
being considered to be cost-effective of greater 
than 50% when the threshold is £20,000–30,000 
per QALY: LS–PFMT extra session–TVT (cure 
rates) and LS–PFMT basic–PFMT extra sessions–
TVT(improvement rates). All of the other strategies 
had between 0% and 20% likelihood of being 
considered cost-effective if society were willing to 
pay between £20,000 and £30,000 per QALY.
Results of probabilistic sensitivity analyses, 
performed to handle the uncertainty around the 
parameter estimates used within the model, were 
broadly consistent with the point estimates for both 
base-case analyses. The likelihood that different 
strategies might be considered cost-effective 
changed slightly in some sensitivity analyses. The 
results of the model were sensitive to changes in 
the long-term cure rates. However, these changes 
did not alter the conclusions.
The results of the sensitivity analyses were broadly 
similar to those of the base cases when different 
values of quality of life were used to estimate 
QALYs and when other assumptions made within 
the model were changed. For example, when the 
proportion of patients that used containment 
products after failure or recurrence for non-surgical 
or surgical treatments were changed.
The modelling performed in this section provided 
and contributed to the evidence available for 
evaluating the cost-effectiveness of non-surgical 
interventions for the treatment of SUI in women. 
This work also provided information on the long-
term costs of managing women with SUI.
The data that were used to estimate cost-
effectiveness came from the MTC model. These 
data represented the best available evidence to date Assessment of cost-effectiveness
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on the relative effectiveness of the non-surgical 
treatments.
The lack of long-term data on the cure and 
recurrence rates of the interventions under 
consideration limits the analyses. Long-term 
performance was extrapolated from short-term 
data. Also assumptions had to be made about these 
parameters; for example, the recurrence rates of 
PFMT with extra sessions were assumed to be the 
same as the PFMT basic. Due to a lack of reliable 
data, it is unclear whether this assumption is valid 
or not.
There was also uncertainty around the costs 
estimates. It was very difficult to determine the 
‘standard’ number of sessions that there were in 
basic PFMT. Therefore, it was assumed that basic 
PFMT consisted of six sessions. These assumptions 
were also applied to all therapies that had some 
form of PFMT. The other area where there was a 
lack of data was the quality-of-life estimates.DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
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S
tress incontinence is the most common type of 
urinary incontinence experienced by women. 
The treatment options can be classified as non-
surgical and surgical. Non-surgical interventions, 
such as PFMT, may require long-term adherence to 
an exercise regimen to produce continued benefit 
but (apart from medical therapies) they have few 
or no adverse events. Surgical treatment, on the 
other hand, may have a higher rate of cure or 
improvement in symptoms but has a greater risk of 
complications.
The choice of treatment is influenced by patient 
preference, professional advice and the research 
evidence. It takes into account factors such as 
symptom severity, degree of interference with 
lifestyle, presence of related problems and degree 
of comorbidity. A woman may seek and receive 
several different treatments during the course of 
her lifetime, and, from a health service perspective, 
it is important to balance effectiveness, potential 
adverse events and costs of individual treatments 
and alternative care pathways. This study aimed 
to assess the clinical effectiveness and cost-
effectiveness of alternative non-surgical treatments 
and treatment pathways for women with SUI.
Main results
Summary of results from the 
survey of factors important to 
women with SUI
Central to the estimation of both effectiveness and 
cost-effectiveness is that the outcome measures 
chosen reflect factors that are important to the 
women themselves. As reported in Chapter 4, 
members of The Bladder and Bowel Foundation 
(formerly members of InContact)99 (n = 188 
women) were prospectively surveyed with the 
aim of gathering information on outcomes of 
importance to them and 105 responses were 
received. Areas of importance to women who 
suffer from SUI were assessed using a PGI. In 
addition, the questionnaire included the King’s 
Health Questionnaire and the EQ-5D. The survey 
identified 38 different areas of life affected by SUI. 
The five most frequently reported were: going out 
or socialising, personal hygiene, sleep, shopping 
and depression. Ideally, these areas would then 
be used to derive outcomes of relevance to 
women in primary studies and systematic reviews. 
However, these outcomes were rarely considered 
in primary studies. PGI scores and EQ-5D scores 
were positively correlated and these correlations 
were statistically significant. Nevertheless, the areas 
identified by the PGI did not map well to the EQ-
5D. Correlations between the seven domains of 
the King’s Health Questionnaire and PGI were all 
negative but only two were statistically significant: 
personal relationships and severity measures. 
These data suggest that the PGI may be capturing 
concerns of women who suffer from SUI which are 
not adequately captured by generic instruments 
such as the EQ-5D.
Summary of results from 
the systematic review of 
effectiveness
The focus of the systematic reviews of effectiveness 
was on the rates of cure and cure or improvement 
(this latter outcome is referred to in the text as 
improvement), quality of life, and adverse events. 
The systematic review of clinical effectiveness 
identified 88 trials reporting data from 9721 
women. The included studies covered five generic 
interventions (PFMT with or without BF, ES, VCs, 
BT and SNRI medications) with many variations 
and combinations of them. Data were available 
for 37 interventions and 68 direct head-to-head 
(pairwise) comparisons. The MTC included 14 
treatments and took data from the 55 trials (6608 
women) that reported data for these treatments. 
Cure data were available for 3560 women (38 trials) 
and improvement data were available for 6140 
women (47 trials). In total, 41% and 61% of these 
data for cure and improvement, respectively, came 
from 10 trials comparing SNRI with placebo.
A summary of the treatment comparisons showing 
both the direct comparisons and the MTC results 
is given in Table 81. PFMT with or without BF 
appeared to be more effective than no treatment 
both in terms of cure and improvement. ES, SNRI, 
BT and PFMT plus ES had, on average, higher 
odds of cure and improvement compared with no 
treatment. VCs, and PFMT plus SNRI had higher 
Chapter 10  
DiscussionDiscussion
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odds of improvement compared with no treatment. 
The direct, head-to-head comparisons were 
inconclusive about whether PFMT with or without 
BF was better than other treatments. For example, 
the ORs (point estimate) for improvement favoured 
PFMT (with or without BF) over other standalone 
treatments (ES, VCs, BT and SNRI), but the CIs 
were wide and included one (no difference).
The MTC results provided similar results to the 
direct comparisons. Because this comparison was 
able to draw upon both the direct and indirect 
comparative evidence, it was able to provide more 
precise estimates of relative effectiveness than 
provided by the direct pairwise comparisons.
Pelvic floor muscle training, when supervised, with 
extra sessions (more than two sessions or contacts 
with a health-care professional per month), was 
better than basic PFMT in terms of both cure and 
improvement, as shown by both direct evidence 
and the MTC model (see the final row of each 
section of Table 81 and, for the MTC model only, 
see Table 82).
Both pelvic floor muscle training with extra 
sessions,and PFMT with BF were also more 
effective in terms of both cure and improvement 
compared with: no treatment; ES; VCs; or SNRI 
(Table 82). There was considerable uncertainty 
about whether either is better than BT.
Evidence about PFMT (with or without BF) 
combined with an adjunct treatment (e.g. ES, VCs) 
was generally inconclusive, largely due to a lack 
of available data. Adding BT to PFMT with BF 
appears to be more effective than PFMT with BF 
alone or BT alone, although interpretation requires 
caution, as this finding is based upon data from a 
single trial that considered a population who had 
both stress and urgency incontinence symptoms. 
The MTC results for these pairs of treatments were 
also inconclusive.
All of these results need to be considered 
cautiously. Importantly, the longevity of any 
treatment effects was unclear because of the small 
amount of data available and limited duration of 
follow-up.
Summary of results from the 
economic model
Data from the MTCs were used to populate 
an economic model. The economic model 
presented in this report compared eight different 
management strategies. These were chosen because 
they were believed to be relevant to the NHS 
and they might potentially be cost-effective. The 
model compared cumulative costs and QALYs for 
a 40-year time horizon for two separate analyses; 
one based on cure rates and the other based on 
improvement rates.
In the model based on cure rates, the least costly 
strategy was lifestyle intervention, followed by 
PFMT with extra sessions (or PFMT plus BF) and 
then surgery if necessary, with a mean cost per 
woman treated of £1644. The most costly strategy 
was lifestyle changes followed by surgery with a 
mean cost per woman treated of £1973. In terms 
of QALYs, the least effective strategy was lifestyle 
changes followed by surgery (mean QALYs per 
woman treated = 16.1). The most effective was 
lifestyle changes followed by PFMT with extra 
sessions followed by surgery if necessary (mean 
QALYs per woman treated = 16.2). There were 
relatively modest differences between treatments in 
terms of both QALYs and costs. One interpretation 
of these results would be that any of these 
treatment strategies could be equally well provided 
by the NHS. Nevertheless, when the incremental 
cost-effectiveness was estimated then it was highly 
likely that lifestyle changes followed by PFMT 
with extra sessions followed by surgery if necessary 
would be cost-effective (there was an over 70% 
chance that this intervention would be considered 
cost-effective at a threshold value of £20,000 per 
QALY).
For the model based on improvement rates, the 
QALYs and costs for each treatment were greater 
than those for the model based on cure rates. This 
is because improvement rates were greater than cure 
rates but no quality-of-life data that were specific 
to improvement were available. Therefore, it was 
assumed that the utility associated with improvement 
was the same as the utility associated with cure. 
Costs were greater because it was assumed that 
women would incur some costs of containment 
products, even if their symptoms were improved. 
As a consequence, comparisons with the analysis 
made using cure rates should be interpreted 
cautiously.
In the model based on improvement rates, the least 
costly strategy was lifestyle changes, followed by 
PFMT basic, PFMT with extra sessions and then 
surgery (mean cost per woman treated = £1795), 
and the most costly was lifestyle changes followed 
by surgery with a mean cost per woman treated 
of £2425. In terms of QALYs, the least effective DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
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TABLE 81  Treatment comparisons from direct- and mixed-treatment methods
Intervention Direct comparison MTC
1 2
Number of 
trials
Number of 
people Est (95% CrI) Est (95% CrI)
Cure
PFMT NT 8 605 5.41 4.56
(1.64 to 17.82) (1.95 to 12.4)
PFMT + BF NT 2 110 21.54 9.65
(3.65 to 126.98) (3.37 to 33.3)
ES NT 6 288 1.10 1.63
(0.41 to 2.94) (0.506 to 5.54)
SNRI NT 3 1292 1.46 1.42
(1.00 to 2.14) (0.377 to 5.35)
BT NT 1 123 4.03 4.87
(0.80 to 20.23) (1.05 to 26.1)
PFMT + ES NT 2 155 1.76 4.59
(0.27 to 11.54) (1.20 to 22.4)
PFMT ES 5 124 2.65 2.82
(0.82 to 8.60) (0.911 to 9.3)
PFMT VC 3 245 0.61 0.963
(0.09 to 3.95) (0.274 to 3.51)
PFMT + BF VC 1 46 0.86 2.03
(0.25 to 2.93) (0.528 to 8.53)
PFMT BT 1 75 2.61 0.935
(0.98 to 6.96) (0.206 to 4. 28)
PFMT + BF BT 1 132 0.67 1.98
(0.25 to 1.76) (0.431 to 9.62)
ES VC 2 106 1.00 0.341
(0.26 to 3.91) (0.0782 to 1.48)
PFMT PFMT + ES 4 133 1.02 0.998
(0.29 to 3.55) (0.257 to 3.47)
PFMT PFMT + VC 1 46 0.44 0.41
(0.09 to 2.10) (0.0246 to 6.2)
PFMT + BF PFMT + BF + BT 1 125 0.32 0.542
(0.13 to 0.79) (0.0614 to 4.95)
PFMT + ES ES 1 22 3.75 2.82
(0.33 to 43.31) (0.598 to 15.5)
PFMT + BF + BT  BT 1 129 2.11 3.64
(0.92 to 4.82) (0.419 to 32.7)
PFMT PFMT + BF 8 370 0.48 0.474
(0.30 to 0.77) (0.2 to 1.07)
PFMT basic PFMT extra  3 118 0.11 0.12
(0.03 to 0.43) (0.0462 to 0.268)
continuedDiscussion
158
Intervention Direct comparison MTC
1 2
Number of 
trials
Number of 
people Est (95% CrI) Est (95% CrI)
Improvement
PFMT NT 11 689 11.75 8.97
(3.49 to 39.55) (4.4 to 20.8)
PFMT + BF NT 2 110 24.20 21.7
(2.02 to 290.58) (7.24 to 75.2)
ES NT 7 369 3.93 4.75
(1.43 to 10.80) (2.02 to 11.9)
VC NT 2 212 5.43 6.99
(0.07 to 396.77) (2.63 to 20.7)
SNRI NT 10 3672 2.02 2.24
(1.67 to 2.44) (1.09 to 4.68)
BT NT 1 123 9.60 11.3
(4.22 to 21.87) (1.92 to 70.1)
PFMT + ES NT 2 108 8.69 13.1
(1.87 to 40.32) (2.91 to 67.5)
PFMT + SNRI NT 1 96 3.28 5.63
(1.41 to 7.64) (0.784 to 43)
PFMT ES 6 190 2.18 1.9
(0.76 to 6.28) (0.81 to 4.67)
PFMT VC 5 331 1.01 1.29
(0.52 to 1.95) (0.527 to 3.18)
PFMT + BF VC 1 46 1.14 3.11
(0.34 to 3.85) (0.948 to 10.7)
PFMT + BF BT 1 129 1.71 1.92
(0.79 to 3.70) (0.336 to 12.1)
PFMT SNRI 1 99 1.60 4.01
(0.71 to 3.60) (1.53 to 12)
ES VC 3 141 1.30 0.675
(0.59 to 2.84) (0.235 to 1.9)
PFMT PFMT + ES 3 160 0.84 0.686
(0.34 to 2.07) (0.153 to 3.12)
PFMT + BF PFMT + BF + ES 2 102 0.86 0.935
(0.36 to 2.08) (0.208 to 4.29)
PFMT PFMT + VC 1 46 0.84 0.509
(0.26 to 2.68) (0.07 to 3.34)
PFMT + BF PFMT + BF + BT 1 124 0.35 0.352
(0.13 to 0.97) (0.0332 to 3.67)
PFMT PFMT + SNRI 1 100 0.78 1.59
(0.34 to 1.82) (0.214 to 12.9)
PFMT + ES ES 1 22 4.67 2.77
(0.77 to 28.47) (0.554 to 14.4)
PFMT + VC VC 1 34 5.00 2.52
(0.52 to 48.46) (0.358 to 20.2)
TABLE 81  Treatment comparisons from direct- and mixed-treatment methods (continued)DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
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Intervention Direct comparison MTC
1 2
Number of 
trials
Number of 
people Est (95% CrI) Est (95% CrI)
PFMT + BF + BT BT 1 127 4.90 5.5
(1.84 to 13.10) (0.551 to 60.8)
PFMT + SNRI SNRI 1 101 2.04 2.52
(0.90 to 4.64) (0.337 to 20)
PFMT PFMT + BF 7 296 0.41 0.414
(0.18 to 0.97) (0.143 to 1.15)
PFMT basic PFMT extra 2 74 0.05 0.174
(0.01 to 0.28) (0.0617 to 0.473)
Est, point estimate; PFMT basic, PFMT with up to two sessions per month; PFMT extra, PFMT with extra sessions (more 
than two per month).
Note:  All mixed-treatment comparison results are taken from the models with PFMT combined as one treatment, 
except those in bold text, which are from those with PFMT split into basic and extra sessions.
strategy was lifestyle changes followed by surgery 
(mean QALYs per woman treated = 16.2). The most 
effective was lifestyle changes followed by PFMT 
with extra sessions followed by surgery if necessary 
(mean QALYs per woman treated = 16.37). Which 
treatment strategy was most likely to be cost-
effective depended upon society’s willingness to 
pay for a QALY. Below a threshold of £30,000 per 
QALY, lifestyle changes followed by PFMT basic 
and then surgery was the intervention most likely to 
be considered cost-effective. Above that a threshold 
of £30,000 per QALY, lifestyle changes followed 
by PFMT with extra sessions followed by surgery 
if necessary was most likely to be considered cost-
effective. This strategy had a 55% likelihood of 
being considered cost-effective when society’s 
willingness to pay for a QALY was between £10,000 
and £30,000.
The role of drug therapy appears limited, as 
strategies involving drug management were 
unlikely to be considered cost-effective. This is 
primarily due to the non-adherence to SNRI 
treatment caused by the side effects of the drugs, 
which limited their effectiveness. Furthermore, 
the strategy involving surgery without the use of 
non-surgical treatments was not likely to be cost-
effective.
When success was defined in terms of cure or 
improvement, the results were insensitive to the 
introduction of strategies involving VCs or ES. It 
was also found that the interpretation of the cost-
effectiveness results did not greatly change when 
the model was adapted to allow women to exercise 
preference not to seek surgery or repeat surgery, 
should cure or sufficient improvement not be 
achieved.
These data suggest that adopting an intervention 
such as PFMT with extra sessions (or potentially 
other more intensive forms of PFMT, such as 
PFMT with BF) would be more efficient than 
PFMT basic. This is important as PFMT basic is 
perhaps closest to the form of PFMT most common 
in the NHS. Therefore, although PFMT basic does 
appear to improve the symptoms of women with 
SUI, consideration should be given to whether 
it is practical and acceptable to both women and 
the NHS to provide some form of more intensive 
PFMT (either alone or with an adjunct, such as BF 
training).
The results were most sensitive to changes in the 
effectiveness of PFMT with extra sessions. Should 
the chance of PFMT with extra sessions achieving 
cure or improvement reduce, or should longer-term 
recurrence rates increase, then the likelihood that 
lifestyle changes followed by PFMT with extra 
sessions followed by surgery is cost-effective would 
fall. For the model based on cure rates, lifestyle 
changes followed by PFMT with extra sessions 
followed by surgery would no longer be the most 
cost-effective strategy when long-term cure rates 
were reduced by more than 60%. For the model 
based on improvement rates, lifestyle changes 
followed by PFMT with extra sessions followed by 
surgery would no longer the most cost-effective 
TABLE 81  Treatment comparisons from direct- and mixed-treatment methods (continued)Discussion
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TABLE 82  Odds ratios for comparisons between PFMT with extra sessions and PFMT plus BF with other treatments (mixed-treatment 
comparison models)
Intervention
Cure, median (95% CrI)
Improvement, median  
(95% CrI) 1 2
PFMT with extra sessions
PFMT extra NT 10.7 (5.03 to 26.2) 25.7 (10.3 to 73.1)
PFMT extra PFMT basic 8.36 (3.74 to 21.7) 5.75 (2.11 to 16.2)
PFMT extra PFMT + BF 0.867 (0.45 to 1.69) 1.01 (0.32 to 3.16)
PFMT extra ES 7.43 (2.72 to 22.3) 4.68 (1.75 to 13.2)
PFMT extra VC 3.02 (1.04 to 9.53) 3.79 (1.32 to 11.5)
PFMT extra SNRI80 7.44 (2.44 to 27.8) 12 (3.92 to 42.4)
PFMT extra BT 1.41 (0.481 to 4.48) 2.13 (0.34 to 14.5)
PFMT extra PFMT + ES 3.51 (1.12 to 10.2) 1.24 (0.27 to 5.79)
PFMT extra PFMT + ES + BF 1.17 (0.07 to 20.5) 1.19 (0.23 to 6.3)
PFMT extra PFMT + VC 3.45 (0.31 to 35.6) 2.11 (0.26 to 16)
PFMT extra PFMT + VC + BF 1.87 (0.04 to 46.2) 9.66 (0.62 to 158)
PFMT extra PFMT + BT + BF 0.422 (0.09 to 2.14) 0.369 (0.03 to 4.4)
PFMT extra PFMT + drug –  – 5.82 (0.73 to 50.7)
PFMT plus BF
PFMT + BF NT 12.3 (5.35 to 32.7) 25.4 (8.68 to 86.9)
PFMT + BF PFMT basic 9.63 (4.12 to 25.9) 5.68 (1.88 to 18.3)
PFMT + BF PFMT extra 1.15 (0.59 to 2.22) 0.99 (0.32 to 3.11)
PFMT + BF ES 8.55 (2.88 to 27.6) 4.63 (1.37 to 16.9)
PFMT + BF VC 3.47 (1.19 to 11) 3.75 (1.17 to 12.5)
PFMT + BF SNRI80 8.58 (2.64 to 33.4) 11.8 (3.37 to 48.4)
PFMT + BF BT 1.62 (0.54 to 5.18) 2.11 (0.38 to 12.5)
PFMT + BF PFMT + ES 4.05 (1.15 to 12.7) 1.23 (0.21 to 7.51)
PFMT + BF PFMT + ES + BF 1.34 (0.07 to 24) 1.18 (0.27 to 5.21)
PFMT + BF PFMT + VC 3.96 (0.35 to 41.2) 2.09 (0.25 to 16.7)
PFMT + BF PFMT + VC + BF 2.14 (0.05 to 53.7) 9.54 (0.57 to 170)
PFMT + BF PFMT + BT + BF 0.49 (0.11 to 2.28) 0.37 (0.04 to 3.61)
PFMT + BF PFMT + drug –  – 5.75 (0.67 to 54.2)
Note:  This table is extracted from Tables 85 and 86 reported in Appendix 23.
strategy when long-term improvement rates of 
PFMT with extra sessions were the same as PFMT 
basic. The long-term success rates of PFMT with 
extra sessions were based upon data from Bø 
and colleagues,115,159 who used a combination of 
group and individual sessions with women, as 
well as longer-term provision of training. It is 
unclear, however, what factors determined the 
outcomes they observed (e.g. was the motivation 
of the women atypical, was it the intensity of the 
intervention or some other factor?) or whether the 
results of this study could be replicated in routine 
NHS practice.
The results were also sensitive to changes in the 
cost of PFMT with extra sessions. Lifestyle changes 
followed by PFMT with extra sessions followed by 
surgery would no longer be cost-effective when 
the cost of PFMT with extra sessions was increased 
by nearly £1000 per woman treated in the model 
based on cure rates, and £400 per woman treated 
when it was in the model based on improvement 
rates.DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
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Overall, the results of the economic evaluation 
suggests that further research to develop and 
test a more intensive PFMT intervention that is 
acceptable to women and feasible for the NHS is 
warranted.
Strengths, assumptions, 
limitations and 
uncertainties
Numerous previous studies have considered the 
relative effectiveness of non-surgical treatments 
for SUI in women.50,56,60,64,68,71,83–85,87,88,106,201,224–228 
What our study has added is the systematic review 
and overview of the treatments relevant to the 
NHS, where evidence on the relative effectiveness 
has been derived using more advanced methods 
of meta-analysis than have been used previously. 
These methods have allowed us to provide clearer 
evidence about which treatments work and how 
well they work than was hitherto available. The 
statistical approach of MTC allowed indirect 
evidence to supplement direct head-to-head 
comparisons of treatments. This made the 
comparison of treatments much easier than trying 
to interpret the data from the 68 direct head-to-
head (pairwise) comparisons.
Despite extensive searching and the identification 
of a large number of studies, few data were 
available for most comparisons. Over time this 
may be rectified, and, indeed, an updated search 
conducted up to June 2009 identified additional 12 
articles that appear to meet our inclusion criteria 
(these studies are listed in Appendix 28).
Of the studies that were identified, nearly one-half 
of the participants in the included trials (46%, 
4554/9803) came from the 12 trials that included 
a SNRI as one of their trial arms. Given this, a 
pragmatic decision was made to include studies 
where women with urgency urinary incontinence 
symptoms also formed part of the study population 
(population types 2 and 3).
Generally, these studies were less likely to show 
large effect sizes than studies that only included 
women with SUI alone. The studies with mixed 
populations, however, tended to have a larger 
sample, but involved fewer supervisory sessions 
than studies of women with only SUI. Both of these 
factors may also have affected the estimated size of 
effect.
Even for the relatively simple clinical outcomes, 
such as cure or improvement, the lack of consensus 
on the most appropriate method for assessing 
incontinence presented a particular problem 
for evidence synthesis. Ideally, the success of a 
treatment should be gauged on the ability of 
women to lead a normal social life. Using this 
definition usually means that the woman herself 
reports a satisfactory resolution (or near resolution) 
of her symptoms. Unfortunately, patient-reported 
measures were not always available. Moreover, 
available data (including proxy measures based 
on the quantification of symptoms derived from 
diaries or pad tests) did not differentiate those who 
are sufficiently better (and do not want further 
treatment) from those who are better but do want 
further treatment.
A further challenge for evidence synthesis that is 
related to the lack of consistency between studies 
and the limited reporting of studies was that 
intervention protocols were complex and varied 
considerably across studies. For example, PFMT 
differed widely in terms of the precise nature of 
the exercises, how patients were instructed, and the 
frequency and duration of therapy (Appendix 12). 
Generally, such data were poorly reported, with 
the exercise protocol not consistently described 
using the same criteria. In an attempt to explore 
the impact of intensity of therapy, PFMT was 
defined solely by the frequency of supervisory clinic 
sessions or contacts with a health-care professional. 
Similarly, the complex nature of the intervention 
protocols also meant that it was difficult to 
decipher which aspect of the intervention actually 
worked. For example, the addition of BF training 
to PFMT appeared beneficial in enhancing the 
effect of PFMT. This may have occurred because 
women made greater use of PFMT and increased 
their adherence to the training programme. 
Introducing a BF device may also intensify the 
nature or the quantity of supervision provided by 
the health-care professional, which, in itself, may 
be beneficial for women. What the research does 
highlight is the importance of intensity of therapy 
on effectiveness and cost-effectiveness, and the 
need for the evidence-based development of more 
intensive regimens that can be taken forward to 
rigorous evaluation in adequately powered RCTs.
When assessing the effectiveness of treatment 
emphasis was given to using the data collected 
at the end of the supervised treatment phase. 
It was expected that these data would represent 
the point where the treatments would show their 
maximum effect. Long-term data beyond the 
supervised treatment phase were sparse but the 
evidence gathered for the economic evaluation 
suggests that the effectiveness was not maintained. Discussion
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This may be due to poor adherence to a muscle 
training programme or whether the effects of 
training can be sustained into the longer term. The 
results of the economic evaluation are sensitive to 
changes in long-term performance of non-surgical 
interventions. Improvements in the long-term 
performance will improve the cost-effectiveness of 
non-surgical treatments.
Although the meta-analyses have limitations, 
one of the strengths of this study is that it has 
used these rigorously assembled data within an 
economic evaluation. This economic evaluation 
compared treatment strategies relevant to the NHS 
and hitherto no such analysis existed. Indeed, 
no economic evaluations were identified which 
compared all the relevant treatments.
Modelling the cost-effectiveness of non-surgical 
treatments was challenging because of the number 
of potential management strategies that might 
be relevant and also the lack of data available. 
As described in Chapter 9, considerable efforts 
were made to identify relevant data, and extensive 
sensitivity analyses were used to explore the impact 
of uncertainties. Useful information to help 
guide practice has been produced but it should 
be remembered that, apart from drug therapy, 
few data were available for any of the treatments, 
and very few data on long-term performance were 
available for any therapy. Therefore, the results of 
this study should be treated cautiously.
All of the strategies considered within the economic 
model included lifestyle advice (e.g. reduce weight, 
restrict caffeine intake, etc.). It was assumed that, 
although advice would be given, it would be 
ineffective. A recent trial has shown that weight 
reduction (lifestyle change) in obese women may 
reduce the symptoms of incontinence and further 
work on lifestyle interventions may be worthwhile.
Within the economic evaluation the effectiveness 
of treatments were measured in QALYs, which 
were derived from EQ-5D values obtained from 
the literature (and in a sensitivity analysis from 
a survey conducted as part of this study). The 
EQ-5D has been recommended as the method of 
valuing health states by NICE,105 but it may not be 
sensitive enough to capture the concerns of women. 
Any failure to accurately measure the benefits of 
treatment may lead to erroneous conclusions about 
cost-effectiveness.
A further limitation of the economic model 
was that there were no quality-of-life data to 
differentiate between cure and improvement. It 
might be expected that the quality of life of women 
whose symptoms had improved but who were 
not cured would be less than women who were 
cured. Alternatively, changes in the frequency of 
incontinence may fail to translate into benefits of 
importance to women. Ideally, further research 
should be conducted on the quality of life of 
women whose symptoms are improved and who no 
longer seek further treatment.
Within all of the economic analyses, the 
preferences of women for the process of care have 
not been considered. Women are likely to have 
preferences about who provides the care, where 
the care is provided, and what risks and costs they 
face themselves. These factors are not captured 
by measures such as the EQ-5D. Therefore, 
research to elicit the preferences of women for the 
different outcomes and processes of treatment in 
a form that is suitable for incorporation into an 
economic evaluation is likely to be worthwhile. 
Such data would be complementary to existing 
data and could help to highlight areas in which the 
preferences of women for outcomes of importance 
to them would lead to different policy decisions.
The economic model has focused on costs to 
the NHS. It has been assumed that certain costs, 
such as those for VCs and containment products, 
may be incurred by the NHS. In practice, women 
may buy the cones and may well incur the costs 
of containment management themselves. Other 
costs that may fall on the women have not 
been included. These include the other costs of 
managing symptoms, such as laundry costs, and 
the time and travel costs related to accessing 
care. It might be expected that the more effective 
treatments would reduce the costs of managing 
symptoms borne by the women and their families. 
However, the more effective treatments may also 
require substantially more time commitment (and 
travel costs to access care) from the women. The 
net effect of these two factors is uncertain.
A further limitation with respect to costs is 
that the handling of facility costs and hospital 
management costs has not been wholly consistent. 
For example, for some interventions, such as the 
use of physiotherapy, the cost has been used upon 
the staff and equipment used to provide a session 
but has not included an element to cover the 
facility and management costs. However, for other 
interventions, for example the cost of surgery, 
these are based on nationally available figures that 
do include an element to cover facility costs and DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
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hospital management costs. The net impact of this 
is to make PFMT interventions more likely to be 
cost-effective compared with surgery. However, as 
the sensitivity analysis has illustrated, increases in 
the cost of PFMT would need to be substantial to 
change the overall results and it is implausible that 
this would actually be the case.
Nevertheless, despite the limitations of the 
evidence base, there is evidence from a number 
of trials that PFMT plus BF and PFMT with extra 
sessions was effective. Furthermore, strategies 
involving these treatments are likely to be 
considered cost-effective at threshold values that 
society might be willing to pay for a QALY.DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
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Implications for the NHS
•  The available data suggest that non-surgical 
treatments for SUI in women are effective 
and could potentially be cost-effective, but 
a judgement is required as to whether the 
benefits are worth the cost.
•  There is no evidence that PFMT basic (which 
is similar to the form of PFMT provided by the 
NHS)43 is any better than no treatment when 
success is measured in terms of cure, although 
it is better than no treatment when success is 
measured in terms of improvement.
•  There is clear evidence from a number of 
trials that ‘PFMT plus BF’ and ‘PFMT with 
extra sessions’ were effective compared with no 
treatment.
•  Both ‘PFMT plus BF’ and ‘PFMT with extra 
sessions’ are more effective (for both cure and 
improvement) than PFMT basic.
•  Evidence from a small number of trials 
suggests that other non-surgical treatments 
may also be effective (PFMT plus BT and BF; 
PFMT plus ES and BF; PFMT plus VCs and 
BF). There is, however, insufficient evidence to 
recommend their routine use by the NHS.
•  A strategy by which women can progress to 
surgery almost immediately is unlikely to be 
cost-effective, primarily because of the cost of 
surgery.
•  Treatment with SNRI drugs are, on average, 
effective (measured in terms of cure or 
improvement), but the frequency of side 
effects mean that women do not tend to use 
this therapy for long. Therefore, strategies 
involving SNRI are unlikely to be cost-effective.
•  As no treatment or treatment strategy is 
perfect, women should be offered support to 
help them articulate what it is that they hope to 
achieve from therapy.
•  The differences between the treatment 
strategies considered (measured in QALYs) 
were relatively modest and, although some 
strategies were found to be more likely to be 
cost-effective, the evidence base was limited.
•  The feasibility of the potentially cost-effective 
more intensive forms of PFMT is questionable, 
as there may not be sufficient trained therapists 
to provide this care at present. For the use of 
these therapies to increase, staff would need 
to be recruited, trained and retained. Recent 
surveys about the provision of care by the NHS 
by the Continence Foundation (Judith Wardle, 
formerly of the Continence Foundation, March 
2009, personal communication) found that 
less costly therapists were being substituted 
for the higher-grade continence nurse 
specialists. Given the potential demand for 
care, non-specialist care providers are likely 
to be necessary, in addition to care provided 
by specialist therapists, but they will need 
appropriate training.
•  Opportunities for self-management by the 
women should be encouraged, as women 
can purchase VCs themselves or they could 
undertake PFMT without formal supervision. 
Therapies are most likely to be effective and 
cost-effective when women receive training so 
that they can perform the exercises correctly.
•  Continuing and ongoing support for women 
with SUI may be required beyond current 
programmes, as long-term performance is 
central to estimates of long-term effectiveness.
•  Conversely, providing therapies when there is 
no sustained follow-up may not be a good use 
of scarce practitioner time or resources.
Implications for women
Non-surgical treatment for SUI can provide either 
cure or improvement in symptoms. A non-surgical 
treatment might not totally resolve symptoms 
but may lead to sufficient improvement so that 
a woman considers that further treatment is 
not worthwhile. Although the woman may not 
desire further treatment, it should be noted that 
symptoms may still be bothersome and may require 
the use of containment products. The cost of using 
containment products and extra laundry will still 
fall on women and their families.
For some women, non-surgical treatments can 
delay or prevent the need for surgery. This may 
be particularly important for those women who 
have no desire to undergo surgery and may be 
prepared to accept severe incontinence rather 
than face surgery. The recourse to surgery early 
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in a treatment pathway might be preferred by 
some women who are unable to use non-surgical 
treatments or who are unwilling to devote the 
sustained time and effort required to obtain and 
maintain an improvement in symptoms. However, 
over the longer term better outcomes might be 
achieved if the women try out a non-surgical 
treatment first.
Some of the therapies do not necessarily need 
involvement of the health service. Women 
can purchase VCs themselves, or they could 
undertake PFMT without formal supervision. 
These treatments can be effective, but whether 
this is worthwhile depends upon the ability of 
the woman to perform the therapy correctly. 
Therefore, women should consider whether some 
formal instruction by suitably trained health-care 
professionals would be helpful to ensure that they 
are performing correct contractions.
The long-term success of the treatments such as 
PFMT declines over time. One potential reason for 
why this happens is that women do not continue 
to perform the exercises in the long term. This 
requires a behaviour change that women might 
find difficult to initiate and maintain. Without 
making and maintaining this change, it is likely 
that symptoms will return and further treatments, 
including surgery, might be required.
Further research
Evidence has been provided to show that several 
of the non-surgical treatments for SUI can be 
effective, at least in the short term, and are 
potentially cost-effective. The evidence, however, is 
based upon a number of small trials, and, for many 
comparisons, only single trials.
•  Further definitive evidence from large well-
designed studies of the most promising 
regimens (in terms of likely effectiveness, cost-
effectiveness and feasibility within the health 
service) is required to provide a definitive 
answer.
•  Any further research, be it from a trial, on 
long-term outcomes, benefit assessment, or 
costs, should be incorporated into an updated 
economic evaluation, as and when it becomes 
available.
•  Such trials should consider the long-term 
effectiveness of more intensive versions of 
PFMT (e.g. PFMT with BF training) in typical 
standard health-care setting and an economic 
modelling exercise that will place the results 
of the trial into the context of other relevant 
research and extrapolate from the trial results.
•  The effectiveness and cost-effectiveness will 
depend upon the long-term effective of 
treatments, which, in turn, may depend upon 
whether any training programme is adhered to 
and sustained into the longer term. Research 
in how this might be achieved in a way that 
is feasible for both the NHS and women is 
required.
•  Further work to understand what outcomes 
are of importance to women and the strength 
of preference of women for these outcomes is 
required.
•  Understanding the preferences of women for 
different ways that care could be provided, and 
the trade-offs between different process and 
outcome measures, would be useful. Women 
may also have preferences about the process 
of care as well as the outcome of care. Ideally, 
such data should be suitable for incorporation 
into a subsequent economic evaluation.
•  The impact of costs (both in terms of out 
of pocket expenses and time) that fall upon 
women and their families should be explored 
further. Specifically, information is needed 
about the trade-off between the costs of 
managing symptoms (use of self-purchased 
containment products, laundry costs, etc.) and 
the time and travel costs of treatment.
•  If an effective and efficient follow-up regimen 
can be developed, then the incentives/
disincentives faced by NHS providers may 
need to be reconsidered. For example, within 
England, performance current monitoring 
goals might lead to a focus on ‘first contacts’ at 
the expense of follow-up care.
Summary of conclusions
More intensive forms of PFMT (‘PFMT with extra 
sessions’ and ‘PFMT with BF’) are effective and 
potentially worthwhile uses of NHS resources. 
Nevertheless, the data came from a few small 
trials and further information from large well-
designed studies is required to establish whether 
these interventions are effective, cost-effective and 
feasible for the NHS to provide.DOI: 10.3310/hta14400  Health Technology Assessment 2010; Vol. 14: No. 40
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